gilead sciences inc annual report filed period ending address lakeside dr foster city california telephone cik industry biotechnology drugs sector healthcare fiscal year quicklinks click rapidly navigate document securities exchange commission washington dc mark one cid annual report pursuant section securities exchange act fiscal year ended december cid transition report pursuant section securities exchange act transition period commission file gilead sciences inc exact name registrant specified charter delaware state jurisdiction incorporation organization irs employer identification lakeside drive foster city california address principal executive offices zip code registrant 's telephone number including area code securities registered pursuant section b act none securities registered pursuant section g act common stock par value title class indicate check mark whether registrant filed reports required filed section securities exchange act preceding months shorter period registrant required file reports subject filing requirements past days yes cid cid indicate check mark disclosure delinquent filers pursuant item regulation sk section chapter contained herein contained best registrant 's knowledge definitive proxy information statements incorporated reference part iii amendment cid indicate check mark whether registrant accelerated filer defined rule b act yes cid cidthe aggregate market value voting stock held nonaffiliates registrant based upon closing price common stock nasdaq stock market june number shares outstanding registrant 's common stock february documents incorporated reference specified portions registrant 's definitive proxy statement filed commission pursuant regulation connection annual meeting incorporated reference part iii report based closing price per share excludes shares registrant 's common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrant gilead sciences inc annual report table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrant 's common stock related stockholder matters item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management item certain relationships related transactions item controls procedures part iv item exhibits financial statement schedules reports form k signatures certifications rights various trademarks copyrights trade names used business including following gilead gilead sciences hepsera leaf shield design leaf shield design bw liver design tablet design bw tablet design color viread vistide daunoxome ambisome tamiflu registered trademark belonging hoffmannla roche report also includes trademarks service marks trade names companies part iitem business forwardlooking statements risk factors report includes forwardlooking statements particular statements expectations beliefs plans objectives assumptions future events performance contained incorporated reference report based forwardlooking statements current expectations future events believe expectations reasonable forwardlooking statements inherently subject risks uncertainties many beyond control actual results may differ materially suggested forwardlooking statements various reasons including discussed report heading risk factors affect gilead given risks uncertainties cautioned place undue reliance forwardlooking statements forward looking statements included report made date hereof undertake specifically decline obligation update statements publicly announce results revisions statements reflect future events developments used report unless otherwise indicated us refers gilead subsidiaries overview gilead sciences inc biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases worldwide six products currently marketed us five also marketed countries worldwide research clinical programs focused antiinfectives including antivirals antifungals endeavor grow existing portfolio products proprietary clinical development programs internal discovery programs active product acquisition inlicensing strategy worldwide headquarters foster city california european headquarters paris france incorporated delaware june january completed acquisition outstanding stock triangle pharmaceuticals inc triangle whollyowned subsidiary gilead aggregate preliminary purchase price million including cash paid outstanding stock fair value options assumed estimated direct transaction costs employee termination costs triangle develops drug candidates antiviral area particular focus potential therapies hiv including aids hepatitis b virus triangle 's portfolio consists several drug candidates clinical trials including emtricitabine treatment hiv infection emtricitabine treatment hepatitis b amdoxovir treatment hiv infection clevudine treatment hepatitis b triangle filed marketing applications emtricitabine treatment hiv united states european union products viread approved sale sold us us commercial team use combination antiretroviral agents treatment hiv infection european union european commercial team use combination antiretroviral agents treatment hiv infection patients experiencing early virological failure ambisome approved sale sold countries treatment lifethreatening fungal infections countries prevention infections market ambisome major countries europe copromote ambisome us fujisawa healthcare inc fujisawa hepsera approved sale sold us us commercial team treatment chronic hepatitis b hepsera received marketing approval european union march tamiflu approved sale sold corporate partner hoffmannla roche roche countries including us european union prevention treatment influenza vistide approved sale sold us us commercial team gilead 's exus partner pharmacia corporation pharmacia countries treatment cytomegalovirus cmv retinitis patients aids daunoxome approved sale sold countries treatment aidsrelated kaposi 's sarcoma sold us us commercial team independent distributors abroad earned revenues million sales royalties products amount sales viread generated aggregate product sales royalty revenues million total revenues sales ambisome generated aggregate product sales royalty revenues million total revenues earned revenues sales royalties ourproducts us million million million outside us earned revenues sales royalties products million million million viread tenofovir disoproxil fumarate viread oral formulation nucleotide analogue reverse transcriptase inhibitor tenofovir df dosed day part combination therapy treat hiv infection adults drug works blocking reverse transcriptase enzyme involved replication hiv sell viread us us commercial team major european countries european commercial team see commercial operations us food drug administration fda approved viread marketing us october european agency evaluation medicinal products emea granted similar approval european union february us viread approved use combination antiretroviral agents treatment hiv infection indication based analyses plasma hiv rna levels cd cell counts controlled study viread weeks duration study controlled dose ranging study viread weeks duration study studies conducted treatmentexperienced adults evidence hiv viral replication despite ongoing antiretroviral therapy studies patients previously received antiretroviral therapy antiretroviralnave patients ongoing february reported week data ongoing threeyear randomized doubleblind clinical trial study designed compare efficacy safety combination treatment regimen viread lamivudine tc efavirenz combination treatment regimen stavudine dt lamivudine efavirenz antiretroviralnave patients hiv infection data study demonstrates treatmentnave patients received viread experienced substantially less lipodystrophy lower elevations fasting cholesterol triglyceride levels well improved levels limb fat weight gain achieving similar reductions hiv viral load increases cd cell counts compared received stavudine adverse events reported less two percent patients included rash bacterial infection depression fever pneumonia low discontinuation rate approximately percent arm study week data supplements week results study submitted fda support use viread patients prior hiv therapy intend submit week data potential inclusion us european labels predict whether fda emea accept interpretation data approve label indicating viread use patients prior hiv therapy based data approval week data study recommended committee proprietary medicinal products cpmp february one major challenges treating hivinfected patients drug resistance many existing therapies treating hiv infection aids rely similarlydesigned drug processes patients developed resistance one drug often develop resistance drugs within class believe viread approved regulatory authorities offers advantages approved hiv treatments available data shown patients developed resistance viread viread effective treating patients developed resistance therapies certain however resistance data may obtain upon completion phase clinical trials show similar resistance characteristics week data study data obtained limited phase clinical trials another major concern hiv treatment convenience dosing combination therapies positive impact require hiv infected patients take numerous drugs drugs require multiple doses every day many timing dietary restrictions results inconvenience patients also contributes patients missing doses adhering therapy viread approved administered oncedaily oral pill schedule may appealing hivinfected patients physicians hiv competitive landscape becoming crowded complicated treatment trends continue evolve twenty branded anti hiv drugs currently sold us many others advance stages clinical development see competition exclusive worldwide license patent rights related technology viread institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega obligated pay percentage net revenues sales viread us european union countries product approved patent protection iocbrega see academic consulting relationshipsiocbrega ambisome amphotericin b liposome injection ambisome proprietary liposomal formulation amphotericin b amphotericin b powerful antifungal agent known ability treat serious invasive fungal infections caused various fungal species infections generally life threatening particularly patients depressed immune systems due aggressive chemotherapy regimens stem cell organ transplant hiv infection ambisome treatment also serious side effects including kidney toxicity studies show however delivering amphotericin b ourproprietary liposomal formulation ambisome reduces rate severity kidney toxicity injectionrelated reactions allows patients receive higher doses amphotericin b ambisome approved sale countries including us european union rest europe australia canada several countries middle east latin america asia countries ambisome approved including us authorized promote ambisome empirical treatment fungal infections ie treatment patients strong suspicion without definite confirmation exists potentially lifethreatening invasive fungal infection remaining countries ambisome approved sale approved use either firstline treatment serious invasive fungal infection secondline treatment conventional amphotericin b therapy fails conventional amphotericin b tolerated finally ambisome approved number countries various indications example cryptococcal meningitis aids patients prophylaxis liver transplant patients visceral leishmaniasis us copromote ambisome fujisawa us commercial team agreement fujisawa entitles us percentage revenues generated sales provides fujisawa purchases ambisome us manufacturing cost see collaborative relationshipsfujisawa major european countries australia sell ambisome international commercial teams certain countries sell ambisome independent distributors revenues ambisome europe expect case foreseeable future licensed commercial rights ambisome japan sumitomo pharmaceuticals co ltd sumitomo exchange royalties generated activities however ambisome yet approved sale japan ambisome faces strong competition several current competitors expected competitors whose treatments late stage clinical trials see competition competition current expected competitors likely erode revenues receive sales ambisome hepsera adefovir dipivoxil hepsera oral formulation nucleotide analogue hbv dna polymerase inhibitor adefovir dipivoxil dosed day treat chronic hepatitis b hepatitis b caused highly contagious hepatitis b hbv virus cause acute liver failure patients develop chronic hepatitis b infection many years lead complications cirrhosis liver cancer liver failure approximately patients result death according recent estimates world health organization centers disease control million people worldwide million people us chronic hepatitis b one million deaths attributable chronic hepatitis b worldwide year one ten leading causes death worldwide hepsera disables hbv interfering activity enzyme known hbv polymerase necessary virus replicate applications us european union marketing authorizations included data two separate phase clinical trials designed evaluate safety effectiveness hepsera mg dosage treating patients hepatitis b virus phase trials designed randomized doubleblind placebocontrolled studies clinical sites us canada europe australia southeast asia study evaluated hepsera treating patients test positive hbv e antigen common type hepatitis b us trial study evaluated hepsera treating patients type hepatitis b known precore mutant hepatitis b common southeast asian mediterranean countries weeks adefovirassociated resistance mutations identified hepatitis b patients treated clinical trials suggests development resistance hepsera hepatitis b patients may delayed infrequent consequently believe hepsera 's resistance profile could make important drug treating chronic hepatitis b certain however resistance data may obtain continuing phase clinical trials hepsera continue show resistance characteristics hepsera approved sale us treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team sells hepsera us march applied approval emea hepsera treatment chronic hepatitis b european union approval emea recommended cpmp november received march plan sell hepsera major european union countries european commercial team vaccine available prevent transmission hbv effective people already become chronicallyinfected hbv expect vaccine becomes widely available incidence new hepatitis b infections decrease however even advances prevention hepatitis b individuals suffering chronic hepatitis b represent patient pool significant risk morbidity mortality due underlying chronic viral infection chronic hepatitis b common china southeast asia december received clinical trials permit initiate phase clinical trials china commenced clinical trials june licensed rights commercialize hepsera solely treatment hepatitis b china korea japan taiwan rest asia latin america certain territories glaxosmithkline gsk part approval commence phase clinical trials china hepsera granted class designation hepsera ultimately approved sale china would give gsk years market exclusivity hepsera respect competitors may otherwise able begin clinical development adefovir dipivoxil following approval receiving chinese government 's approval phase study given approval move forward phase program began patient enrollment december several existing therapies treating patients infected hbv compete hepsera treatments represent significant competition hepsera see competition exclusive worldwide license patent rights related technology adefovir dipivoxil iocbrega pay percentage net revenues sales hepsera iocbrega countries product patent protection including us member states european union addition pay small variable percentage net revenues us sales hepsera md anderson cancer center see academic consulting relationships tamiflu oseltamivir phosphate tamiflu oral pill treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors act disabling common strains flu virus preventing virus spreading patient used approved treatment influenza tamiflu shown reduce duration flu adults average reduce severity flu symptoms incidence secondary infections taken approved prevention influenza studies shown tamiflu effective preventing development flu tamiflu approved countries treatment influenza including us japan european union treatment influenza children adults tamiflu also approved us european union prevention influenza adolescents adults developed tamiflu roche roche exclusive right manufacture sell tamiflu subject obligation pay us percentage net revenues roche generates tamiflu sales date roche 's sales tamiflu significantly expectations moreover roche experienced problems manufacturing distribution tamiflu reduced net sales royalty based material effect revenues see collaborative relationshipsroche several products available treat flu time shown effective safe neuraminidase inhibitors see competition tamiflu marketed alternative influenza vaccinations believe influenza vaccinations remain effective method preventing flu vistide cidofovir injection vistide antiviral medication treatment cmv retinitis patients aids cmv retinitis condition characterized lesions form patient 's retina affects persons weakened immune systems common patients aids left untreated cmv retinitis lead blindness vistide approved sale us european union several countries demand vistide low product revenues immaterial us commercial team sells vistide us outside us pharmacia exclusive right sell vistide pharmacia pays us percentage revenues generates sales vistide see collaborative relationshipspharmacia active agent vistide cidofovir considered part us government strategy dealing potential bioterrorism attacks involving smallpox lifethreatening highly communicable infectious disease laboratory tests cidofovir demonstrated activity strains virus causes smallpox current clinical trials diluted smallpox vaccine conducted national institute allergy infectious diseases cidofovir considered potential treatment vaccinia infection adverse reaction sometimes caused smallpox vaccine additionally us national institutes health holds ind allows emergency use cidofovir smallpox outbreaks without marketing approval fda know efficacy cidofovir might emergency use side effects may appear use cidofovir smallpox also predict whether us countries ' governments may stockpile vistide treatment smallpoxdaunoxome daunorubicin citrate liposome injection daunoxome liposomal formulation anticancer agent daunorubicin firstline therapy treating patients suffer certain types hivassociated kaposi 's sarcoma disease characterized widely disseminated lesions skin mucous membranes lymph nodes viscera life threatening patients suffering aids daunoxome approved sale us countries sell daunoxome us sell abroad independent distributors demand daunoxome low product revenues immaterial products clinical trials emtricitabine hiv acquired emtricitabine result acquisition triangle completed january nucleoside analogue emtricitabine shown inhibitor hiv hbv replication laboratory studies emtricitabine antiviral agent hiv strains obtained geographically diverse set hivinfected patients laboratory studies shown emtricitabine shares crossresistance patterns lamivudine common resistance mutation two agents also reverses resistance hiv azt cases four phase clinical studies emtricitabine completed one collaboration agence nationale de recherches sur le sida anrs france one studies study ftc compared emtricitabine mg onceaday stavudine mg twiceaday combination didanosine mg onceaday efavirenz mg onceaday patients without previous antiretroviral therapy july study unblinded recommendation independent data safety monitoring board dsmb established provide oversight study interim results evaluated study 's dsmb showed emtricitabine arm statistically superior stavudine arm primary secondary endpoints safety efficacy eightyseven percent patients onceaday emtricitabine arm persistent virologic response six months compared twicedaily stavudine arm patients emtricitabine arm also significant improvements immunologic function view compelling difference favor emtricitabine arm dsmb recommended study unblinded patients offered regimen containing emtricitabine application marketing approval emtricitabine submitted treatment hiv us september european union december applications accepted review us fda advised us date review july emtricitabine hepatitis b emtricitabine shown inhibitor hepatitis b virus replication patients chronically infected hbv currently phase clinical development emtricitabine treatment chronic hepatitis b development activities undertaken emtricitabine treatment hiv also used assessment emtricitabine treatment hepatitis b amdoxovir acquired amdoxovir result acquisition triangle completed january amdoxovir purine dioxolane nucleoside may offer advantages nucleosides currently market activity drug resistant viruses exhibited laboratory studies early triangle initiated two phase clinical trials amdoxovir august fda placed clinical development program amdoxovir partial clinical hold result concerns lenticular opacities possible side effect characterized clouding lens eye extent amdoxovir increased occurrence lenticular opacities patients receiving amdoxovir unknown patients clinical studies benefiting amdoxovir new studies involving patients failed treatments contained drug currently approved class antihiv medications require amdoxovir regimens may continue treatment discussions fda regarding partial clinical hold planned clevudine acquired clevudine result acquisition triangle completed january clevudine pyrimidine nucleoside analogue shown potent inhibitor hepatitis b virus replication laboratory studies november triangle initiated phase studies currently conducting phase clinical trials clevudine treatment chronic hepatitis b chronic toxicology studies completed reproductive toxicology studies progress gs gs novel nucleotide analogue reverse transcriptase inhibitor processed body yields tenofovir activechemical yielded viread within cells chemical composition gs however may allow cross cell membranes easily viread leading greater potency viread first quarter began phase clinical trials gs treatment hiv infection research development research scientists foster city san dimas california durham north carolina engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus areas life threatening infectious diseases total research development rd expenses million compared million million nucleotide analogues scientists working proprietary nucleotide analogues develop treatments viral infections compounds treat viral infections interfering activity certain enzymes necessary virus grow believe small molecule nucleotide analogues offer advantages therapeutics first molecules demonstrated ability work infected uninfected cells could enable us develop drugs treat patient infected virus also prevent healthy person becoming infected first place second drugs developed using molecules shown treatment activity patient longer periods time available drugs could enable us develop drugs require less frequent dosing thus convenient patients hiv protease inhibitors evaluating number small molecule compounds known protease inhibitors potential treatment hiv infection protease inhibitors act interfering activity protease enzyme like reverse transcriptase necessary replication hiv conducted number preclinical experiments compounds demonstrated potent antiviral activity lead candidate gs currently undergoing extensive preclinical evaluations antiviral research undertaking additional research area treatment viral diseases many efforts focus potential targets hiv therapeutic drugs liposomes also scientists focused applying proprietary liposomal drug delivery technology develop safer effective convenient drugs liposomes submicroscopic hollow spheres drugs packed believe research supports belief influence way compounds released distributed body placing liposomes turn improve safety treatment benefits compounds commercial operations us international commercial sales operations marketing subsidiaries united kingdom germany italy spain france portugal greece australia commercial teams promote sell viread hepsera ambisome us viread ambisome europe australia ambisome also sold fujisawa us sell vistide daunoxome us commercial partner pharmacia sells vistide outside us sell daunoxome outside us independent distributors commercial partner roche promotes sells tamiflu everywhere sold commercial teams promote viread hepsera direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv viread chronic hepatitis b hepsera also promote ambisome infectious disease specialists hospitals home health care providers cancer specialists international commercial operations europe australia european commercial team supported medical operational financial regulatory manufacturing human resources personnel located primarily european headquarters paris france us australian commercial teams supported worldwide headquarters foster city california countries outside us agreements thirdparty distributors including distributors certain countries marketing operations promote sell distribute viread ambisome daunoxome international distribution agreements generally provide distributor exclusive right sell viread ambisome daunoxome particular country several countries specified period time january announced program pursuant selling viread cost countries africa countries designated least developed countries united nations taking steps ensure viread product sold program used serve patients developing world diverted markets see international distribution support expand commercialization viread hepsera significantly increased sales force us devoting additional marketing resources us improve coverage healthcare professionals treating hivinfected hbv infected patients also significantly increased size commercial operations europe manage commercialization viread anticipated commercialization hepsera european union current intention retain commercial rights hepsera market directly distributors us canada europe australia new zealand turkey april entered licensing agreement gsk gsk received rights commercialize hepsera asia latin america africa certain territories agreement retained rights hepsera us canada eastern western europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment hepatitis b countries significant include china korea japan taiwan gsk full responsibility development commercialization hepsera territories us viread hepsera vistide returnable original unopened containers one year beyond expiration date damaged received customer customers may return ambisome daunoxome shelf life expired product damaged defective customer receives ambisome approved shelf life months us months european countries daunoxome shelf life weeks us european countries viread shelf life months us european union hepsera shelf life months us additionally certain governmental agency customers state aids drug assistance programs entitled receive discounts required provide rebates state medicaid programs date returns rebates discounts material financial results fujisawa establishes return policy ambisome north america roche establishes return policy tamiflu end flu season significant returns tamiflu roche reduces net sales royalty roche based collaborative relationships part business strategy establish collaborations companies assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring companies products rights products technologies complementary business accounting relationships found note consolidated financial statements included report existing collaborative relationships follows anadys pharmaceuticals inc june entered collaboration anadys pharmaceuticals inc discover novel antiviral compounds addition access fees milestone payments subject limitations gilead pay anadys royalties products developed research collaboration archemix corporation october entered agreement archemix corporation archemix agreement granted archemix exclusive sublicense selex technology identify aptamers subject exclusion development areas rights already granted forfeited rights selex technology derive license us university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation financial terms agreement archemix provide lump sum payments us totaling million archemix made payments also received warrants purchase archemix stock agreement required agreements ulehi shared portion cash payments warrants ulehi see academic consulting relationshipsuniversity license equity holdings incbukwang pharm ind co ltd february triangle entered acquired part acquisition triangle license agreement bukwang pharm ind co ltd bukwang pursuant received exclusive license bukwang 's rights clevudine use hepatitis b field well human antiviral applications license includes countries world except korea license obligated make milestones royalty payments bukwang including annual minimum royalty beginning third year first fda registration granted fdaapproved product incorporating clevudine technology glaxosmithkline april entered licensing agreement gsk giving exclusive rights commercialize hepsera solely treatment hepatitis b asia latin america certain territories addition fees milestone payments contract revenues gsk required pay us percentage revenue generate sales hepsera licensed territories agreement gsk required enter clinical commercial supply agreements gsk would required arrange supply clinical commercial requirements fully burdened cost subject reasonable forecasting ordering procedures agreement gsk expires individual country basis later patent expiration ten years first commercial sale particular country addition gsk right electively terminate agreement months notice gilead subject fee elective termination circumstances early term agreement eyetech pharmaceuticals march entered agreement eyetech pharmaceuticals inc eyetech relating product named macugen developed treatment agerelated macular degeneration amd diabetic macular edema dme gilead invented compound upon macugen based nx using selex technology licensed gilead ulehi see academic consulting relationshipsuniversity license equity holdings inc gilead licensed nx eyetech developed macugen license gilead eyetech required pay us fees milestone payments well percentage revenue generate worldwide sales macugen agreement eyetech expires upon later ten years first commercial sale product developed date last patent expires agreement eyetech granted pfizer sublicense relating macugen december december connection sublicense gilead agreed enter license pfizer terms contained agreement eyetech roche entered collaboration agreement roche granting roche exclusive worldwide rights tamiflu well proprietary influenza neuraminidase inhibitors december received license fees milestone payments roche totaling million relating execution agreement regulatory filings approvals tamiflu roche also funded research development costs tamiflu including reimbursement us million period january december agreement roche responsible pricing manufacturing promoting selling tamiflu worldwide basis pays us percentage net revenues sales tamiflu subject reduction certain defined manufacturing costs agreement roche terminates individual country basis later patent expiration ten years first commercial sale particular country addition roche right terminate agreement entirety individual country basis prior expiration time upon months notice fujisawa entered agreement granting fujisawa exclusive right promote sell ambisome canada primary responsibility promote sell ambisome us gilead copromoter fujisawa pays us approximately fujisawa 's net revenues sales ambisome us reserved right promote sell ambisome rest world pay fujisawa net revenues ambisome sales significant asian markets including japan korea taiwan china india manufacture ambisome sold worldwide sell ambisome fujisawa sale us price equal cost manufacture product sale canada price equal cost manufacture product plus specified percentage agreement fujisawa terminates last patent covering ambisome us japan expires osi pharmaceuticals december sold osi pharmaceuticals osi pipeline clinical stage oncology products related intellectual property well boulder colorado operations consideration assets received osi million cash shares osi common stock additionally osi pay us additional million either cash combination cash osi common stock upon achievement osi certain milestones related development nx advanced oncology product candidates separately manufacturing agreement osi agreed produce osi liposomalformulations two products including nx manufacturing facility san dimas california pharmacia entered agreement pharmacia relating vistide agreement pharmacia exclusive right market sell vistide countries outside us subject payment us percentage net revenues required sell pharmacia bulk vistide maintain vistide patents agreement pharmacia expires individual country basis upon patent expiration ten years first commercial sale countries product covered patent addition pharmacia may terminate agreement whole upon six months notice upon notice individual country basis three months applying marketing approval competitive product sumitomo entered agreement sumitomo gave sumitomo exclusive right develop market ambisome japan addition milestone payments sumitomo required pay us percentage revenue generate japanese sales ambisome ambisome approved sale japan would manufacture ambisome sale sumitomo japan price would charge sumitomo supply ambisome percentage revenues would required pay us would determined price ambisome japan agreement sumitomo terminates later patent expiration japan ten years first commercial sale japan termination agreement cubist pharmaceuticals cidecin september jointly announced cubist pharmaceuticals inc termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin terminated license agreement executed january granted us exclusive commercialization rights products european countries following regulatory approval terms termination agreement owe future payments cubist cubist reacquired european rights products academic consulting relationships supplement research development efforts part regular business enter arrangements universities medical research institutions arrangements often provide us rights patents patent applications technology owned institutions return payments fees relating use rights emory university university georgia research foundation inc emtricitabine april triangle obtained acquired part acquisition triangle exclusive worldwide license emory university 's rights purified forms emtricitabine use hiv hepatitis b fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology us third year first registration granted antihepatitis b product incorporating emtricitabine technology certain major market countries hiv hepatitis b indications respectively triangle began paying license maintenance fees development milestones yet achieved may emory gsk settled litigation pending united states district court relating emtricitabine became exclusive licensee us foreign patents patent applications filed burroughs wellcome co use emtricitabine treat hepatitis b license settlement agreements emory also given access development clinical data drug substance held gsk relating emtricitabine may emory gsk shire pharmaceuticals group plc shire settled worldwide patent disputes involving lamivudine emtricitabine terms settlement emory received exclusive license shire shire 's patents relating emtricitabine methods use manufacture shire gsk received exclusive licenses emory 's patents relating lamivudine terms license agreement emory automatically acquired exclusive sublicense shire patents relating emtricitabine granted terms settlement thereby resolving previously pending patent disputes regarding emtricitabineamdoxovir march triangle entered acquired part acquisition triangle license agreement emory university georgia research foundation inc ugrf pursuant received exclusive worldwide license emory 's ugrf 's rights series nucleoside analogues including amdoxovir dxg ie active antihiv agent use hiv hepatitis b fields obligated make milestone royalty payments emory ugrf march triangle began paying license maintenance fees development milestones yet achieved beginning third year first fda registration granted fdaapproved product incorporating amdoxovir technology required pay emory ugrf minimum annual royalty august triangle resolved outstanding patent disputes involving amdoxovir shire terms settlement emory ugrf received exclusive license shire 's patent rights covering amdoxovir methods use manufacture terms license agreement acquired exclusive sublicense rights exchange obligation pay shire incremental royalty future amdoxovir sales settlement agreement emory ugrf gilead granted shire exclusive license patent rights bch methods use manufacture license agreements emory terminate upon later patent expiration expiration obligation pay royalties addition right terminate agreement entirety respect one indications hiv hbv one countries prior expiration time upon days notice md anderson cancer center entered agreement md anderson cancer center relating hepsera agreement currently pay md anderson cancer center percentage net revenues based upon sales hepsera agreement md anderson cancer center terminates later patent expiration ten years first commercial sale iocbrega entered agreements iocbrega relating viread hepsera vistide agreements received iocbrega exclusive right manufacture use sell nucleotide compounds covered agreements currently pay net revenues based upon sales viread hepsera vistide iocbrega agreements iocbrega terminate individual country basis later patent expiration ten years first commercial sale addition iocbrega may terminate licenses particular product key market absence commercial sales product within months regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi technology holding company university colorado boulder relating selex technology identify aptamers arrangement ulehi granted us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology computer software related selex technology required pay ulehi certain variable royalties based revenues generated sales products derived using selex technology developing world collaborations bill melinda gates foundation family health international october entered agreement bill melinda gates foundation family health international fhi provide viread fhi 's multinational clinical trial evaluating viread 's effectiveness method reducing risk hiv infection among sexually active adults regularly exposed hiv clinical trials conducted fhi funded million threeyear grant gates foundation dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart trial development antiretroviral therapy africa aimed studying clinical versus laboratory monitoring practices structured treatment interruptions versus continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart studythe institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis clinical trial conducted institute one world health partnership world health organization international distribution various agreements distributors europe asia latin america middle east africa grant distributors exclusive right sell ambisome cases daunoxome particular country countries specified period time agreements also provide collaborative efforts us distributor obtaining regulatory approval product particular country marketing product country agreements establish price distributor must pay product require us deliver quantities product ordered distributor entered similar distribution agreements viread countries promote sell directly january announced program pursuant supply viread cost countries africa countries designated least developed countries united nations humanitarian effort recognition extreme impact hiv disease resourcepoor countries world 's cases hiv located countries taking steps ensure viread product sold program used serve patients developing world diverted markets manufacturing ambisome daunoxome manufacture ambisome daunoxome commercial quantities two separate adjacent facilities san dimas california medicines control agency united kingdom fda approved commercial production ambisome daunoxome facility produced import ambisome daunoxome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere use commercially available materials equipment manufacture products currently obtain amphotericin b use manufacture ambisome daunorubicin hcl distearoylphosphatidylcholine use manufacture daunoxome cholesterol use manufacture ambisome daunoxome single approved suppliers ambisome sold freezedried product currently freezedry ambisome san dimas manufacturing facility also use third party freezedry additional product given current projections growth ambisome demand sufficient capacity meet future demand also option installing additional freezedrying capacity san dimas additional supply become necessary prove unable install additional freezedrying capacity san dimas locate appropriate third parties meet need ability meet increased ambisome demand would diminished manufacturing liposomal products particularly complex process new liposomal product develop require unique complex variations manufacturing process antiviral products contract third parties manufacture antiviral drugs clinical commercial purposes including viread hepsera vistide emtricitabine amdoxovir clevudine manufacture viread tablets single contract manufacturer us european union sales distribution territories addition second contract manufacturer europe european union distributed product approved respective agencies obtained qualification us seeking qualification european union two contract manufacturers active ingredient hepsera one contract manufacturer final hepsera drug product commercial supply seeking qualify second supplier january roche announced due production problems liquid suspension form tamiflu approved treatment children young one yearold available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roche 's sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales royalty roche based date production commercialization issues material effect earnings expect material effect earnings future entered agreement abbott manufacture emtricitabine bulk drug substance final drug product us currently seeking qualification abbott us european union contract manufacturer also seeking qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violations current good manufacturing practice regulations cited us fda working towards corrections fda consent decree fda conducted preapproval inspection abbott new drug application emtricitabine issued form observation abbott december january abbott submitted response form observation fda deems abbott 's response form observation inadequate abbott unable supply initial launch quantities emtricitabine timely manner emtricitabine launch could delayed two suppliers approved fda european union manufacture cidofovir used vistide single fda emea approved supplier final vistide drug product commercialscale manufacturing facilities antiviral products current plans establish facilities future antiviral products need develop additional manufacturing capabilities establish additional third party suppliers order manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities products approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct largescale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable believe compliance material environmental regulations related manufacture products patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates us europe primary patents patents may issue pending applications cover compounds marketed products product candidates us patent expiration european patent expiration products viread hepsera ambisome tamiflu vistide daunoxome product candidates emtricitabine amdoxovir clevudine applications patents pending patents applications issue would patent protection dates indicated would instead rely patents expire earlier example european patent viread issue patents expire provide protection patents covering viread hepsera vistide emtricitabine clevudine amdoxovir held third parties acquired exclusive rights patents agreements parties see collaborative relationships academic consulting relationships patents cover active ingredients ambisome daunoxome instead hold patents liposomal formulations compounds also protect formulations trade secrets patent filings covering forms hepsera china certain asian countries although applications pending various asian countries including china relate specific forms formulations hepsera asia major market hbv therapies may obtain patents compounds many years obtain marketing approval limits time prevent companies developing compounds therefore reduces value product however apply patent term extensions example extensions patents vistide granted us number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time including sometimes us patent issues may pending patent applications patents eventually issue prevent us developing selling certain products unless obtain license use patented technology patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developing also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements would adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions competitionour products development programs target number diseases conditions including viral fungal bacterial infections many commercially available products diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases current products compete available products based primarily efficacy safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing products market future also compete products offered competitors competitors introduce data shows improved characteristics products improve increase marketing efforts simply lower price products sales products could decrease also certain products may develop future compare favorably products offered competitors existing future products compare favorably new products developed competitors ability competitive also depends upon ability attract retain qualified personnel obtain patent protection otherwise develop proprietary products processes secure sufficient capital resources substantial period takes develop product viread hiv competitive landscape becoming crowded complicated treatment trends continue evolve growing number antihiv drugs currently sold advance stages clinical development branded drugs available us zerit stavudine dt sold bristolmyers squibb bms fixed combination products combivir azt tc trizivir azt tc abc sold gsk represent direct competition viread companies process launching formulations existing drugs indicated fda oncedaily oral dosing include gsk 's mg dose epivir tc bms 's new extended release formulation zerit antiretroviral product candidates expected enter market next years include atazanivir qd protease inhibitor bms fuzeon injectable integrase inhibitor rochetrimeris gsk also pursuing oncedaily dose ziagen abacavir well new fixed dose combination ziagen epivir companies competing hiv therapeutic category pfizer merck boehringeringelheim abbott laboratories ambisome ambisome faces strong competition several current expected competitors current competitors include conventional amphotericin b made bms numerous generic manufacturers caspofungin product developed merck marketed cancidas us caspofungin elsewhere voriconazole developed pfizer marketed vfend lipidbased amphotericin b products approved us throughout europe including abelcet sold enzon corp us canada japan elan corporation 's marketing distribution partners countries amphotec sold intermune pharmaceuticals inc presently unapproved expected competitors include class treatments called echinocandins including fujisawa 's micafunginwhich received marketing approval japan october submission regulatory approval us canada anidulafungin versicor inc product candidate evaluated multiple latestage clinical trials finally schering plough developing noxafil posaconazole currently phase trials competition current expected competitors eroded likely continue erode revenues receive sales ambisome hepsera hepsera faces significant competition existing therapies treating patients infected hbv significantly epivirhbv lamivudine developed collaboration shire pharmaceuticals sold gsk major countries throughout north south america europe asia orally administered nucleoside analogue inhibits hbv dna polymerase introna interferon alfab sold schering plough major countries throughout north south america europe asia introna injectable drug immunomodulatory effects hepsera also faces competition clinicalstage candidates including bristolmyers squibb 's entecavir idenix 's ldt two oral nucleoside analogues currently phase trials competition includes roche 's pegasys pegylated interferon alfaa currently studied chronic hepatitis b tamiflu tamiflu competes relenza antiflu drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder addition biocryst pharmaceuticals developing neuraminidase inhibitor antiflu drug peramivir represent significant competition fda approves drug may administered oncedaily pill opposed tamiflu must taken twice daily treatment certain tamiflu compare favorably drug based performance price length dosing side effects criteria vistide vistide competes number drugs also treat cmv retinitis including ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valganciclovir also marketed roche foscarnet intravenous drug sold astrazeneca formivirsen drug injected directly eye sold cibavision daunoxome daunoxome competes expected compete number drugs approved awaiting approval treatment kaposi 's sarcoma us europe including doxil product ortho biotech like daunoxome sold liposomal formulation number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products government regulation operations activities subject extensive regulation numerous government authorities us countries us drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval process expensive time consuming fda must approve drug sold us general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data tosupport drug 's potential safety benefits submit data fda investigational new drug application ind seeking approval test compound humans clinical trials fda accepts investigational new drug application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase compound appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase clinical trials fail rigorous reliable phase clinical trials fda approval process believe data phase clinical trials show adequate level safety effectiveness file new drug application nda fda seeking approval sell drug particular use fda review nda often hold public hearing independent advisory committee expert advisors asks additional questions regarding drug committee makes recommendation fda binding fda generally followed fda fda agrees compound required level safety effectiveness particular use allow us sell drug us use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials conducting including viread emtricitabine hiv infection hepsera chronic hepatitis b conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require us complete additional testing provide additional data information improve manufacturing processes procedures facilities require extensive postmarketing testing surveillance monitor safety benefits product candidates determine new drug application contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug approvals also withdrawn fda believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug manufacturing facilities drug sell including companies manufacture drugs us well must approved fda subject periodic inspections fda foreign establishments manufacture products sold us must also approved fda subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs may designated fast track products fda may eligible priority six month review accelerated approval case viread drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penaltiesdrugs also subject extensive regulation outside us european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used decentralized system approval one country european union used obtain approval another country european union simplified application process approval centralized procedure pricing reimbursement approvals also required countries vistide viread approved european union centralized procedure viread hiv drug reviewed accelerated approval european union hepsera received traditional review emtricitabine pricing reimbursement insurance companies health maintenance organizations hmos thirdparty payors governments seek limit amount charge drugs example certain foreign markets pricing negotiations often required obtain approval product us expect continue number federal state proposals implement drug price control addition managed care organizations becoming common us continue seek lower drug prices announcement proposals efforts cause stock price lower proposals adopted revenues could decrease ability sell drugs also depends availability reimbursement governments private insurance companies governments insurance companies often demand rebates predetermined discounts list prices expect products developing particularly aids indications subject reimbursement issues certain products obtain regulatory approval reimbursed government insurance companies regulatory approval prices generally required foreign countries particular certain countries condition approval product agreement seller sell product certain price country past required price reductions connection product approval certain regulatory authorities future establish lower prices regulatory action reducing price products one country practical effect requiring us reduce prices countries european governments notably germany italy implemented considering legislation would require pharmaceutical companies sell products subject reimbursement mandatory discount mandatory discounts would reduce revenue receive drug sales certain developing countries significantly affected hiv aids parallel importing generic competition may occur adversely affect revenues sales market share viread management changes march announced john f milligan phd promoted senior vice president chief financial officer reporting directly ceo part restructuring combined responsibility corporate functions support strategic financial communications technological planning broadened senior management role corporate development finance corporate communications information technology groups centralized leadership dr milligan addition announced time completion organization changes including alignment manufacturing group san dimas operational areas reporting mark l perry executive vice president operations establishing paris france headquarters european operations employees february approximately fulltime employees believe good relations employees website website address wwwgileadcom make available free charge website annual report quarterly reports form q current reports form k amendments reports soon reasonably practicable filing providing hyperlink edgar website directly reports risk factors affect gilead evaluating business carefully consider following risks addition information report following risks could materially adversely affect business operating results financial condition viread maintain increase market acceptance results operations suffer rely sales viread significant portion operating income viread faces extremely competitive marketplace anumber drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among companies significant competitors hivaids market gsk bristolmyers squibb roche pfizer merck boehringeringelheim abbott laboratories competitors potential competitors substantially greater resources resources include greater experience promoting marketing hiv drugs superior product development capabilities financial scientific manufacturing marketing managerial human resources order viread continue success maintain expand position marketplace competitors ' drugs viread 's market penetration may limited particularly use treatmentnave patients given data data supporting marketing approvals reflects use viread treatmentexperienced patient population although obtained data safety efficacy viread treatmentnave patients regulatory authorities may allow us include data labeling viread marketing efforts unsuccessful include information viread 's use treatmentnave patients viread 's labeling data may unsuccessful convincing physicians prescribe viread treatmentnave patients government reimbursers private insurance companies may pay viread prescribed patients prior hiv therapy viread maintain increase market acceptance results operations suffer significant reduction viread ambisome hepsera sales would significantly reduce operating income could require us scale back manufacturing operations reduce sales force viread product sales years ended december million million total revenues respectively expect product sales viread constitute substantial part total revenues foreseeable future ambisome sales years ended december million million million total revenues expect revenues sales ambisome continue provide material portion total product revenues hepsera product sales began september year ended december approximately million total revenues expect product sales hepsera constitute substantial part total revenues foreseeable future accordingly foreseeable future expect continue rely heavily sales viread ambisome hepsera support existing manufacturing sales infrastructure provide operating income fund significant portion administrative research development expenditures significant reduction sales viread ambisome hepsera whether result introduction competitive products otherwise would hurt business would scale back manufacturing operations reduce sales force safety issues arise marketed products could significantly reduce limit sales adversely affect results operations data support marketing approvals products including viread ambisome hepsera form basis safety warnings product labels obtained controlled clinical trials limited duration case viread limited post approval use following approval products used longer periods time many patients taking numerous medicines underlying health problems monitored dosing compliance new safety issues reported postmarketing use rule contributory role products may required provide additional warnings labels narrow approved indications could reduce market acceptance products example observe kidney toxicity clinical trials viread kidney toxicity reported postapproval use viread viread label updated include warning serious safety issues marketed products arise could face potential product liability claims sales products could halted us regulatory authorities similarly discontinued development adefovir dipivoxil mg treatment hiv infection due safety benefit concerns arising studies doubleblind placebo controlled studies adefovir dipivoxil mg demonstrated safety efficacy treatment patients chronic hepatitis b studies shown adefovir dipivoxil significantly effective hbv hiv allowing us use lower dose mg adefovir dipivoxil hepsera used treatment hiv infection mg dose adefovir dipivoxil used hepsera hasnot associated significant kidney toxicity clinical trials date patients preexisting kidney problems taking drugs known cause kidney toxicity fda granted marketing approval hepsera certain results phase clinical studies hepsera demonstrate satisfaction regulatory agencies including european union hepsera safe effective treatment chronic hepatitis b hepsera new drug may gain significant market acceptance hepsera new drug faces competitive marketplace currently two drugs sold us treatment chronic hepatitis b potential drugs late stages clinical development competitors potential competitors substantially greater resources resources include greater experience promoting marketing pharmaceuticals including hbv drugs superior product development capabilities greater financial scientific manufacturing marketing managerial human resources order hepsera successful establish marketplace competitors ' drugs early determine hepsera achieve significant market acceptance welldeveloped market generally accepted treatment strategy hepatitis b never marketed sold drug treatment chronic hepatitis b might successful may able develop therapeutic market effectively long term use hepsera may reveal safety issues development resistance hepsera patients marketing efforts unsuccessful hepsera turns safety resistance issues may unsuccessful convincing physicians prescribe hepsera patients government reimbursers private insurance companies may pay hepsera hepsera gain significant market acceptance expected future results operations suffer fiscal year first full year operating profitability may able maintain profitability sustainable basis never profitable operating basis full year may continue profitable future expect merger triangle reduce earnings effect earnings increase earnings although certain estimates correct december accumulated deficit approximately million losses resulted principally expenses associated research development programs lesser extent sales general administrative expenses operating results may adversely affected reduced sales products increased marketing development expenses acquisitions products companies triangle unprofitable time acquisition result risks described report develop drugs treat hiv infection aids related conditions therefore changes regulatory commercial environment hiv infection aids therapies could harm business several products products development address hiv infection aids related conditions products include viread emtricitabine hiv infection aids vistide cmv retinitis daunoxome hivassociated kaposi 's sarcoma develop products based upon current policy current marketplace hiv infection aids therapies well prediction future policy future marketplace therapies business subject substantial risk policies markets change quickly unpredictably ways could impair ability maintain regulatory approval commercial acceptance products operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay commercialization products products develop must approved marketing sale regulatory authorities subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials ambisome viread hepsera currently approved additional uses anticipate conduct variety clinical trials file marketing approval additional products next several years products may fail receive marketing approval timely basis certain hepsera approved european union regulatory authorities countries us whether hepsera receive marketing approvals countries significant limitations placed use certain emtricitabine approved us european union whether marketing approvals significant limitations use also certain able obtain regulatory approvals necessary expand commercial efforts new markets failures delays limitations well regulatory changes actions recalls could delay commercialization products adversely affect results operations addition even products marketed products manufacturers subject continual review later discovery previously unknown problems products manufacturing production thirdparty manufacturers may result restrictions products manufacture products including withdrawal products market fail comply withapplicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution results clinical trials uncertain may support regulatory approval products required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials order obtain regulatory approval products results preclinical early clinical studies always accurately predict results later largescale clinical trials several reasons including preliminary results may indicative effectiveness clinical trials may achieve desired result clinical trials may reveal unduly harmful side effects may show drugs less effective drugs delivery systems desired indications even successfully completed largescale clinical trials may result marketable products several reasons including potential products shown safe effective regulatory authorities disagree results design studies trials potential products difficult develop commercially viable products number companies industry suffered setbacks advanced clinical trials despite promising results earlier trials end may unable develop additional marketable products delays enrolling patients developing suitable protocols clinical trials could increase costs delay regulatory approvals rate completion clinical trials depend rate patient enrollment substantial competition enroll patients clinical trials drugs development competition delayed clinical trials past addition recent improvements existing drug therapy particularly hiv hepatitis b may make difficult us enroll patients clinical trials patient population may choose enroll clinical trials sponsored companies choose alternative therapies delays planned patient enrollment result increased development costs delays regulatory approvals clinical trials must carried protocols acceptable regulatory authorities committees responsible clinical studies sites studies conducted may delays preparing protocols receiving approval may delay either start finish clinical trials addition feedback regulatory authorities results earlier stage clinical studies might require modifications delays later stage clinical trials types delays result increased development costs delayed regulatory approvals approximately half product sales occur outside us currency fluctuations may impair financial results significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar equivalent sales negatively impact financial condition results operations effective january began use foreign currency forward contracts hedge percentage forecasted international sales primarily denominated euro currency also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currency denominated accounts payable although use forward contracts reduce impact foreign currency fluctuations future results certain efforts successful fluctuations could adversely affect results operations face credit risks international accounts receivable subject credit risk accounts receivable related european product sales european product sales government owned supported customers greece spain portugal italy subject significant payment delays due government funding reimbursement practices significant changes occur reimbursement practices european governments government funding becomes unavailable financial position results operations would adversely affectedproduct development expenses cause operating expenses fluctuate quarter quarter clinical trials required regulatory approval products extremely expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected activity programs causes operating results fluctuate quarter quarter depend relationships companies sales marketing performance revenues failure maintain relationships would negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance include collaborations fujisawa sumitomo ambisome gsk hepsera roche tamiflu pharmacia vistide certain countries rely international distributors sales ambisome viread european countries intend rely international distributors sales hepsera relationships also involve clinical development products partners reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products including viread hepsera ambisome tamiflu could decline january roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roche 's sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales royalty roche based april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories including asia africa latin america include major markets hepsera china japan taiwan korea success hepsera territories depend almost entirely efforts gsk receive royalties gsk equal percentage net sales made gsk gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera may substantially reduced existing products products development may accepted physicians insurers patients ability products achieve sustain market acceptance countries approved marketing depend scope regulatory approvals whether government authorities managed care organizations adequately reimburse patients use products addition need convince medical patient advocacy community effectiveness products treating disease safety products administered patients advantages products competitive products physicians patients patient advocates payors medical community general may accept use products may develop products accepted results operations suffer many companies targeting diseases conditions competitive products companies could significantly reduce market acceptance products products development programs target number diseases conditions including viral infections fungal infections many commercially available products diseases certain products wellestablished therapies generated substantial sales addition large number companies institutions conducting wellfunded research development activities directed developing treatments diseases products currently market development competitors could make technology products obsolete noncompetitive expect competition treatment diseases increase future new products enter market advanced technologies become available also competing license acquire technology companies plan supply viread cost certain developing countries reduce viread 's gross profit margin could give rise unforeseen liabilities launching distribution program pursuant supply viread cost countries africa countries designated least developed countries united nations receive profit viread supply program reduce viread product 's gross profit margin amount reduction depend upon volume viread flows program predict certainty additionally supply distribution drugs resourcepoor environment complicated undertaking program develops could face unforeseen challenges risks could give rise unforeseen liabilities existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide daunoxome significant percentage sales viread hepsera subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general us recent years new legislation proposed federal state levels would effect major changes health care system either nationally state level proposals included prescription drug benefit proposals medicare beneficiaries introduced congress although us federal reform legislation states enacted health care reform legislation federal state developments possible although predict exact nature legislative health care reforms results operations could adversely affected reforms europe success hepsera approved sale tamiflu viread also depend largely obtaining maintaining government reimbursement europe many european countries including united kingdom france patients reluctant pay prescription drugs pocket also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis addition many international markets governments control prices prescription pharmaceuticals markets regulatory marketing approval received pricing negotiations governmental authorities take another six twelve months longer sales competing products attempts gain market share introductory pricing programs competitors could also require us lower prices countries could adversely affect results operations foreign governments passed considering legislation require us sell products subject reimbursement mandatory discount product revenues could reduced imports countries products available lower pricesour sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world exported european countries could resold much higher prices happens products particularly viread agreed provide cost countries africa countries designated least developed countries united nations revenues would adversely affected addition european union required permit cross border sales allows buyers countries government approved prices products relatively high purchase products legally countries must sold lower prices crossborder sales adversely affect revenues may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others rights us foreign issued patents filed continue file patent applications us abroad relating technologies risk however patents may issue applications patents sufficient protect technology patent applications confidential least period time sometimes us patent issues result may know competitors filed patent applications technology covered pending applications also certain first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera although applications pending various asian countries relate various forms formulations adefovir dipivoxil asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale commercial value product may limited addition patents may provide adequate protection certain countries africa asia including china competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even successful success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties certain would able obtain alternative technologies required license even obtain technologies licenses certain terms would reasonable fail obtain licenses alternative technologies may unable develop commercialize products addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors countries may required grant compulsory licenses hiv products face generic competition hiv products number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost cases governmental authorities indicated pharmaceutical companies patents might enforceable prevent generic competition major pharmaceutical companies greatly reduced prices hiv drugs certain developing countries certain countries permit enforcement patents sales viread countries could reduced generic competition alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions viread countries thereby reducing viread sales could respond governmental concerns reducing prices viread situations results operations could adversely affected manufacturing problems could delay product shipments regulatory approvalswe depend third parties perform manufacturing obligations effectively timely basis third parties fail perform required could impair ability deliver products timely basis cause delays clinical trials applications regulatory approval events could harm competitive position viread hepsera vistide rely third parties manufacture bulk drug substance final drug product clinical commercial purposes example roche responsible manufacturing tamiflu january roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roche 's sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales royalty roche based additionally emtricitabine seeking qualification abbott us european union contract manufacturer bulk drug substance final drug product also seeking qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violations current good manufacturing practice regulations cited fda working towards corrections fda consent decree fda conducted preapproval inspection abbott new drug application emtricitabine issued form observation abbott december january abbott submitted response form observation fda deems abbott 's response form observation inadequate abbott unable supply initial launch quantities emtricitabine timely manner emtricitabine launch could delayed manufacture ambisome daunoxome facilities san dimas california formulation manufacturing facilities san dimas california although manufacturing facility ireland performs certain quality control testing labeling packaging use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome daunoxome meet market needs may able obtain materials necessary manufacture products many materials utilize operations made one facility example depend single suppliers high quality amphotericin b daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products suppliers key components materials must named new drug application filed fda product significant delays occur qualification new supplier required supplies suppliers interrupted reason may unable ship viread ambisome hepsera vistide daunoxome supply products development clinical trials limited experience manufacturing existing products may need develop additional manufacturing capacity products potential future products potential products development need develop production technologies use larger scale order conduct clinical trials produce products commercial sale acceptable cost certain able implement developments successfully manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations fda 's current good manufacturing practices extensive regulations governing manufacturing processes stability testing recordkeeping quality standards addition manufacturing operations subject routine inspections regulatory agencies similar regulations effect countries business may give rise product liability claims covered insurance indemnity agreements testing manufacturing marketing use viread ambisome hepsera tamiflu vistide daunoxome well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others successful product liability claim us could require us pay substantial amounts could impair financial condition ability clinically test market productsadditionally required governmental regulations test products even sold used patients result tests may required may determine recall products already market subsequent testing product recalls may increase potential exposure product liability claims internal research programs efforts obtain rights new products third parties may yield potential products clinical development long term success depends ability either identify internal research programs potential product candidates may developed new pharmaceutical products obtain new products product candidates licenses third parties significant portion research conduct involve new unproven technologies research programs identify product candidates require substantial technical financial human resources whether candidates identified research programs may appear promising route identifying potential product candidates yet fail yield product candidates clinical development number reasons including research methodology used may successful identifying potential product candidates potential product candidates may study shown unduly harmful side effects characteristics indicate unlikely effective drugs may unable develop larger scale manufacturing methods efficient costeffective capable meeting stringent regulatory standards others may hold intellectual property rights prevent us developing making selling certain products may unable obtain suitable product candidates products third parties number reasons including may unable purchase license compounds terms would allow us make appropriate return product competitors may unwilling assign license product rights us may unable identify suitable products product candidates within areas expertise product candidates acquire may approved regulatory authorities due problems safety effectiveness unable develop suitable potential product candidates internal research programs obtain rights new products third parties future revenue growth suffer use hazardous materials chemicals viruses radioactive compounds exposes us potential liabilities research development involves controlled use hazardous materials chemicals viruses various radioactive compounds although believe safety procedures handling disposing materials comply standards prescribed state federal regulations completely eliminate risk accidental contamination injury materials event accident could held liable significant damages fines risks related triangle acquisition january emtricitabine may receive marketing approval single agent could prevent delay commercial sale co formulation viread emtricitabine submitted applications marketing approval emtricitabine treatment hiv infection us european union ability obtain marketing approval coformulation viread emtricitabine depend emtricitabine receiving marketing approval single agent treatment hiv infection regulatory authorities us european union countries may grant marketing approval emtricitabine conclude safe efficacious intended use addition regulatory authorities european union require new products sufficient efficacy safety advantages currently marketed products extensive preclinical toxicity data authorities may conclude emtricitabine approvable single agent emtricitabine similar chemical level epivir gsk 's lamivudine product already marketed treatment hiv infection andavailable data indicates products comparable safety efficacy profiles emtricitabine receive marketing approval single agent may unable obtain marketing approval coformulation viread emtricitabine may conduct lengthy expensive clinical trials coformulation order obtain approvals proposed coformulation viread emtricitabine may technically possible may effective safe may approved regulatory authorities intend develop commercialize coformulation viread emtricitabine achieving anticipated synergies potential benefits coformulation significant motivations behind merger triangle depend successfully creating obtaining marketing approval coformulation viread emtricitabine expect emtricitabine receives marketing approval major requirement obtaining marketing approval coformulation viread emtricitabine would clinical study showing coformulation emtricitabine viread biologically equivalent emtricitabine viread administered together separate formulations need chemistry manufacturing bioequivalence package shows coformulated tablet gives exposure viread emtricitabine two drugs given individually uncertain whether possible bring co formulation market emtricitabine approved marketing regulatory authorities may approved might require additional clinical trials order obtain regulatory approval addition physical combination emtricitabine viread may technically feasible costeffective even two drugs coformulated regulatory authorities may approve coformulation may require additional clinical trials granting marketing approval requirement clinical trials delay failure developing commercializing coformulation emtricitabine viread would material adverse effect business financial condition results operations successfully integrate triangle operations business adversely affected integrating gilead triangle complex timeconsuming process prior merger gilead triangle operated independently business corporate culture locations employees systems gilead triangle operate combined organization begin utilizing common information communication systems operating procedures financial controls human resource practices including benefits training professional development programs may substantial difficulties costs delays involved integration gilead triangle may include distracting management business combined company potential incompatibility corporate cultures potential inability coordinate research development efforts successfully costs delays implementing common systems procedures operating combined company three sites us nine international sites one factors may increase operating costs lower anticipated financial performance addition combined company may lose corporate partners distributors suppliers manufacturers employees many factors also outside control company achieving anticipated synergies potential benefits underlying two companies ' reasons merger depend successful integration two companies failure integrate gilead triangle successfully would material adverse effect business financial condition results operations unable manufacture emtricitabine successfully reasonable cost potential future results could suffer manufactured emtricitabine familiar manufacturing process emtricitabine completion merger triangle responsible making arrangements obtain supplies emtricitabine third party anticipated commercial launch following receipt marketing approvals us european union triangle made adequate arrangements supplies supply problems third party manufacturers emtricitabine may sufficient supplies emtricitabine meet commercial demand case future results could suffer triangle entered agreement abbott abbott agreed manufacture emtricitabine bulk drug substance final drug product us transfer manufacturing technology emtricitabine third party manufacturers rely abbott third parties manufacture emtricitabine period time seeking qualification abbott us european union contract manufacturer abbott recent history violations current good manufacturing practice regulations cited fda working towards corrections fda consent decree fda conducted preapproval inspection abbott new drug application emtricitabine issued form observation abbott december january abbott submitted response form observation depend abbott perform obligations effectively timely basis fda deems abbott 's response form observation inadequate abbott unable supply initial launch quantities ofemtricitabine timely manner timing emtricitabine launch could impacted event could harm competitive position new manufacturers emtricitabine would also approved regulatory authorities delays approval may rely abbott emtricitabine supplies longer period currently anticipated costs supplies emtricitabine third party manufacturers unacceptably high results operations would suffer able arrange manufacture emtricitabine lower cost manufactured emtricitabine sure emtricitabine manufacturing costs reduced acceptable level profitability depend part upon triangle 's operations incurred losses since triangle 's inception triangle incurred losses since inception december accumulated deficit approximately million triangle 's losses resulted primarily expenses associated acquisition development drug candidates general administrative costs triangle generated revenue sale product candidates date expecting triangle 's operations may never generate significant revenue achieve profitability trading price securities could subject significant fluctuations trading price common stock volatile may volatile future factors announcements fluctuations competitors ' operating results changes prospects market conditions biotechnology stocks general could significant impact future trading prices common stock particular trading price common stock many biotechnology companies including us experienced extreme price volume fluctuations times unrelated operating performance companies whose stocks affected factors may cause volatility price securities include clinical trial results regulatory developments quarterly variations results business product market cycles fluctuations customer requirements availability utilization manufacturing capacity timing new product introductions ability develop implement new technologies price securities may also affected estimates projections investment community general economic market conditions cost operations product markets predict individual effect factors may price securities factors either individually aggregate could result significant variations price given period time assurance factors adverse effect trading prices common stock item properties corporate headquarters including principal executive offices research facilities located foster city california location lease approximately square feet space eight proximately located buildings one leases covering approximately square feet space group buildings expires december renewal options remaining leases expire march september option renew leases two additional fiveyear periods also occupy facilities san dimas california location lease approximately square feet space houses research development activities manufacturing certain administrative functions leases expire may november two fiveyear renewal options addition lease adjacent warehouse facility square feet space use product distribution administrative functions lease expires april two additional fiveyear extensions durham north carolina lease approximately square feet administrative office laboratory space sublease approximately square feet third parties lease expires september currently negotiations lessor another lease term addition lease approximately square feet space sales marketing regulatory finance information technology human resource operations europe australia including prepaid year lease square foot manufacturing distribution facility ireland leases various expiration dates believe facilities adequate suitable least current nearterm future needs item legal proceedings reached settlement elan corporation plc successor company liposome company companies agreed dismiss legal proceedings involving ambisome terms initial settlement agreement made initial payment elan million agreed make additional royalty payments based ambisome sales recorded million accounting charge accrued litigation settlement expenses representing net present value future minimum payments required make june entered agreement elan terminating remaining ambisome payment obligations initial settlement agreement exchange payment elan million november ulehi notified us ulehi believes gilead materially breached licensing agreement ulehi concerning selex technology identify aptamers amongst things assigning rights agreement without ulehi 's consent contest ulehi 's allegations met ulehi regarding allegations actively engaged negotiations settle disagreement negotiations prove unsuccessful ulehi chooses terminate ulehigilead agreement arbitration concerning termination would likely result unfavorable outcome arbitration could give rise award us monetary damages adverse remedies possibly including conveyance ulehi gilead 's rights obligations ulehi licensing agreement sublicenses also party various legal actions arose ordinary course business believe legal actions significant impact business item submission matters vote securities holders matters submitted vote securities holders quarter ended december part ii item market registrant 's common stock related stockholder matters common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception anticipate paying foreseeable future december issued million convertible senior notes due december private offering goldman sachs co resold notes qualified institutional investors net proceeds approximately million following table provides certain information respect equity compensation plans effect end fiscal year ended december shares thousands equity compensation plan information number common shares number common remaining available shares weightedaverage issuance equity issued upon exercise price compensation plans exercise outstanding excluding securities outstanding options options warrants reflected warrants rights rights column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes approximately million shares issuable gilead 's employee stock purchase plan see note consolidated financial statements item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues total costs expenses income loss operations gain sale oncology assets income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible debt accumulated deficit total stockholders ' equity completed sale oncology assets related technology osi pharmaceuticals inc recorded non operating gain million also recorded nonoperating gain million sale percent interest proligo gilead sold shares osi common stock recognized loss sale marketable securities million shares partial consideration sale oncology assets gilead sciences inc selected consolidated financial data continued thousands except per share data prior period restated reflect merger nexstar pharmaceuticals inc july accounted pooling interests gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle effective first quarter gilead adopted sec 's staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle cash dividends declared paid common stock item management 's discussion analysis financial condition results operations overviewgilead incorporated delaware june biopharmaceutical company focused discovery development commercialization antivirals antibacterials antifungals treat lifethreatening infectious diseases multinational company revenues six approved products marketing operations ten countries currently market viread tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection antifungal agent daunoxome daunorubicin citrate liposome injection drug approved treatment kaposi 's sarcoma vistide cidofovir injection treatment cmv retinitis roche markets tamiflu oseltamivir phosphate treatment influenza collaborative agreement us seeking add existing portfolio products clinical development programs internal discovery programs active product acquisition inlicensing strategy acquisition triangle completed january internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing products treat hiv hbv infections also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective december completed sale oncology assets osi pharmaceuticals inc transaction valued million cash osi stock transaction allow us focus continue strengthen core expertise infectious diseases see note consolidated financial statements information year ended december gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities resulted cumulative effect change accounting principle year ended december gilead adopted securities exchange commission 's staff accounting bulletin revenue recognition financial statements also resulting cumulative effect change accounting principle certain prior period amounts reclassified conform current presentation forwardlooking statements risk factors following discussion contains forwardlooking statements involve risks uncertainties gilead 's actual results could differ materially discussed forwardlooking statements factors could cause contribute differences include limited discussed section well caption business including risk factors affect gilead part forwardlooking statements included document based information currently available gilead include effect acquisition triangle guidance unless specifically noted since still evaluating detailed financial impact triangle 's operations consolidated financial statements assume obligation update forwardlooking statements following discussion read conjunction consolidated financial statements notes included elsewhere report viread sales rely sales viread significant portion operating income number drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among companies significant competitors hivaids market gsk bms roche pfizer merck boehringeringelheim abbott laboratories given broad range competitors depth resources viread 's market penetration may limited particularly use treatmentnave patients given data supporting viread 's us approval treatmentexperienced patient population ambisome sales also rely sales ambisome significant portion operating income lower priced products compete ambisome two products compete ambisome recently approved us european union products developed could compete ambisome future antifungal products achieve market acceptance antifungal products development become commercially available revenues sales ambisome would likely decrease resulting reduction operating income acquisition integration january completed acquisition triangle acquisition carries inherent risks may able successfully integrate triangle operations obtain anticipated synergies cost savings may also unsuccessful obtaining marketing approval emtricitabine developing coformulated product failure successfully integrate triangle operations business obtain marketing approval emtricitabine could adversely affect financial position results operations market acceptance products ability products achieve sustain market acceptance depend number factors including receipt scope regulatory approvals availability public private insurance reimbursement products safety efficacy tolerability cost products ease administration dosing products compare competitive products products achieve sustain market acceptance results operations suffer regulatory process us food drug administration foreign agencies could reject limit commercialization products number reasons including disagree results designs clinical trials believe products haveunacceptable efficacy toxicity tolerability believe products manufactured commercial basis compliance applicable safety quality standards agencies reject limit commercialization products financial results would adversely affected clinical trials required regulatory approval products extremely expensive difficult us accurately predict control amount timing expenses quarter quarter addition regulatory agencies could require us conduct additional unanticipated clinical trials products cost could substantial governmental legislation reimbursement programs regulatory legal legislative issues may adversely affect pricing sales products us federal legislation lowers price products purchased reimbursed federal agencies states enacted legislation lower prices products addition growing number us federal state legislative proposals enacted would lower price products many countries outside us government sponsored health care programs set lower drug prices patient reimbursement levels sales countries relatively higher prices may reduced products imported countries lower price markets particular concern european union required permit cross border sales could concern us legislation easing import restrictions enacted applied international credit risk subject credit risk accounts receivable related european product sales european product sales government owned supported customers greece spain portugal italy subject significant payment delays due government funding reimbursement practices significant changes occur reimbursement practices european governments government funding becomes unavailable financial position results operations would adversely affected compulsory licensing generic competition number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost cases governmental authorities indicated pharmaceutical companies patents might enforceable prevent generic competition major pharmaceutical companies greatly reduced prices hiv drugs certain developing countries certain countries permit enforcement patents sales viread countries could reduced generic competition alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions viread countries thereby reducing viread sales could respond governmental concerns reducing prices viread situations results operations could adversely affected collaborations depend collaborations development commercialization certain products revenue including collaboration fujisawa sales ambisome us canada collaboration gsk clinical regulatory development commercialization hepsera asia latin america certain territories collaboration roche sales tamiflu worldwide may also seek additional collaborations collaborations could fail number reasons including partners devote sufficient resources development commercialization marketing products disputes arise partners existing collaborations fail financial results would adversely affected foreign currency fluctuations significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition prior january hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency hedge portion accounts receivable balances denominated foreign currencies minimizes eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currency denominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable uncertain financial results expect financial results continue fluctuate quarter quarter fluctuations may substantial fluctuations caused many factors beyond control including risk factors listed december accumulated deficit million critical accounting policies estimates gilead 's discussion analysis financial condition results operations based upon consolidated financial statements prepared accordance accounting principles generally accepted united states preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis evaluate estimates including related revenue recognition bad debts inventories accrued clinical preclinical expenses contingencies base estimates historical experience various market specific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates gilead believes following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements record estimated reductions revenue expected returns expired products medicaid reimbursements customer incentives cash discounts prompt payment estimates medicaid reimbursements cash discounts based contractual terms expectations regarding utilization rates programs estimates product returns including new products based ongoing analysis industry historical return patterns expected returns marketed drugs generally low shelf life products ranges months viread months ambisome us conditions become competitive markets served drugs circumstances change may take actions increase product return estimates may offer additional customer incentives would result incremental reduction future revenue time return estimate changed incentives offered also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required write inventory based quality control reviews individual raw material batches generally maintain inventory reserves based estimated obsolescence risk competition primarily shelf life products long however current assumptions future demand competition change actual market conditions less favorable projected management additional inventory reserves may required record accruals estimated clinical preclinical study costs costs significant component research development expenses management accrues costs clinical studies performed contract research organizations based estimates generally work upfront costs remaining activity occurring straightline basis life individual contract study estimate may may match actual services performed organizations determined patient enrollment levels related activities monitor patient enrollment levels related activity extent possible however management underestimated activity levels associated various studies given point time would record additional research development expenses future periods could significant results operations revenues total revenue million million million included total revenue net product sales royalty income contract revenue including revenue research development rd manufacturing collaborations net product sales revenue million compared million million product sales increased compared primarily due significant increases sales viread approved sale us october european union february significant percentage gilead 's product sales continue denominated foreign currencies prior hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january began use forward contracts hedge percentage forecasted international sales reduce eliminate fluctuations sales due changes foreign currency exchange rates primarily denominated euro currency losses revenue hedges reduced product revenues million sales viread million total product sales compared million total product sales viread sales million us sales million international sales continued market expansion viread expect viread sales approximately double range million million sales ambisome million increase ambisome sales million sales ofambisome million prior revenues primarily derived sales ambisome represented total product sales total product sales total product sales excluding impact foreign currencies relative us dollar ambisome sales grew year ended december comparable period increase sales compared primarily due volume sales increases europe offset declining sales us increase sales compared primarily due volume price increases us europe addition excluding impact decline foreign currencies relative us dollar sales ambisome would increased expected increase competition expect ambisome sales lower range million million recorded royalty revenue million compared million million three year period significant source royalty revenue sales ambisome us fujisawa copromotion arrangement us royalty revenue fujisawa million compared million million also recorded royalty revenue million million million related sales tamiflu tamiflu orally administered compound developed treat prevent viral influenza humans gilead codeveloped tamiflu roche owns worldwide commercial rights tamiflu required pay us royalty net sales product began recognizing royalties tamiflu first quarter june roche received european regulatory approval tamiflu treatment influenza adults children prevention adolescents adults difficult estimate third party product sales record royalty revenue one quarter arrears total contract revenue million compared million million primary source contract revenue licensing selex process patent estate archemix due collectibility concerns recognized cash basis provided million contract revenue million roche made milestone payments million european prophylaxis treatment approvals tamiflu made million milestone payment relating development tamiflu rd collaboration agreement contract revenue roche consisted million milestone payments related roche completing regulatory filings approvals tamiflu us japan december gilead entitled additional milestone payments million upon roche achieving certain developmental regulatory milestones april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera gilead 's antiviral treatment chronic hepatitis b asia latin america certain territories agreement gilead retained rights hepsera us canada eastern western europe australia new zealand gsk received exclusive rights develop hepsera solely treatment hepatitis b territories significant include china korea japan taiwan addition gsk paid gilead upfront licensing fee million first payment additional obligations may pay million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera september gsk also pay gilead royalty net sales hepsera gsk territories gsk full responsibility development commercialization hepsera gsk 's territories million upfront fee million us approval fee recorded deferred revenue total million recognized contract revenue balance deferred revenue december amortized contract revenue period gilead 's remaining obligations agreement approximately years december completed sale oncology assets osi date received million cash million osi stock agreement entitled additional payments osi million either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal products included sale manufacturing facility san dimas california recognized million contract revenue manufacturing agreement october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million required license agreement ulehi paid million million payments ulehi also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant ulehi march entered agreement eyetech pharmaceuticals inc relating gilead 's proprietary aptamer eye currently known macugen currently early clinical trials macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provided clinical supplies product toeyetech march received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue million recognized revenue also entitled additional cash payments eyetech million eyetech reaches certain macugen development milestones additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors gross margins product gross margins compared improvement primarily driven product mix viread higher margin product contributed significantly net product sales whereas modest sales viread recorded foreign exchange also impacts gross margins price products currency country products sold significant majority manufacturing costs us dollars example increase value foreign currencies relative us dollar positively impact gross margins since manufacturing costs remain approximately revenues translated us dollars increase gross margins positively impacted weakening us dollar gross margins negatively impacted factors discussed product sales section caption revenues except potential impact unpredictable uncontrollable changes exchange rates relative us dollar mix product sales viread hepsera ambisome expect gross margins remain relatively stable compared operating expenses rd expenses total costs expenses total rd expenses million compared million million major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various support facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis following table breaks major components research development spending thousands research clinical development pharmaceutical development oncology divested total million decrease rd spending compared primarily due reduction expenses associated clinical program viread approved october elimination expenses associated oncology program result sale oncology program osi december additionally recognized expense million million upfront license fee paid cubist pharmaceuticals related european licensing agreement daptomycin also known cidecin signed january upon termination agreement september million recorded rd represented remaining unamortized asset related preclinical oral formulation daptomycin excluding impact triangle acquisition expect rd expenses approximately million million approximately higher expenses million increase rd spending versus attributable part recognition million million upfront payment million clinical milestone payments cubist european licensing agreement cidecin addition expenses associated clinical programs viread hepsera increased approximately million million respectively year recent industry reports indicate biopharmaceutical company generally takes years average years research develop bring market new prescription medicine us averages generally consistent projects develop internally although recent product development timelines accelerated basis drug development us process includes several steps defined fda process begins filing ind successful allows opportunity clinical study potential new medicine clinical development typically involves three phases study phase generally accounts average seven years drug 's total development time significant costs associated clinical development phase trials tend longest largest studies conducted drug development process currently products development phase studies successful development products highly uncertain estimation completion dates rd expenses vary significantly product difficult predict even successful development fda approval product undertake additional studies try expand product 's label market potential complete discussion risks uncertainties associated completing development products see risk factors affect gilead section item selling general administrative sga expenses million compared million million increase expenses compared primarily due global sales marketing efforts including expansion gilead 's us european sales forces support commercial launches viread hepsera increase sga expenses versus primarily due gilead 's increased global marketing efforts expansion sales force support commercial launch viread expect sga expenses excluding impact triangle acquisition approximately million million higher levels primarily due increase marketing activities associated continued promotion viread hepsera ambisome gain sale oncology assets december completed sale oncology assets pipeline clinical stage oncology products related intellectual property well boulder colorado operations including clinical research drug development personnel infrastructure facilities osi pipeline clinical candidates includes nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor closing date received million cash osi common stock valued approximately million recorded nonoperating gain million fourth quarter result transaction addition recorded income taxes million connection transaction loss sale marketable securities july company sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million year ended december gain sale unconsolidated affiliate august also sold percent interest proligo llc proligo degussa corporation million cash proligo joint venture gilead skw americas inc focused manufacturing oligonucleotides skw americas subsidiary degussa corporation held remaining percent proligo proceeds net gilead 's investment proligo reflected million gain sale unconsolidated affiliate interest income interest expense recorded interest income million compared million million decrease compared attributable significant decline interest rates partially offset higher average cash balance due positive cash flow operations proceeds sale oncology assets osi increase due higher average balances invested funds interest income depend principally upon prevailing interest rates control level cash cash equivalent marketable securities balances incurred interest expense million compared million million significantincrease due full year interest million convertible subordinated notes interest expense consisted primarily interest million convertible notes converted common stock august expect interest expense increase compared expense levels primarily due issuance million convertible senior notes december income taxes provision income taxes million million million respectively income tax expense primarily associated income earned foreign subsidiaries significant net operating losses reduce us tax liability significant increase income tax expense resulted principally gain sale oncology assets osi recorded approximately million federal state alternative minimum taxes provision reduced change us income tax law law allows net operating loss carryforward deductions offset alternative minimum taxable income resulting reduction us income tax recorded previous years million record valuation allowance reduce deferred tax assets amount likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance determined would able realize part deferred tax assets future adjustment deferred tax asset would increase income period determination made likewise determine would able realize part deferred tax asset future adjustment deferred tax asset would charged income period determination made evaluate realizibility deferred tax assets quarterly basis equity loss unconsolidated affiliate recorded million equity loss unconsolidated affiliate proligo prior date sale percent interest recorded million equity loss proligo represented percent share proligo 's loss thirteenmonth period ended december fourth quarter proligo changed fiscal yearend december november cumulative effect change accounting principle year ended december gilead adopted sfas accounting derivative instruments hedging activities resulted cumulative effect change accounting principle million year ended december gilead adopted securities exchange commission 's staff accounting bulletin revenue recognition financial statements resulting cumulative effect change accounting principle million see notes consolidated financial statements discussion liquidity capital resources fourth quarter misclassification discovered december balance sheet cash flow statement year ended december million osi stock received consideration divestiture oncology assets misclassified balance sheet cash cash equivalents instead marketable securities misclassification impact statement operations period including revenues net income december consolidated balance sheet consolidated statement cash flows report changed reflect correct classification cash cash equivalents marketable securities totaled million december million december increase million primarily due million net proceeds received issuance convertible senior notes december major sources uses cash included net cash provided operations million proceeds issuances stock employee stock plans million partially offset capital expenditures million million convertible note received triangle million loan triangle returned us connection completed acquisition january approximately million paid complete acquisition triangle working capital december million compared million december significant changes working capital included million increase accounts receivable million increase inventory accounts receivable increase primarily due increased sales viread us europe million increase inventory primarily due increase production viread inventory meet increasing sales demand significant changes current liabilities included million increase accrued liabilities million decrease accrued clinical preclinical expenses million increase accrued compensation million increase accounts payable million increase deferred revenue million increase accrued liabilities primarily due medicaid rebate obligations associated higher sales viread million decrease accrued clinical preclinical expenses primarily due decreasing activity associated clinical trial programs viread hepsera million increase accrued compensation primarily due increased bonus accruals theexpansion sales force million increase accounts payable primarily due increases raw material purchases support viread sales growth million increase deferred revenue primarily relates million received collaboration gsk entered april million effect exchange rate changes cash primarily due weakening us dollar relative euro translation foreign subsidiaries ' accounts receivable balances primarily denominated euro currency made capital expenditures million million million expenditures primarily facilities improvements accommodate growth well laboratory manufacturing equipment capital expenditures related research development million spent million spent expect capital spending significantly higher levels due increased infrastructure needs higher rd spending december issued million convertible senior notes due december private offering notes currently convertible total shares gilead common stock per share conversion price higher gilead 's common stock price notes ' issuance date notes redeemable whole part option time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes december issued million convertible subordinated notes due december private offering notes currently convertible total shares gilead common stock per share conversion price higher gilead 's common stock price notes ' issuance date notes redeemable whole part option time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straight line basis contractual term notes august redeemed convertible subordinated debentures cash price per principal amount debentures outstanding plus accrued interest redemption price provided original debenture indenture upon redemption entire million principal amount debentures outstanding time converted newly issued shares gilead common stock august deferred debt issuance costs million related debentures charged additional paid capital connection conversion debentures common stock believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including commercial performance viread hepsera ambisome commercial performance products development receive marketing approval including emtricitabine acquisition triangle completed january success partners ' research development commercialization efforts products partnered us progress research development efforts scope results preclinical studies clinical trials cost timing outcome regulatory reviews rate technological advances determinations commercial potential products development administrative expenses status competitive products establishment manufacturing capacity thirdparty manufacturing arrangements expansion sales marketing capabilities possible geographic expansion establishment additional collaborative relationships companies may future require additional funding could form proceeds equity debt financings additional collaborative agreements corporate partners funding required assure available favorable terms subsidiaries established variety subsidiaries various countries purpose conducting business locations subsidiaries consolidated financial statements special purpose entities unconsolidated financial statements including defined variable interest entities financial accounting standards board fasb interpretation consolidation variable interest entities also involved nonexchange traded commodity contracts accounted fair value commercial commitments related parties except employee loans contractual obligations form capital operating leases notes payable clinical research organization contracts recent accounting pronouncements june fasb issued sfas accounting costs associated exit disposal activities sfas requires liability costs associated exit disposal activity recognized measured initially fair value liability incurred sfas effective exit disposal activities initiated december adoption sfas expected material impact financial position results operations november eitf reached consensus issue addressing account arrangements involve delivery performance multiple products services andor rights use assets revenue arrangements multiple deliverables divided separate units accounting deliverables arrangement meet following criteria delivered item value customer standalone basis objective reliable evidence fair value undelivered items delivery undelivered item probable arrangement consideration allocated among separate units accounting based relative fair values amount allocated delivered item limited amount contingent delivery additional items meeting specified performance conditions final consensus applicable agreements entered fiscal periods beginning june early adoption permitted reviewing provisions consensus determine effect may company 's financial position results operations november fasb issued interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin elaborates existing disclosure requirements guarantees including residual value guarantees issued conjunction operating lease agreements also clarifies time company issues guarantee company must recognize initial liability fair value obligation assumes guarantee must disclose information interim annual financial statements initial recognition measurement provisions apply prospective basis guarantees issued modified december disclosure requirements effective financial statements interim annual periods ending december adoption disclosure provisions fin material impact results operations financial position december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amendment sfas accounting stockbased compensation issued october sfas provides alternative methods transition voluntary change fair value based method accounting stockbased compensation addition statement amends disclosure requirements statement require prominent disclosures annual interim financial statements method accounting stockbased employee compensation effect method used reported results additional disclosure requirements sfas effective fiscal years ending december elected continue follow intrinsic value method accounting prescribed accounting principles board opinion apb accounting stock issued employees account employee stock options item quantitative qualitative disclosures market riskforeign currency exchange risk operations include manufacturing sales activities us well sales activities europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business mitigate impact changes currency exchange rates cash flows foreign currency sales transactions enter foreign exchange forward contracts hedge foreign currencydenominated accounts receivable additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition prior hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million insignificant fair value december maturity months average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands fair value currency notional amount average rate december british pound euro total notional amount million fair value million open foreign exchange forward contracts december compares total notional amount million fair value million open foreign exchange forward contracts december interest rate risk portfolio availableforsale investment securities fixedrate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestbearing assets fixedrate liabilities december dollars thousands years ending december fair value december thereafter total assets availableforsale securities average interest rate liabilities longterm obligations including current portion average interest rate convertible senior debentures interest rate convertible subordinated debentures interest rate longterm obligations consist capital leases operating leases net noncancelable subleases debt secured property plant equipment interest portion payments due included international credit risk accounts receivable balance december million compared million december growth primarily due higher product sales viread us europe certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece spain portugal italy totaled approximately million approximately million days past due december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe accounts receivable balances reflected consolidated balance sheet including due customers four countries collectible continually seek improve collection processes ensure fully collect amounts due us based product sales collections timely item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statementunder headings nominees executive officers compliance section securities exchange act item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee report item security ownership certain beneficial owners management information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings compensation committee interlocks insider participation certain transactions executive compensation item controls procedures within days prior date report carried evaluation supervision participation principal executive officer principal financial officer effectiveness design operation disclosure controls procedures based evaluation principal executive officer principal financial officer concluded disclosure controls procedures effective timely alerting material information required included periodic reports securities exchange commission noted design system controls based part upon certain assumptions likelihood future events certain design succeed achieving stated goals potential future conditions regardless remote significant changes internal controls factors could significantly affect controls subsequent date last evaluation part iv item exhibits financial statement schedules reports form k following documents filed part index list financial statements report ernst young llp independent auditors report independent accountants audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders ' equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated referenceexhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc dated november agreement plan merger among registrant simbolo acquisition sub inc whollyowned subsidiary registrant triangle pharmaceuticals inc dated december amended restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc agreement plan merger dated february among registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture dated december registrant chase manhattan bank trust company national association including therein forms notes indenture dated december registrant jp morgan trust company national association including herein forms notes registration rights agreement dated december registrant goldman sachs co form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees registrant 's incentive stock option plan related agreements registrant 's supplemental stock option plan related agreements registrant 's employee stock purchase plan amended march registrant 's stock option plan amended restated april amended january amended january form nonqualified stock option issued certain executive officers directors vintage park research development net lease registrant vintage park associates dated march premises located b lakeside drive foster city california related addendum exhibits amendments letter agreement dated september registrant iocbrega exhibits certain confidential information omitted vintage park research development net lease registrant vintage park associates dated september premises located lakeside drive foster city california related exhibits amendment agreement dated october registrant iocbrega related license agreements exhibits certain confidential information omitted amendment agreement dated december registrant iocbrega loan agreement dated october among registrant mark l perry melanie p pea registrant 's nonemployee directors ' stock option plan amended january amended january vintage park research development lease registrant wcb sixteen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located b lakeside drive foster city california license supply agreement registrant pharmacia upjohn sa dated august certain confidential information omitted development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc dated september certain confidential information omitted amendment vintage park research development lease registrant spieker properties lp dated august premises located lakeside drive foster city california nexstar pharmaceuticals inc 's incentive stock plan adopted february amended nexstar pharmaceuticals inc 's director option plan adopted july vestar inc stock option plan lease dated march vestar inc majestic realty co patrician associates inc amendment thereto amendment thereto dated june third amendment dated january majestic realty co patrician associates inc registrant lease dated march vestar inc majestic realty co patrician associates inc assignment royalty agreement dated december effective june vestar inc city hope national medical center license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc dated august amendment thereto dated may amendment agreement fujisawa usa inc vestar inc dated april fujisawa usa inc vestar inc certain confidential information omitted amendment agreement fujisawa usa inc registrant dated march agreement fujisawa usa inc vestar inc dated august lease dated april vestar inc majestic realty co patrician associates inc first amendment lease dated april majestic realty co patrician associates inc vestar inc amending lease dated april majestic realty co patrician associates inc vestar inc license distribution agreement dated september sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc certain confidential information omitted settlement agreement dated august among nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omitted amendment dated april sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc license distribution agreement dated september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement dated april gilead world markets limited glaxo group limited employment agreement dated july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch dated august license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd dated march license agreement triangle pharmaceuticals inc emory university coviracil ftc dated april license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd dated february exclusive license agreement among triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may settlement agreement among triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may amendment license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd dated april first amendment license agreement triangle pharmaceuticals inc emory university dated may first amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated july second amendment license agreement triangle pharmaceuticals inc emory university dated july amendment license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd dated september third amendment license agreement triangle pharmaceuticals inc bukwang pharm co ltd dated august supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories dated july settlement exclusive license agreement among triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august second amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated august sublease triangle pharmaceuticals inc eli lilly company dated january sublease amendment triangle pharmaceuticals inc eli lilly company dated march second amendment sublease triangle pharmaceuticals inc eli lilly company dated august third amendment sublease triangle pharmaceuticals inc eli lilly company dated february manufacturing supply agreement gilead world markets ltd ppgsipsy sas entered january subsidiaries registrant consent ernst young llp independent auditors consent pricewaterhousecoopers llp independent auditors power attorney reference made signature certification filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's current report form k filed october incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's current report form k filed march incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed march exhibit nexstar pharmaceuticals inc 's registration statement form file incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarter ended june incorporated herein reference filed exhibit registrant 's fiscal year ended december incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's fiscal year ended december incorporated herein reference filed exhibit registrant 's current report form k filed january incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's fiscal year ended december incorporated herein reference filed exhibit registrant 's current report form k filed december incorporated herein reference filed exhibit registrant 's registration statement form filed january incorporated herein reference filed exhibit registrant 's registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals inc 's registration statement form amended incorporated herein reference filed exhibit triangle pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's current report form k filed september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals inc 's fiscal year ended december incorporated herein reference certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrant 's application requesting confidential treatment rule b securities exchange act b reports form k registrant filed report form k december regarding tender offer purchase outstanding common shares triangle pharmaceuticals inc price per share registrant filed reports form k december december regarding sale million convertible notes million overallotment exercised full rule offering qualified institutional buyers gilead sciences inc consolidated financial statements years ended december contents report ernst young llp independent auditors report independent accountants audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders ' equity consolidated statements cash flows notes consolidated financial statements report ernst young llp independent auditors board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders ' equity cash flows three years period ended december audits also included financial statement schedule listed item annual report financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits audit financial statements proligo llc limited liability company investment reflected accompanying consolidated financial statements using equity method accounting company 's equity net loss proligo llc financial statements proligo llc audited auditors whose report furnished us opinion insofar relates amounts included proligo llc based solely report auditors conducted audits accordance auditing standards generally accepted united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits report auditors provide reasonable basis opinion opinion based audits report auditors consolidated financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity accounting principles generally accepted united states also opinion financial statement schedule referred considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed notes consolidated financial statements effective january company changed method accounting derivative instruments hedging activities effective january changed method accounting non refundable upfront fees received connection collaboration agreements ernst young llp palo alto california january report independent accountants board directors members proligo llc opinion accompanying consolidated balance sheets related consolidated statements operations members ' equity cash flows present fairly material respects financial position proligo llc subsidiaries december november results operations cash flows thirteenmonths ended december year ended november period august november respectively conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecoopers llp broomfield colorado january gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowance doubtful accounts december december note receivable triangle pharmaceuticals inc inventories prepaid expenses total current assets property plant equipment net noncurrent assets liabilities stockholders ' equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits accrued liabilities deferred revenue longterm obligations due within one year total current liabilities longterm deferred revenue accrued litigation settlement expenses due one year longterm obligations due one year convertible senior debt convertible subordinated debt commitments contingencies see accompanying notes stockholders ' equity preferred stock par value per share issuable series shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december december respectively additional paidin capital accumulated comprehensive income accumulated deficit total stockholders ' equity see accompanying notes gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenue contract revenue total revenues costs expenses cost goods sold research development selling general administrative total costs expenses income loss operations gain sale oncology assets gain sale unconsolidated affiliate loss sale marketable securities interest income net interest expense income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle provision income taxes equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted see accompanying notes gilead sciences inc consolidated statement stockholders ' equity thousands common stock accumulated additional paid comprehensive deferred total stockholders ' shares amount capital income loss compensation accumulated deficit equity balance december net loss unrealized gain availablefor sale securities net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december net income unrealized gain availablefor sale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income employee stock purchase plan option exercises net tax benefits employee stock plans amortization deferred compensation compensatory stock transactions balance december net income unrealized loss availablefor sale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income employee stock purchase plan option exercises net tax benefits employee stock plans compensatory stock transactions balance december see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided used operating activities depreciation amortization net effect change accounting principle gain sale oncology assets gain sale unconsolidated affiliate loss sale marketable securities equity loss unconsolidated affiliate net movement provision doubtful accounts tax benefits employee stock plans net unrealized gain loss foreign currency transactions noncash transactions changes operating assets liabilities accounts receivable inventories prepaid expenses assets longterm prepaid royalties accounts payable accrued liabilities deferred revenue net cash provided used operating activities investing activities purchases marketable securities sales marketable securities maturities marketable securities capital expenditures issuance note triangle pharmaceuticals inc proceeds sale oncology assets proceeds sale unconsolidated affiliate investment unconsolidated affiliate net cash provided used investing activities financing activities proceeds issuances common stock repayments longterm obligations proceeds issuance convertible senior notes net issuance costs proceeds issuance convertible subordinated notes net issuance costs net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities osi common stock received upon sale oncology assets common stock issued upon conversion debentures reclassification deferred debt issuance costs additional paidin capital upon conversion subordinated debentures see accompanying notes gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead company incorporated delaware june biopharmaceutical company focused discovery development commercialization antivirals antibacterials antifungals treat lifethreatening infectious diseases multinational company revenues six approved products operations ten countries currently market viread treatment hiv infection hepsera treatment chronic hepatitis b infection ambisome antifungal agent daunoxome drug approved treatment kaposi 's sarcoma vistide treatment cmv retinitis roche markets tamiflu treatment influenza collaborative agreement us seeking add existing portfolio products clinical development programs internal discovery programs active product acquisition inlicensing strategy acquisition oftriangle pharmaceuticals inc completed january internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing products treat hiv infection also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective accompanying consolidated financial statements include accounts gilead wholly majorityowned subsidiaries significant intercompany transactions eliminated certain prior period amounts including certain cash cash equivalents marketable securities reclassified consistent current presentation stock split february march gilead completed twoforone stock splits effected form stock dividend stockholders record february february respectively accordingly share per share amounts periods presented reflect splits changes accounting principles gilead adopted statement financial accounting standards sfas nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle see note effective first quarter gilead adopted sec 's staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle see note critical accounting policies estimates preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis management evaluates estimates including related revenue recognition bad debts inventories accrued clinical preclinical expenses contingencies base estimates historical experience various market specific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery occurred price fixed determinable collectibility reasonably assured provide customers general right product return however accept returns product expired deemed damaged defective delivered provisions made estimated product returns cash discounts government discounts rebates based contractual terms expectations regarding utilization rates programs contract revenue research development recorded earned based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized manufacturing obligation fulfilled ratably development period period manufacturing obligation appropriate revenue associated substantive performance milestones recognized based upon achievement milestones defined respective agreements revenue research development cost reimbursement contracts recognized related costs incurred advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales vistide tamiflu recognized received quarter following quarter corresponding sales occur shipping handling costsshipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various administrative facilities related costs research development activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis record accruals estimated clinical preclinical study costs costs significant component rd expenses management accrues costs clinical studies performed contract research organizations based estimates typically work upfront costs remaining activity generally incurred straightline basis life individual contract study estimate may may match actual services performed organizations determined patient enrollment levels related activities monitor patient enrollment levels related activity extent possible adjust estimates line actual activity incurred ongoing basis advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation accordance provisions sfas accounting stockbased compensation company elected continue follow accounting principles board opinion apb accounting stock issued employees interpretation fin accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stock option plans apb exercise price gilead 's employee director stock options equals exceeds fair value underlying stock date grant compensation expense recognized see note pro forma disclosures stockbased compensation pursuant sfas amended sfas accounting stockbased compensationtransition disclosure table presents combined net income loss basic diluted net income loss per common share compensation cost gilead nexstar stock option plans espp determined based estimated fair value awards plans grant purchase date thousands except per share amounts year ended december net income lossas reported deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income loss thousands earnings loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option pricing model used multiple option approach following assumptionsyear ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield weighted average estimated fair value espp shares purchased per share computations basic net income per common share computed based weighted average number common shares outstanding period diluted net income per common share includes effects approximately million stock options include effect million convertible notes would convert approximately million shares million convertible notes would convert approximately million shares effect assumed conversion antidilutive diluted net income per common share includes effects approximately million stock options warrants include effect million convertible notes would convert approximately million shares effect assumed conversion antidilutive basic diluted loss per common share computed based weighted average number common shares outstanding period potential common shares convertible notes stock options warrants well convertible debentures previously outstanding excluded computation diluted loss per share effect would antidilutive cash cash equivalents consider highly liquid investments insignificant interest rate risk remaining maturity three months less purchase date cash equivalents may enter overnight repurchase agreements purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repurchase agreements repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead fourth quarter misclassification discovered previously reported december balance sheet cash flow statement december million osi stock received consideration divestiture oncology assets misclassified balance sheet cash cash equivalents instead marketable securities december consolidated balance sheet consolidated statement cash flows report changed reflect correct classification marketable securities management determines appropriate classification marketable securities consists solely debt securities time purchase reevaluates designation balance sheet date marketable securities classified availableforsale carried estimated fair values reported either cash equivalents marketable securities december cash cash equivalents include million securities designated availableforsale million december unrealized gains losses availableforsale securities excluded earnings reported separate component stockholders ' equity interest income includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline reductions required past three years concentrations credit risk gilead subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government gilead exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flowrequirements competitive aftertax rate return gilead also subject credit risk accounts receivable related product sales significant amount trade accounts receivable arises sales ambisome viread primarily sales european subsidiaries export sales distributors europe certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece spain portugal italy totaled approximately million approximately million days past due december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable reflected consolidated balance sheet including due customers four countries collectible perform credit evaluations customer 's financial condition generally required collateral many materials utilize operations made one facility example depend single suppliers high quality amphotericin b daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products supplies suppliers interrupted reason may unable ship viread ambisome hepsera vistide daunoxome supply products development clinical trials december million note receivable triangle pharmaceuticals inc incurred conjunction acquisition completed january note included cash cash equivalents marketable securities subsequently eliminated consolidation result closing acquisition january inventories inventories recorded lower cost market cost determined firstin firstout basis management periodically reviews composition inventory order identify obsolete slowmoving otherwise unsaleable items items observed alternate uses inventory record writedown net realizable value period units identified impaired historically inventory writedowns insignificant consistent management 's expectations property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method estimated useful lives follows description estimated useful life years building leasehold improvements laboratory manufacturing equipment office computer equipment office computer equipment includes capitalized computer software capitalized software purchased internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term item 's useful life capitalized interest construction progress included property plant equipment noncurrent assets noncurrent assets december includes million respectively prepaid royalties paid institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega discussed iocbrega caption note also included noncurrent assets december net deferred debt issuance costs million million respectively related million convertible seniornotes issued december million subordinated convertible notes gilead issued december longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment us food drug administration another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment confirm comparing estimated future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets grouped lowest level identifiable cash flows largely independent cash flows generated asset groups sum expected future cash flows undiscounted without interest changes less carrying amount asset impairment loss measured excess carrying value asset fair value recognized cash flow estimates used calculations based management 's best estimates using appropriate customary assumptions projections time foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income accumulated separate component stockholders ' equity net foreign exchange transaction gains losses reported selling general administrative expense consolidated statements operations realized gains losses million million million hedge certain foreign currency exposures related outstanding trade accounts receivable firmly committed purchase transactions forecasted product sales foreign exchange forward contracts general contracts expose us market risk gains losses contracts offset gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major us banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions write options presently hedge net investment foreign subsidiaries accounting hedges accounts receivable record changes fair value selling general administrative expense derivative instruments designated hedges fas selectively hedge anticipated currency exposures purchasing forward contracts hedge firmly committed purchases transactions anticipated products sales designated cash flow hedges sfas unrealized gains losses underlying forward contracts recorded comprehensive income recognized earnings forecasted transaction occurs december december net unrealized losses open foreign exchange forward contracts million million respectively losses revenue hedges reduced product revenues million notional amounts forward exchange contracts outstanding million december million december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million insignificant fair value december maturity months see note discussion derivative financial instruments adoption sfas fair value financial instruments company 's financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm obligations convertible notes cash cash equivalents marketable securities forward foreign exchange contracts hedge accounts receivable reported respective fair values balance sheet forward foreign exchange contracts hedge firmly committed purchases recorded fair value net related deferred gain loss resulting reported net balance zero fair value convertible senior notes december million carrying value december million fair value convertible subordinated notes december million fair value december million carrying value end period million fair values december december convertible notes determined obtaining quotes market maker notes management believes remaining financial instruments reported balance sheet amounts approximate current fair values recent accounting pronouncements june fasb issued sfas accounting costs associated exit disposal activities sfas requires liability costs associated exit disposal activity recognized measured initially fair value liability incurred sfas effective exit disposal activities initiated december adoption sfas expected material impact financial position results operations november eitf reached consensus issue addressing account arrangements involve delivery performance multiple products services andor rights use assets revenue arrangements multiple deliverables divided separate units accounting deliverables arrangement meet following criteria delivered item value customer standalone basis objective reliable evidence fair value undelivered items delivery undelivered item probable arrangement consideration allocated among separate units accounting based relative fair values amount allocated delivered item limited amount contingent delivery additional items meeting specified performance conditions final consensus applicable agreements entered fiscal periods beginning june early adoption permitted reviewing provisions consensus determine effect may company 's financial position results operations november fasb issued interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin elaborates existing disclosure requirements guarantees including residual value guarantees issued conjunction operating lease agreements also clarifies time company issues guarantee company must recognize initial liability fair value obligation assumes guarantee must disclose information interim annual financial statements initial recognition measurement provisions apply prospective basis guarantees issued modified december disclosure requirements effective financial statements interim annual periods ending december adoption disclosure provisions fin material impact results operations financial position december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amendment sfas accounting stockbased compensation issued october sfas provides alternative methods transition voluntary change fair value based method accounting stockbased compensation addition statement amends disclosure requirements statement require prominent disclosures annual interim financial statements method accounting stockbased employee compensation effect method used reported results additional disclosure requirements fas effective fiscal years ending december elected continue follow intrinsic value method accounting prescribed accounting principles board opinion apb accounting stock issued employees account employee stock options cumulative effect change accounting principle december securities exchange commission issued staff accounting bulletin sab revenue recognition financial statements among things sab describes sec staff 's position recognition certain nonrefundable upfront fees received connection collaboration agreements previously recognized nonrefundable technology access fees received connection collaboration agreements revenue received collectibility probable technology transferred effective january gilead changed method accounting fees recognize related manufacturing obligation fulfilled straightline basis term related research development collaboration manufacturing supplyarrangement appropriate method best matches effort provided management believes change accounting principle preferable based guidance provided sab cumulative effect change accounting principle recorded fourth quarter retroactively effective january deferred revenue recognized contract revenue remaining term research development manufacturing supply arrangements appropriate year ended december net impact change accounting principle increase net loss million per share loss consists million cumulative effect change january net million related deferred revenue recognized contract revenue year additional million contract revenue recognized remainder million related deferred revenue balance december expected recognized revenue derivative financial instruments january gilead adopted sfas standard requires gilead recognize derivatives either assets liabilities measured fair value company enters foreign currency forward contracts hedge changes fair value monetary assets liabilities denominated nonfunctional currency derivative designated meets definition fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings company also enters foreign currency forward contracts generally maturities months less hedge future cash flows related purchase transactions forecasted product sales foreign denominated currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified accordance sfas hedges related anticipated foreign currency purchases raw materials forecasted product sales designated documented inception respective hedge designated cash flow hedges evaluated effectiveness quarterly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract change forward value underlying hedged item upon adoption sfas recorded fair value million related forward contracts previously reflected balance sheet recognized cumulative transition adjustment comprehensive income million effective component hedge substantially values reported comprehensive income december reclassified earnings within months residual changes fair value instruments ineffectiveness recognized immediately selling general administrative expense ineffectiveness significant gilead holds warrants purchase stock two nonpublic companies warrants net exercise features sfas classified derivative instruments upon adoption gilead recorded fair value one warrants million offsetting adjustment cumulative change accounting principle million loss hedging contracts recognized income statement million increase fair value derivatives recognized comprehensive income december fair value derivatives included comprehensive income material sale oncology assets december gilead completed sale oncology assets pipeline clinical candidates oncology related intellectual property well boulder colorado operations including clinical research drug development operations infrastructure facilities osi three clinical development candidates sold osi nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor consideration gilead received million cash shares osi common stock valued approximately million december number shares issued gilead determined dividing million average closing sale price osi common stock days preceding december also entitled additional payments osi million either cash combination cash osi common stock osi reaches certain development milestones nx advanced oncology product candidates sold osi milestone payments received osi recognized contract revenues upon receipt based upon december net book value oncology assets sold million transaction costs million million related acceleration approximately options purchase gilead common stock realized pretax gain million fourth quarter carrying value transferred assets relates primarily certain property equipment osi assumed gilead 's oncologyrelated clinical preclinical obligations well various lease obligations related manufacturing agreement produce osi liposomal formulations nx gs l two liposomal products sold osi manufacturing facility san dimas ca sale marketable securities july gilead sold remaining shares osi common stock approximately million shares partialconsideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million reflected results year ended december availableforsale securities following summary availableforsale securities estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total december us treasury securities obligations us government agencies certificates deposit corporate debt securities corporate equity securities assetbacked securities debt securities total debt securities consist primarily money market funds also maintain marketable securities nominal value recorded noncurrent assets december securities net unrealized loss approximately million following table presents certain information related sales availableforsales securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december million portfolio marketable securities excluding million assetbacked securities contractual maturity less one year million portfolio contractual maturity greater one year less three years none estimated maturities assetbacked securities exceed three years note receivable december part arrangements contemplated proposed acquisition triangle gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissorynote upon completion triangle acquisition january loan eliminated consolidated results result closing acquisition january see note balance sheet detail thousands december inventories raw materials work process finished goods total property plant equipment net building improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress less accumulated depreciation amortization total accrued liabilities accrued medicaid rebates accrued sales marketing expenses liabilities total collaborative arrangements contracts glaxosmithkline april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera gilead 's antiviral treatment chronic hepatitis b asia latin america certain territories agreement gilead retained rights hepsera united states canada eastern western europe australia new zealand gsk received exclusive rights develop hepsera solely treatment hepatitis b territories significant include china korea japan taiwan addition gsk paid us upfront licensing fee million entitled receive additional cash payments million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera september gsk also pay gilead royalty net sales hepsera gsk territories gsk full responsibility development commercialization hepsera gsk 's territories million upfront fee million us approval fee recorded deferred revenue total million recognized contract revenue balance deferred revenue december amortized contract revenue period gilead 's remaining obligations agreement approximately yearsin december gilead entered agreement glaxo wellcome gsk giving gilead rights gs l novel anti tumor compound gilead developing gs l liposome evaluating preclinical studies agreement gilead exclusive worldwide rights develop commercialize gs l indications malaria gilead paid gsk upfront fee included rd expense december compound assigned osi part sale oncology assets may gilead entered threepart collaboration gsk gsk received nonexclusive right use gilead 's proprietary selex process target validation b gilead received exclusive rights subject gsk 's right elect participate activities develop commercialize nx liposomal formulation gsk 's proprietary topoisomerase inhibitor lurtotecan c gsk acquired shares gilead common stock million private offering december collaboration license agreement modified revised terms agreement gsk waived right participate development commercialization nx right receive royalties giving gilead exclusive rights compound december compound also assigned osi part sale oncology assets cubist pharmaceuticals september gilead cubist pharmaceuticals jointly announced termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin agreement executed january granted gilead exclusive commercialization rights products european countries following regulatory approval terms termination agreement gilead owe future payments cubist cubist reacquired european rights products upon termination million recorded research development expense represented remaining unamortized asset related preclinical oral formulation daptomycin archemix october entered agreement archemix corporation relating selex technology agreement archemix obtained exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million required license agreement university license equity holdings inc ulehi paid million million payments ulehi recognized million million revenue respectively also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant ulehi additional payments due archemix agreement eyetech march gilead entered agreement eyetech pharmaceuticals inc relating proprietary aptamer eye known macugen currently early clinical trials macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provided clinical supplies product eyetech march also received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue agreement remainder license fee recognized revenue also entitled additional cash payments eyetech million eyetech reaches certain macugen development milestones additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note description accounting treatment warrant fujisawa rights market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa terms fujisawa agreement amended fujisawa gilead copromote ambisome us fujisawa sole marketing rights ambisome canada exclusive marketing rights ambisome rest world provided pay royalties fujisawa connection sales significant asian markets including japan connection us sales fujisawa purchases ambisome gilead cost sales canada fujisawa purchases ambisome cost plus specified percentage fujisawa collects payments sale ambisome us canada receive fujisawa 's gross profits sale ambisome us gross profits include deduction cost goods sold giving us current effective royalty rate approximately fujisawa 's net sales ambisome us connection agreement us fujisawa recorded royalty revenue million million million sumitomo september gilead sumitomo entered agreement pursuant sumitomo agreed develop market ambisome japan terms agreement sumitomo paid us initial million licensing fee less withholding taxes million october million milestone payment less withholding taxes million march sumitomo also required make additional payments us certain clinical commercial milestones met pay us royalties japanese ambisome sales agreement gilead obligated provide certain quantity ambisome sumitomo charge ambisome yet approved marketing japan subsequent cumulative effect change accounting principle recorded effective first quarter resulting adoption sab gilead recognized initial license fee remaining free supply arrangement period net impact change accounting principle sumitomo license increase net loss million cumulative effect change accounting principle charge million contract revenue million related initial licensing fee sumitomo recognized contract revenue million recognized contract revenue remaining million recognized contract revenue roche september gilead entered collaboration agreement roche develop commercialize therapies treat prevent viral influenza roche agreement roche agreement roche received exclusive worldwide rights gilead 's proprietary influenza neuraminidase inhibitors prior roche made license fee developmental milestone payments totaling million gilead recognized million contract revenue milestone payments roche related tamiflu milestones achieved year milestones included filing regulatory approval japan treatment influenza japanese approval application filing us regulatory approval prevention influenza receipt approval us recognized million milestone payment filing application market tamiflu prophylaxis european union recognized million milestone payments european approval tamiflu treatment prophylaxis december gilead entitled additional cash payments roche million upon roche achieving additional developmental regulatory milestones addition roche required pay gilead royalties net product sales gilead began receiving royalties roche 's sales tamiflu first quarter recorded total million tamiflu royalties million royalties million royalties recognize royalty revenue roche quarter following quarter related tamiflu sales occur roche agreement roche also reimburses us related rd costs program funding costs quarterly generally advance based annual budget reimbursements included contract revenue incur related rd costs amounts incurred us excess amounts funded may also reimbursed subject roche 's approval event revenue recognized approval obtained conversely amounts funded roche exceed related rd costs may required repay excess funding roche recorded contract revenue rd reimbursements related roche agreement approximately million previous three years ending rd costs related roche agreement approximate reimbursement revenue included rd expenses pharmacia august gilead pharmacia corporation pharmacia entered license supply agreement pharmacia agreement market vistide countries outside us terms pharmacia agreement pharmacia paid gilead initial license fee million subsequent cumulative effect change accounting principle recorded effective first quarter gilead recognizing initial license fee straightline basis supply arrangement period sixteen years agreement date net impact change accounting principle pharmacia agreement increase net loss million cumulative effect change accounting principle related initial license fee pharmacia million charge results operations additional contract revenue million recognized subsequent accounting change remaining million related deferred revenue expected recognized straightline basis contract revenue remaining supply period terms pharmacia agreement related agreements covering expanded access programs vistide outside usgilead responsible maintaining cidofovir patent portfolio supplying pharmacia bulk cidofovir used manufacture finished vistide product gilead entitled receive royalty based upon pharmacia 's sales vistide gilead receives portion royalty upon shipping either bulk drug substance vistide pharmacia remainder upon pharmacia 's sale vistide third parties royalties gilead receives product sold third parties recorded deferred revenue thirdparty sales occur december recorded balance sheet approximately million deferred revenue million december recognized royalty revenue sales vistide outside united states pharmacia million million million somalogic november gilead somalogic inc somalogic entered agreement whereby gilead assigned somalogic sole exclusive license certain intellectual property related selex process diagnostic purposes including patents patent applications terms agreement somalogic required pay gilead total million two nonrefundable installments first million paid november included contract revenue year ended december remaining million reported deferred revenue december received recorded contract revenue gilead ongoing research funding obligations agreement iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered agreement include vistide hepsera viread exclude tamiflu gilead currently makes quarterly payments iocbrega based percentage vistide hepsera viread sales december agreements iocbrega amended provide reduced royalty rate future sales hepsera viread return upfront payment gilead million upon signing agreement payment recorded longterm prepaid royalty classified noncurrent assets balance sheet december recognized royalty expense expected commercial life viread hepsera amortization million payment began product launch dates viread hepsera totaled million december southern research institute december gilead entered agreement southern research institute giving gilead worldwide rights develop commercialize gs antitumor compound gilead evaluating preclinical studies terms agreement gilead paid southern research institute upfront fee included research development expense december compound assigned osi part sale oncology assets investment sale unconsolidated affiliate july established proligo llc delaware limited liability company proligo wholly owned subsidiary transferred assets nexstar technology products division proligo proligo supplies nucleic acid peptide synthesis products pharmaceutical biopharmaceutical industry sale use laboratory research reagents therapeutic diagnostic products august sold interest interest proligo skw americas inc skw payment interest received million cash interest perseptive biosystems gmbh company hamburg germany hamburg company specializes manufacture nucleoside phosphoramidite monomers interest hamburg company fair market value approximately million recorded million gain connection sale january october gilead made two additional cash investments proligo total million maintain ownership interest proligo gilead commitments provide additional funding proligo beyond january accounted investment proligo using equity method accounting recognized million equity proligo 's net loss representing share proligo 's loss thirteenmonth period ended december fourthquarter proligo changed fiscal year end december november gilead sold interest proligo degussa corporation million cash proceeds net gilead 's investment proligo reflected million gain sale unconsolidated affiliate prior date sale gilead recorded million equity loss proligo longterm obligations longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging fixed rate debt monthly installments secured equipment interest rates ranging total longterm obligations less current portion longterm obligations due one year maturities longterm obligations including capital lease obligations follows thousands year ending december less amount representing interest total terms various debt agreements require us comply certain financial operating covenants december compliance covenants convertible notes december gilead issued million convertible senior notes due december private offering goldman sachs co resold notes qualified institutional investors notes convertible total shares gilead common stock per share conversion price higher gilead 's common stock price note 's issuance date notes redeemable whole part option gilead time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes december gilead issued million convertible subordinated notes due december private offering jp morgan co lehman brothers morgan stanley dean witter resold notes private institutional investors notes convertible total shares gilead common stock per share conversion price higher gilead 's common stock price note 's issuance date notes redeemable whole part option gilead time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis overthe contractual term notes commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases foster city san dimas california expire various dates leases two five year renewal options exception one lease foster city expires contains renewal options also operating leases sales marketing administrative facilities europe australia various terms equipment leases also include corporate airplane initial term two years annual renewal option ten years lease expense net sublease income operating leases totaled approximately million million million addition assumed facility lease durham north carolina connection acquisition triangle january lease approximately square feet administrative office laboratory space sublease approximately square feet third parties lease expires september currently negotiations lessor extend lease term aggregate noncancelable future minimum rental payments operating capital leases net aggregate future minimum rentals received us noncancelable subleases follows thousands operating leases net noncancelable subleases years ending december excluding triangle leases capital leases thereafter less amount representing interest total capital lease obligations less current portion capital lease obligations due one year december placed million bank escrow deposit included noncurrent assets secure aggregate future payments due one facilities leases contingent liability gilead subleased certain facilities primarily california sublessees default obligations subleases would primarily liable original lessor total future amounts due leases december million legal proceedings reached settlement elan corporation plc elan successor company liposome company companies agreed dismiss legal proceedings involving ambisome gilead 's liposomal formulation amphotericin b terms initial settlement agreement made initial payment elan million agreed make additional royalty payments based ambisome sales recorded million accounting charge accrued litigation settlementexpenses representing estimated net present value future minimum payments required make june elan gilead entered agreement terminating remaining ambisome payment obligations initial settlement agreement exchange payment elan million excess million settlement amount remaining accrued litigation settlement expenses balance million amortized remaining life patents approximately four years november ulehi notified us ulehi believes gilead materially breached licensing agreement ulehi concerning selex technology identify aptamers amongst things assigning rights agreement without ulehi 's consent contest ulehi 's allegations met ulehi regarding allegations actively engaged negotiations settle disagreement negotiations prove unsuccessful ulehi chooses terminate ulehigilead agreement arbitration concerning termination would likely result unfavorable outcome arbitration could give rise award us monetary damages adverse remedies possibly including conveyance ulehi gilead 's rights obligations ulehi licensing agreement sublicenses also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position stockholders ' equity preferred stock gilead shares authorized preferred stock issuable series board directors board authorized determine designation powers preferences rights series reserved shares preferred stock potential issuance preferred share purchase rights plan preferred stock outstanding december employee stock purchase plan gilead 's employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensation purchase price per share must equal least lower percent market value date offered date purchased total shares common stock reserved issuance espp december shares total shares reserved issued espp shares december stock option plans december gilead adopted incentive stock option plan supplemental stock option plan issuance common stock employees consultants scientific advisors april board approved granting certain additional nonqualified stock options terms conditions substantially similar granted supplemental stock option plan none options issued plans described exercise prices less fair value underlying stock date grant options vest five years pursuant formula determined board expire ten years shares available grant future options plans november gilead adopted stock option plan plan issuance common stock employees consultants options issued plan shall discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gilead 's common stock date grant options vest five years pursuant formula determined board expire ten years plan amended restated april extend term plan may stockholders approved amendment plan increased total number authorized shares plan december shares available grant future options plan november gilead adopted nonemployee directors ' stock option plan directors ' plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors ' plan must least equal fair value gilead 's common stock date grant options vest five years date grant quarterly five percent installments expire ten years may stockholders approved amendment directors ' plan increased total number authorized shares plan december shares available forgrant future options directors ' plan stock plans assumed gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plans options pursuant plan incentive stock plan issued outstanding july converted options purchase gilead common stock result merger remain subject original terms conditions shares available grant future options nexstar plans nexstar 's plan allows certain option holders execute cashless exercises options cashless exercise transaction option holder specifies many shares exercised gilead issues specified number shares less number would required cover exercise price based fair value stock exercise date several option holders performed cashless exercises result option awards considered variable therefore recognized nominal amount compensation expense million million july options outstanding category following table summarizes activity gilead nexstar stock option plans three years period ended december option grants presented table exercise prices less fair value underlying stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted forfeited exercised outstanding end year exercisable end year weighted average fair value options granted following summary gilead options outstanding options exercisable december options thousands options outstanding weighted options exercisable average weighted remaining average weighted options contractual exercise options average range exercise prices outstanding life years price exercisable exercise price total company reserved aggregate shares common stock future issuance equity compensation plans december pro forma disclosures elected follow accounting principles board opinion apb account employee stock options apb compensation expense recognized exercise price employee stock options equals market price underlying stock date grant information regarding net income loss earnings loss per share prepared accordance fas determined accounted employee stock options employee stock purchase plan fair value method prescribed fas earnings loss per share method fas resulting effect net income loss earnings loss per share pursuant fas likely representative effects net income loss earnings loss per share pursuant fas future years due subsequent years including additional grants years vesting table presents combined net income loss basic diluted net income loss per common share compensation cost gilead nexstar stock option plans espp determined based estimated fair value awards plans grant purchase date thousands except per share amounts year ended december net income lossas reported deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income loss earnings loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option pricing model used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield weighted average estimated fair value espp shares purchased preferred share purchase rights plan november adopted preferred share purchase rights plan plan provides distribution preferred stock purchase right dividend share gilead common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment aspecified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade gilead common stock october board directors approved amendment purchase rights plan amendment provided among things increase exercise price right plan extension term plan november october acceleration stock options december completed sale oncology assets osi part transaction accelerated approximately options purchase gilead common stock value million see note discussion comprehensive income loss following reclassification adjustments required avoid doublecounting net realized gains losses sales securities previously included comprehensive income prior sales securities thousands year ended december net gain loss sales securities comprehensive income net unrealized gain loss arising year reclassification adjustment net unrealized gain loss reported comprehensive income loss balance accumulated comprehensive income reported balance sheet consists following components thousands december net unrealized gain availableforsale securities net unrealized gain cash flow hedges net foreign currency translation loss accumulated comprehensive income disclosures segments enterprise related information gilead determined one reportable segment management organized business along functional lines product sales consist following thousands year ended december viread ambisome following table summarizes revenues external customers collaborative partners geographic region revenues attributed countries based location customer collaborative partner thousands year ended december united states united kingdom france spain germany italy switzerland european countries countries consolidated total revenues december net book value property plant equipment million approximately assets located us december net book value property plant equipment million approximately assets located us product sales three distributors accounted approximately total revenues product sales one distributor exceed total revenues product sales one distributor accounted approximately total revenues total revenues fujisawa included product sales royalties approximately total revenues revenues roche including royalties milestone payments reimbursement research development expenses exceed total revenues account approximately total revenues income taxes gilead deferred provision income taxes current provision income taxes consisted following thousands year ended december current provision federal state foreign foreign pretax loss million million million difference provision taxes income amount computed applying federal statutory income tax rate income provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle explained thousands year ended december income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate benefitted unbenefitted losses federal alternative minimum taxes december us federal net operating loss carryforwards million state net operating loss carryforwards million federal net operating loss carryforwards expire various dates beginning utilized state net operating loss carryforwards expire various dates utilized addition federal state tax credit carryforwards approximately million million respectively expire years utilization net operating losses credits may subject annual limitation due ownership change limitations provided internal revenue code similar state provisions annual limitation may result expiration net operating losses credits utilization significant increase income tax expense resulted principally gain sale oncology assets osi recorded approximately million federal state alternative minimum taxes provision reduced change us income tax law law allows net operating loss carryforward deductions offset alternative minimum taxable income resulting reduction us income tax recorded previous years million deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities december follows thousands december net operating loss carryforwards research credits capitalized research development expenses reserves accruals currently deductible net total deferred tax assets valuation allowance net deferred tax assets recognized valuation allowance increased million year ended december decreased million year ended december approximately million valuation allowance december relates tax benefits stock option deductions credited additional paidin capital realized retirement savings planas december gilead maintains one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code prior january gilead maintained two separate retirement savings plans one plan primarily covered former nexstar employees nexstar plan plan primarily covered gilead 's remaining eligible employees gilead plan nexstar plan employee contributions could exceed eligible annual compensation addition nexstar plan included company match employee contributions maximum contributions annual maximum company match december approximately million representing shares gilead common stock held nexstar plan trust plan participants effective january nexstar plan terminated combined gilead plan shares gilead common stock held nexstar plan subsequently liquidated proceeds deposited various investment options available gilead plan gilead plan employees may contribute eligible annual compensation effective january gilead began making matching contributions gilead plan contribute employee 's first contributions annual maximum match total matching contribution gilead plan million million combined million plans related party transactions december chairman gilead 's board directors senior advisor investment fund owns controlling interest pharmaresearch corporation contract research organization performs services connection clinical studies gilead 's payments pharmaresearch corporation million december part arrangements contemplated proposed acquisition triangle pharmaceuticals inc gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissory note upon completion triangle acquisition january loan eliminated consolidated results result closing acquisition january see note subsequent events january completed acquisition outstanding stock triangle development stage company triangle active development antiviral drug candidates aggregate preliminary purchase price million including cash paid outstanding stock fair value options assumed estimated direct transaction costs employee termination costs intend account transaction first quarter expect record substantial portion aggregate purchase price inprocess research development expense quarterly results unaudited following table thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues total costs expenses net income loss net income loss per common sharebasic net income loss per common sharediluted st quarter nd quarter rd quarter th quarter total revenues total costs expenses income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted year ended december gilead adopted sfas reported cumulative effect change accounting principle first quarter diluted net income per common share fourth quarter includes effects stock options million convertible subordinated notes december completed sale oncology assets osi recorded nonoperating gain million fourth quarter result transaction gilead sciences inc schedule ii valuation qualifying accounts additions balance balance beginning charged charged end period expense deductions period year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets charged current tax expense charged deferred tax benefit signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized gilead sciences inc john c martin john c martin president chief executive officer power attorney know persons presents person whose signature appears constitutes appoints john c martin mark l perry true lawful attorneysinfact agents full power substitution resubstitution name place stead capacities sign amendments report file exhibits thereto documents connection therewith securities exchange commission granting unto said attorneysinfact agents full power authority perform every act thing requisite necessary done connection therewith fully intents purposes might could person hereby ratifying confirming said attorneysinfact agents substitute substitutes may lawfully cause done virtue hereof pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date john c martin president chief executive officer director march principal executive officer john c martin john f milligan senior vice president chief financial officer march principal financial accounting officer john f milligan james denny chairman board directors march james denny paul berg director march paul berg etienne f davignon director march etienne f davignon cordell w hull director march cordell w hull gordon e mooredirector march gordon e moore george p shultz director march george p shultz gayle e wilson director march gayle e wilson certifications john c martin certify reviewed annual report gilead sciences inc based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent functions significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknessesdate march john c martin john c martin president chief executive officer certifications john f milligan certify reviewed annual report gilead sciences inc based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent functions significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated quarterly report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses date march john f milligan john f milligan senior vice president chief financial officer quicklinks gilead sciences inc annual report table contentspart item business risk factors affect gilead risks related triangle acquisition january item properties item legal proceedings item submission matters vote securities holders part ii item market registrant 's common stock related stockholder matters equity compensation plan information item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management item certain relationships related transactions item controls procedures part iv gilead sciences inc consolidated financial statements years ended december contents report ernst young llp independent auditors report independent accountants gilead sciences inc consolidated balance sheets thousands except per share amounts gilead sciences inc consolidated statements operations thousands except per share amounts gilead sciences inc consolidated statement stockholders ' equity thousands gilead sciences inc consolidated statements cash flows thousands gilead sciences inc notes consolidated financial statements december gilead sciences inc schedule ii valuation qualifying accounts signatures certifications exhibit gilead sciences inc issuer jp morgan trust company national association trusteeindenture dated december convertible senior notes due december crossreference table trust indenture act section indenture section na na b c na b c na b c b b c b na c c c na na e f na b c e alast sentence aa ab na b c b b na c crossreference table part indenturetable contents article definitions provisions general application section definitions section compliance certificates opinions section form documents delivered trustee section acts holders securities section notices etc trustee company section notice holders securities waiver section effect headings table contents section successors assigns section separability clause section benefits indenture section governing law section legal holidays section conflict trust indenture act article ii security forms section form generally section form security section form certificate authentication section form conversion notice section form assignment article iii securities section title terms section denominations section execution authentication delivery dating section global securities nonglobal securities bookentry provisions section registration registration transfer exchange restrictions transfer section mutilated destroyed lost stolen securities section payment interest interest rights preserved section persons deemed owners section cancellation section computation interest section cusip numbers itable contents continued article iv satisfaction discharge section satisfaction discharge indenture section application trust money article v remedies section events default section acceleration maturity rescission annulment section collection indebtedness suits enforcement trustee section trustee may file proofs claim section trustee may enforce claims without possession securities section application money collected section limitation suits section unconditional right holders receive principal premium interest convert section restoration rights remedies section rights remedies cumulative section delay omission waiver section control holders securities section waiver past defaults section undertaking costs section waiver stay usury extension laws article vi trustee section certain duties responsibilities section notice defaults section certain rights trustee section responsible recitals issuance securities section may hold securities act trustee indentures section money held trust section compensation reimbursement section corporate trustee required eligibility section resignation removal appointment successor section acceptance appointment successor iitable contents continued section merger conversion consolidation succession business section authenticating agents section disqualification conflicting interests section preferential collection claims company article vii consolidation merger conveyance transfer lease section company may consolidate etc certain terms section successor substituted article viii supplemental indentures section supplemental indentures without consent holders securities section supplemental indentures consent holders securities section execution supplemental indentures section effect supplemental indentures section reference securities supplemental indentures section notice supplemental indentures article ix meetings holders securities section purposes meetings may called section call notice place meetings section persons entitled vote meetings section quorum action section determination voting rights conduct adjournment meetings section counting votes recording action meetings article x covenants section payment principal premium interest section maintenance offices agencies section money security payments held trust section existence iiitable contents continued section intentionally left blank section payment taxes claims section registration listing section statement officers default section delivery certain information section resale certain securities section registration rights section waiver certain covenants article xi redemption securities section right redemption section applicability article section election redeem notice trustee section selection trustee securities redeemed section notice redemption section deposit redemption price section securities payable redemption date section conversion arrangement call redemption article xii conversion securities section conversion privilege conversion rate section exercise conversion privilege section fractions shares section adjustment conversion rate section notice adjustments conversion rate section notice certain corporate action section company reserve common stock section taxes conversions section covenant common stock section cancellation converted securities section provision case consolidation merger sale assets section rights issued respect common stock section responsibility trustee conversion provisions ivtable contents continued article xiii repurchase securities option holder upon change control section right require repurchase section conditions companys election pay repurchase price common stock section notices method exercising repurchase right etc section certain definitions section consolidation merger etc article xiv holders lists reports trustee company nonrecourse section company furnish trustee names addresses holders section preservation information section reports trustee section reports company article xv immunity incorporators stockholders officers directors section indenture securities solely corporate obligations vindenture dated december gilead sciences inc corporation duly organized existing laws state delaware principal office lakeside drive foster city california herein called company jp morgan trust company national association national banking association trustee hereunder herein called trustee recitals company company duly authorized creation issue convertible senior notes due december herein called securities substantially tenor amount hereinafter set forth provide therefor company duly authorized execution delivery indenture things necessary make securities securities executed company authenticated delivered hereunder valid obligations company make indenture valid agreement company accordance terms done things necessary duly authorize issuance common stock company issuable upon conversion securities duly reserve issuance number shares common stock issuable upon conversion done therefore indenture witnesseth consideration premises purchase securities holders thereof mutually covenanted agreed equal proportionate benefit holders securities follows article definitions provisions general application section definitions purposes indenture except otherwise expressly provided unless context otherwise requires terms defined article meanings assigned article include plural well singular accounting terms otherwise defined herein meanings assigned accordance generally accepted accounting principles united states except otherwise herein expressly provided term generally accepted accounting principles respect computation required permitted hereunder shall mean accounting principles generally accepted date computation words herein hereof hereunder words similar import refer indenture whole particular article section subdivisionact used respect holder security meaning specified section affiliate specified person means person directly indirectly controlling controlled direct indirect common control specified person purposes definition control used respect specified person means power direct management policies person directly indirectly whether ownership voting securities contract otherwise terms controlling controlled meanings correlative foregoing agent member means member participant depositary applicable procedures means respect transfer transaction involving global security beneficial interest therein rules procedures dtc successor depository case extent applicable transaction effect time time authenticating agent means person authorized pursuant section act behalf trustee authenticate securities board directors means either board directors company duly authorized committee board board resolution means resolution duly adopted board directors copy certified secretary assistant secretary company duly adopted board directors full force effect date certification shall delivered trustee business day used respect place payment place conversion place case may means monday tuesday wednesday thursday friday day banking institutions place payment place conversion place case may authorized obligated law executive order close change control meaning specified section closing price per share means respect common stock day last reported sale price regular way nasdaq national market ii common stock quoted nasdaq national market last reported sale price regular way per share case reported sale takes place day average reported closing bid asked prices regular way either case principal national securities exchange common stock listed admitted trading iii common stock quoted nasdaq national market listed admitted trading national securities exchange average closing bid asked prices overthecounter market furnished new york stock exchange member firm selected time time company purpose code meaning specified section l commission means united states securities exchange commission time time constituted created exchange act time execution indenture commission existing performing duties assigned trust indenture act body performing duties time common stock means common stock par value per share company authorized date indenture originally executed stock may constituted time time including upon change par value securities subject provisions section shares issuable conversion securities shall include shares common stock shares class classes common stock resulting reclassification reclassifications thereof provided however time shall one resulting class shares issuable conversion securities shall include shares classes shares class issuable shall substantially proportion total number shares class resulting reclassifications bears total number shares classes resulting reclassifications provided references common stock payable connection purchase securities upon change control accordance terms section shall deemed include common stock entity including parent company entity consolidate merge merged us sell transfer substantially assets common stock includes stock class capital stock preference respect dividends amounts payable event voluntary involuntary liquidation dissolution winding issuer thereof unrestricted voting rights subject redemption issuer thereof company means person named company first paragraph indenture successor person shall become pursuant applicable provisions indenture thereafter company shall mean successor person company notice meaning specified section company request company order means written request order signed name company officer company delivered trustee constituent person meaning specified section conversion agent means person authorized company convert securities accordance article xii company initially appointed trustee conversion agent pursuant section hereof conversion price meaning specified section conversion rate meaning specified section corporate trust office means office trustee particular time trust created indenture shall principally administered date indenture located mission street th floor san francisco california attention institutional trust services corporation means corporation company association jointstock company business trust defaulted interest meaning specified section depositary means respect securities including global securities clearing agency registered exchange act designated company act depositary securities successor securities clearing agency registered dollar us means dollar equivalent unit coin currency united states time shall legal tender payment public private debts dtc means depository trust company new york corporation effective failure meaning specified section effectiveness period meaning specified section event default meaning specified section exchange act means united states securities exchange act successor statute amended time time global security means security registered security register name depositary nominee thereof holder means person whose name security registered security register indenture means indenture originally executed may time time supplemented amended one indentures supplemental hereto entered pursuant applicable provisions hereof including purposes indenture supplemental indenture provisions trust indenture act deemed part govern indenture supplemental indenture respectively initial purchaser means goldman sachs co initial purchaser option meaning specified section interest payment date means stated maturity installment interest securities issue date means december liquidated damages meaning specified section makewhole payment meaning specified section maturity used respect security means date principal security becomes due payable therein herein provided whether stated maturity declaration acceleration call redemption exercise repurchase right set forth article xiii otherwise nonelecting share meaning specified section notice date meaning specified section notice default meaning specified section officer means chairman cochairman board directors vice chairman board directors chief executive officer chief operating officer president executive vice president vice president chief financial officer company officers certificate means certificate signed officer company delivered trustee opinion counsel means written opinion counsel may counsel company general counsel company shall reasonably acceptable trustee outstanding used respect securities means date determination securities theretofore authenticated delivered indenture except securities theretofore canceled trustee delivered trustee cancellation ii securities money necessary amount pay redeem securities theretofore deposited trustee paying agent company trust set aside segregated trust company company shall act paying agent holders securities provided securities redeemed notice redemption duly given pursuant indenture provision therefor reasonably satisfactory trustee made iii securities paid pursuant section exchange lieu securities authenticated delivered pursuant indenture securities respect shall presented trustee proof satisfactory securities held bona fide purchaser whose hands securities valid obligations company iv securities converted common stock pursuant article xii provided however determining whether holders requisite principal amount outstanding securities present meeting holders securities quorum purposes given request demand authorization direction notice consent waiver hereunder securities owned company obligor upon securities affiliate company obligor shall disregarded deemed outstanding except determining whether trustee shall protected relying upon determination presence quorum upon request demand authorization direction notice consent waiver securities responsible officer trustee notified writing owned shall disregarded securities owned pledged good faith may regarded outstanding pledgee company obligor upon securities affiliate company obligor trustee shall protected relying upon officers certificate effect paying agent means person authorized company pay principal interest securities behalf company except otherwise specifically set forth herein term shall include company shall act paying agent company initially appointed trustee paying agent pursuant section hereof person means individual corporation limited liability company partnership joint venture trust estate unincorporated organization government agency political subdivision thereof place conversion meaning specified section place payment meaning specified section predecessor security particular security means every previous security evidencing portion debt evidenced particular security purposes definition security authenticated delivered section exchange lieu mutilated destroyed lost stolen security shall deemed evidence debt mutilated destroyed lost stolen security provisional redemption meaning specified section purchase agreement means purchase agreement dated december company initial purchaser agreement may amended time time qualified institutional buyer shall mean qualified institutional buyer defined rule record date means regular record date special record date record date period means period close business regular record date next preceding interest payment date opening business interest payment date redemption date used respect security redeemed means date fixed redemption pursuant indenture redemption price used respect security redeemed means price redeemed pursuant indenture registrable securities meaning specified section registration default meaning specified section registration rights agreement means registration rights agreement dated december company initial purchaser agreement may amended time time accordance terms regular record date interest payable respect security interest payment date means june december whether business day case may next preceding interest payment date repurchase date meaning specified section repurchase price meaning specified section responsible officer used respect trustee means officer within corporate trust office trustee direct responsibility administration indenture also means respect particular corporate trust matter officer matter referred knowledge familiarity particular subject restricted global security meaning specified section restricted securities means securities required pursuant section bear restricted securities legend term includes restricted global security restricted securities legend means collectively legends substantially forms legends required form security set forth section placed upon restricted security rule means rule securities act successor provision may amended time time rule means rule securities act successor provision may amended time time rule information meaning specified section securities meaning ascribed first paragraph caption recitals company securities act means united states securities act successor statute amended time time security register security registrar respective meanings specified section shelf registration statement meaning specified section significant subsidiary means respect person subsidiary person would constitute significant subsidiary term defined rule regulation sx securities act exchange act special record date payment defaulted interest means date fixed company pursuant section stated maturity used respect security installment interest thereon means date specified security fixed date principal security installment interest due payable subsidiary means corporation outstanding voting stock owned directly indirectly company one subsidiaries company one subsidiaries purposes definition voting stock means stock similar interests corporation ordinarily voting power election directors persons performing similar functions whether times long senior class stock interests voting power reason contingency successor security particular security means every security issued evidencing portion debt evidenced particular security purposes definition security authenticated delivered section exchange lieu mutilated destroyed lost stolen security shall deemed evidence debt mutilated destroyed lost stolen security surrender certificate means certificate substantially form set forth annex b trading day means common stock quoted nasdaq national market system automated dissemination quotations securities prices days trades may effected system ii common stock listed admitted trading national regional securities exchange days national regional securities exchange open business iii common stock listed national regional securities exchange quoted nasdaq national market system automated dissemination quotation securities prices days common stock traded regular way overthecounter market closing bid closing asked price common stock available trust indenture act means trust indenture act rules regulations thereunder force date indenture executed provided however event trust indenture act amended date trust indenture act means extent required amendment trust indenture act rules regulations thereunder amended trustee means person named trustee first paragraph indenture successor trustee shall become pursuant applicable provisions indenture thereafter trustee shall mean successor trustee united states means united states america including states district columbia territories possessions areas subject jurisdiction possessions including puerto rico us virgin islands guam american samoa wake island northern mariana islands unrestricted securities certificate means certificate substantially form set forth annex section compliance certificates opinions upon application request company trustee take action provision indenture company shall furnish trustee officers certificate stating conditions precedent provided indenture relating proposed action complied opinion counsel stating opinion counsel conditions precedent complied except case application request furnishing documents specifically required provision indenture relating particular application request additional certificate opinion need furnished every certificate opinion respect compliance condition covenant provided indenture including certificates provided section shall include statement individual signing certificate opinion read covenant condition definitions herein relating thereto brief statement nature scope examination investigation upon statements opinions contained certificate opinion based statement opinion individual made examination investigation necessary enable express informed opinion whether covenant condition complied statement whether opinion individual condition covenant complied section form documents delivered trustee case several matters required certified covered opinion specified person necessary matters certified covered opinion one person certified covered one document one person may certify give opinion respect matters one persons matters person may certify give opinion matters one several documents certificate opinion officer company may based insofar relates legal matters upon certificate opinion representations counsel unless officer knows exercise reasonable care know certificate opinion representations respect matters upon certificate opinion based erroneous certificate opinion counsel may based insofar relates factual matters upon certificate opinion representations officer officers company person stating information respect factual matters possession company person unless counsel knows exercise reasonable care know certificate opinion representations respect matters erroneous person required make give execute two applications requests consents certificates statements opinions instruments indenture may need consolidated form one instrument section acts holders securities request demand authorization direction notice consent waiver action provided permitted indenture given taken holders securities may embodied evidenced one instruments substantially similar tenor signed holders person agent proxy duly appointed writing holders b record holders securities voting favor thereof either person proxies duly appointed writing meeting holders securities duly called held accordance provisions article ix action shall become effective instrument instruments record delivered trustee hereby expressly required company trustee shall promptly deliver company copies instruments records delivered trustee instrument instruments records action embodied therein evidenced thereby herein sometimes referred act holders securities signing instrument instruments voting meeting proof execution instrument writing appointing agent proxy holding person security shall sufficient purpose indenture subject section conclusive favor trustee company made manner provided section record meeting holders securities shall proved manner provided section fact date execution person instrument writing may proved affidavit witness execution certificate notary public officer authorized law take acknowledgments deeds certifying individual signing instrument writing acknowledged execution thereof execution signer acting capacity individual capacity certificate affidavit shall also constitute sufficient proof authority principal amount serial number security held person date holding shall proved security register fact date execution instrument writing authority person executing may also proved manner trustee deems sufficient trustee may instance require proof respect matters referred section company may set day record date purpose determining holders entitled give take request demand authorization direction notice consent waiver action vote action authorized permitted indenture given taken holders promptly case later ten days setting record date company shall notify trustee holders record date set company prior first solicitation holder made person respect action case vote prior vote record date action vote shall th day later date recent list holders required provided pursuant section prior first solicitation vote case may regard record date holders date duly appointed agents proxies persons shall entitled give take vote relevant action whether holders remain holders record date notwithstanding foregoing company shall set record date provisions paragraph shall apply respect notice declaration direction referred next paragraph upon receipt trustee holder notice default breach referred section default breach occurred continuing trustee shall given notice company ii declaration acceleration referred section event default occurred continuing trustee shall given declaration company iii direction referred section trustee shall taken action specified direction respect clauses ii iii record date shall automatically without action company trustee set determining holders entitled join declaration direction record date shall close business tenth day day business day first business day thereafter following day trustee receives declaration direction respect clause trustee may set day record date purpose determining holders entitled join notice default promptly receipt trustee declaration direction referred clause ii iii promptly setting record date respect clause soon practicable thereafter trustee shall notify company holders record date fixed holders record date duly appointed agents proxies persons shall entitled join notice declaration direction whether holders remain holders record date provided unless notice declaration direction shall become effective virtue holders requisite principal amount securities record date duly appointed agents proxies joined therein prior th day record date notice declaration direction shall automatically without action person canceled effect nothing paragraph shall construed prevent holder duly appointed agent proxy thereof giving expiration day period notice declaration direction contrary different expiration period identical notice declaration direction record date relates event new record date respect thereof shall set pursuant paragraph addition nothing paragraph shall construed render ineffective notice declaration direction type referred paragraph given time trustee company holders duly appointed agents proxies requisite principal amount securities date notice declaration direction given except provided sections request demand authorization direction notice consent election waiver act holder security shall bind every future holder security holder every security issued upon registration transfer thereof exchange therefor lieu thereof respect anything done omitted suffered done trustee company reliance thereon whether notation action made upon security provisions section subject provisions section section notices etc trustee company request demand authorization direction notice consent election waiver act holders securities document provided permitted indenture made upon given furnished filed trustee holder securities company shall sufficient every purpose hereunder made given furnished filed writing responsible officer trustee received corporate trust office attention institutional trust services company trustee holder securities shall sufficient every purpose hereunder unless otherwise herein expressly provided writing mailed firstclass postage prepaid telecopied confirmed mail firstclass postage prepaid delivered hand overnight courier addressed company lakeside drive foster city california attention chief financial officer address previously furnished writing trustee company section notice holders securities waiver except otherwise expressly provided herein indenture provides notice holders securities event notice shall sufficiently given holders writing mailed firstclass postage prepaid delivered overnight delivery service holder security affected event address holder appears security register earlier earliest date later latest date prescribed giving notice neither failure mail notice defect notice mailed particular holder security shall affect sufficiency notice respect holders securities case reason suspension regular mail service reason cause shall impracticable give notice mail notification holders securities shall made approval trustee approval shall unreasonably withheld shall constitute sufficient notification holders every purpose hereunder notice shall deemed given three days mailing mail one day mailing overnight courier date notice furnished telecopy hand indenture provides notice manner notice may waived writing person entitled receive notice either event waiver shall equivalent notice waivers notice holders securities shall filed trustee filing shall condition precedent validity action taken reliance upon waiver section effect headings table contents article section headings herein table contents convenience shall affect construction hereof section successors assigns covenants agreements indenture company shall bind successors assigns whether expressed section separability clause case provision indenture securities shall invalid illegal unenforceable validity legality enforceability remaining provisions shall way affected impaired thereby section benefits indenture nothing indenture securities express implied shall give person parties hereto successors assigns hereunder holders securities benefit legal equitable right remedy claim indenture section governing law indenture securities shall governed construed accordance laws state new york united states america section legal holidays case interest payment date redemption date repurchase date stated maturity security last day holder security right convert security shall business day place payment place conversion case may notwithstanding provision indenture securities payment principal premium interest payment redemption price repurchase price whether payable cash shares common stock combination thereof case repurchase price respect delivery conversion security need made place payment place conversion case may day may made next succeeding business day place payment place conversion case may force effect made interest payment date redemption date repurchase date stated maturity last day conversion provided however case payment made succeeding business day interest shall accrue amount payable period interest payment date redemption date repurchase date stated maturity last day conversion case may section conflict trust indenture act provision hereof limits qualifies conflicts provision trust indenture act required act part govern indenture latter provision shall control provision indenture modifies excludes provision trust indenture act may modified excluded latter provision shall deemed apply indenture modified excluded case may time indenture shall qualified trust indenture act indenture company trustee shall deemed purposes hereof subject governed trust indenture act extent would case indenture qualified date hereof article ii security forms section form generally securities shall substantially form set forth article appropriate insertions omissions substitutions variations required permitted indenture may letters numbers marks identification legends endorsements placed thereon may required comply rules securities exchange internal revenue code amended regulations thereunder code may consistent herewith determined officers executing securities evidenced execution thereof securities shall fully registered form trustees certificates authentication shall substantially form set forth section conversion notices shall substantially form set forth section repurchase notices shall substantially form set forth section securities shall printed lithographed typewritten engraved produced combination methods may produced manner permitted rules automated quotation system securities exchange including steel engraved borders required securities exchange upon securities may listed securities may quoted listed case may determined officers executing securities evidenced execution thereof upon original issuance securities issued contemplated purchase agreement qualified institutional buyers reliance rule shall issued form one global securities definitive fully registered form without interest coupons bearing restricted securities legend global security shall registered name dtc depositary nominee deposited trustee custodian dtc credit dtc respective accounts beneficial owners securities represented thereby accounts may direct global security together successor securities global securities collectively herein called restricted global security section form security form face following legend shall appear face restricted security note common stock issuable upon conversion note registered us securities act amended securities act may sold otherwise transferred absence registration applicable exemption therefrom purchaser note hereby notified seller note may relying exemption provisions section securities act provided rule thereunder note common stock issuable upon conversion note may offered sold pledged otherwise transferred except person transferor reasonably believes qualified institutional buyer within meaning rule securities act acquiring account account qualified institutional buyer transaction meeting requirements rule pursuant exemption registration securities act provided rule thereunder available institutional investor accredited investor within meaning rule regulation securities act pursuant exemption registration securities act available pursuant effective registration statement securities act b accordance applicable securities laws states united states jurisdictions note shares common stock issuable upon conversion related documentation may amended supplemented time time modify restrictions resales transfers note shares reflect change applicable law regulation interpretation thereof practices relating resale transfer restricted securities generally holder note shares shall deemed acceptance note shares agreed amendment supplement following legend shall appear face global security security global security within meaning indenture hereinafter referred registered name depositary nominee depositary may treated company trustee agent thereof owner holder security purposes unless certificate presented authorized representative depository trust company new york corporation dtc company agent registration transfer exchange payment certificate issued registered name cede co name requested authorized representative dtc payment made cede co entity requested authorized representative dtc transfer pledge use hereof value otherwise person wrongful inasmuch registered owner hereof cede co interest herein unless exchanged whole part securities definitive registered form limited circumstances referred indenture global security may transferred except whole depositary nominee depositary nominee depositary depositary another nominee depositary depositary nominee successor depositary nominee successor depositary gilead sciences inc convertible senior note due december cusip ac gilead sciences inc corporation duly organized existing laws state delaware herein called company term includes successor person indenture referred reverse hereof value received hereby promises pay registered assigns principal sum united states dollars us security global security insert principal amount may time time increased decreased principal amounts taken together principal amounts outstanding securities shall exceed initial purchaser option exercised full adjustments made records trustee hereinafter referred accordance indenture december pay interest thereon december recent interest payment date defined interest paid duly provided semiannually arrears june december year interest payment date commencing june rate per annum principal hereof due rate per annum overdue principal premium extent permitted law overdue interest interest payable punctually paid duly provided interest payment date provided indenture paid person whose name security one predecessor securities registered close business regular record date interest shall june december whether business day case may next preceding interest payment date except otherwise provided indenture interest punctually paid duly provided forthwith cease payable holder regular record date may either paid person whose name security one predecessor securities registered close business special record date payment defaulted interest fixed company notice whereof shall given holders securities less days prior special record date paid time lawful manner inconsistent requirements automated quotation system securities exchange securities may quoted listed upon notice may required exchange fully provided indenture payments principal shall made upon surrender security option holder corporate trust office trustee office agency company may designated purpose borough manhattan city new york lawful monies united states america time payment shall legal tender payment public private debts offices agencies company may designate united states dollar check drawn wire transfer united states dollar account wire transfer made holder aggregate principal amount securities excess us holder shall furnished wire instructions writing trustee later days prior relevant payment date payment interest security may made united states dollar check mailed address person entitled thereto address shall appear security register upon written application holder security registrar setting forth wire instructions later relevant record date transfer united states dollar account wire transfer made holder aggregate principal amount securities excess us holder shall furnished wire instructions writing trustee later days prior relevant payment date except specifically provided herein indenture company shall required make payment respect tax assessment governmental charge imposed government political subdivision taxing authority thereof therein reference hereby made provisions security set forth reverse hereof provisions shall purposes effect set forth place unless certificate authentication hereon executed trustee referred reverse hereof authenticating agent manual signature one respective authorized signatories security shall entitled benefit indenture valid obligatory purpose witness whereof company caused security duly executed gilead sciences inc name title trustees certificate authentication one securities referred withinmentioned indenture dated jp morgan trust company national association trustee authorized signatory form reverse security one duly authorized issue securities company designated convertible senior notes due december herein called securities limited aggregate principal amount us initial purchasers option exercised full issued issued indenture dated december herein called indenture company jp morgan trust company national association trustee herein called trustee term includes successor trustee indenture indenture indentures supplemental thereto reference hereby made statement respective rights limitations rights duties immunities thereunder company trustee holders securities terms upon securities authenticated delivered provided indenture subject certain limitations therein set forth securities exchangeable like aggregate principal amount securities authorized denominations requested holder surrendering upon surrender security securities exchanged corporate trust office trustee trustee upon surrender holder issue new securities requested denominations sinking fund provided securities securities subject provisional redemption company provisional redemption whole part time june prior december upon notice set forth section indenture redemption price equal principal amount securities redeemed plus accrued unpaid interest redemption date closing price per share common stock shall exceeded conversion price effect least trading days consecutive trading day period ending trading day prior date mailing notice redemption pursuant section indenture notice date ii shelf registration statement covering resales securities common stock effective available use expected remain effective available use days following redemption date unless registration longer required upon redemption company shall make additional payment makewhole payment respect securities called redemption holders notice date amount equal per principal amount securities less amount interest actually paid accrued unpaid securities prior redemption date company shall make makewhole payment securities called redemption including securities converted common stock pursuant terms indenture notice date prior redemption date makewhole payment securities converted common stock pursuant terms indenture notice date prior redemption date shall reduced accrued unpaid interest unless redemption date occurs business day following record date prior next succeeding interest payment date case makewhole payment shall reduced interest due interest payment date company may make makewhole payment x cash subject fulfillment company conditions set forth following paragraph shares common stock combination cash common stock company shall specify type consideration makewhole payment company notice purposes paragraph fair market value shares common stock shall determined company shall equal average closing prices per share five consecutive trading days ending third trading day prior redemption date following shall constitute conditions election company pay makewhole payment portion thereof shares common stock shares common stock issued payment makewhole payment portion thereof hereunder shall require registration federal securities law shares may freely transferable without subject transfer restrictions securities act upon repurchase registration required registration shall completed shall become effective prior redemption date company shall state notice provisional redemption company expects registration statement shall remain effective least days following redemption date b shares common stock issued payment makewhole payment portion thereof hereunder shall require registration approval governmental authority state law federal law shares may validly issued delivered upon repurchase registration required approval must obtained registration shall completed approval shall obtained prior redemption date c shares common stock issued payment makewhole payment portion thereof hereunder shall approved quotation nasdaq national market listed national securities exchange either case prior redemption date shares common stock may issued payment makewhole payment portion thereof issued companys authorized unissued common stock upon issue duly validly issued fully paid non assessable free preemptive similar rights e conditions set forth clauses satisfied accordance terms thereof make whole payment shall paid company cash securities also subject redemption option company time december whole part upon less days notice holders prior redemption date redemption prices expressed percentages principal amount set forth securities redeemed following periods described period redemption price beginning december december beginning december december thereafter redemption price equal principal amount together case accrued interest excluding redemption date provided however interest installments securities whose stated maturity prior redemption date payable holders securities one predecessor securities record close business relevant record dates referred face hereof provided indenture event redemption securities company required register transfer exchange securities period days immediately preceding date notice given identifying serial numbers securities called redemption b register transfer exchange security portion thereof called redemption case due date payment principal premium interest liquidated damages security last day holder security right convert security shall place payment place conversion case may day banking institutions place payment place conversion authorized obligated law executive order close payment principal premium interest liquidated damages delivery conversion security need made date place may made next succeeding day place day banking institutions authorized obligated law executive order close force effect made date payment date fixed redemption repurchase last day conversion interest shall accrue amount payable period date subject upon compliance provisions indenture holder security entitled option time close business date maturity case security portion hereof called redemption holder hereof exercised right require company repurchase security portion hereof respect security second business day immediately preceding unless company defaults making payment due upon redemption repurchase case may close business second business day immediately preceding redemption date repurchase date case may convert security portion principal amount hereof integral multiple us provided unconverted portion principal amount us integral multiple us excess thereof fully paid nonassessable shares common stock company initial conversion rate shares common stock us principal amount securities current adjusted conversion rate adjustment made provided indenture surrender security duly endorsed assigned company blank case surrender shall made period close business regular record date next preceding interest payment date opening business interest payment date except security portion thereof called redemption redemption date repurchasable repurchase date occurring either case period close business regular record date next preceding interest payment date close business third business day following interest payment date result right convert security would otherwise terminate period exercised also accompanied payment new york clearing house funds acceptable company amount equal interest payable interest payment date principal amount security converted also conversion notice hereon duly executed company corporate trust office trustee office agency company subject laws regulations applicable thereto subject right company terminate appointment conversion agent defined may designated purpose borough manhattan city new york offices agencies company may designate conversion agent provided security portion hereof called redemption except pursuant call provisional redemption redemption date repurchasable repurchase date occurring either case period close business regular record date next preceding interest payment date close business third business day following interest payment date result right convert security would otherwise terminate period exercised security surrendered conversion period holder security regular record date entitled receive interest accruing hereon interest payment date next preceding date conversion succeeding interest payment date holder security converts security portion hereof period shall required pay interest upon surrender security conversion subject provisions preceding sentence case conversion close business regular record date next preceding interest payment date close business third business day following interest payment date right holder security predecessor security record regular record date receive related installment interest extent circumstances provided indenture cash payment adjustment made conversion interest accrued hereon interest payment date next preceding day conversion dividends common stock issued conversion hereof company shall thereafter deliver holder fixed number shares common stock together cash adjustment provided indenture security convertible delivery deemed satisfy companys obligation pay principal amount security fractions shares scrip representing fractions shares issued conversion instead fractional interest calculated nearest th share company shall pay cash adjustment provided indenture conversion rate subject adjustment provided indenture addition indenture provides case certain consolidations mergers company party consolidation merger result reclassification conversion exchange cancellation common stock conveyance transfer sale lease mere grant security interest substantially property assets company indenture shall amended without consent holders securities security outstanding convertible thereafter period security shall convertible specified kind amount securities cash property receivable upon consolidation merger conveyance transfer sale lease holder number shares common stock company security could converted immediately prior consolidation merger conveyance transfer sale lease assuming holder common stock constituent person affiliate constituent person failed exercise rights election received per share kind amount received per share plurality nonelecting shares adjustment conversion rate made adjustment would require increase decrease least one percent rate provided adjustment would otherwise made carried forward taken account computation subsequent adjustment security registrable security defined indenture holder security security global security insert including person beneficial interest security common stock company issuable upon conversion hereof entitled benefits registration rights agreement dated december registration rights agreement company initial purchaser pursuant registration rights agreement company agreed benefit holders time time registrable securities expense within days issue date file shelf registration statement shelf registration statement commission respect resales registrable securities b use reasonable best efforts cause shelf registration statement declared effective commission within days issue date securities provided however company may upon written notice holders postpone shelf registration statement declared effective reasonable period exceed days company possesses material nonpublic information disclosure would material adverse effect company subsidiaries taken whole c use reasonable best efforts maintain shelf registration statement effective securities act earliest two years effective date shelf registration statement ii expiration period referred rule k securities act respect registrable securities held nonaffiliates company iii outstanding registrable securities effectiveness period company permitted suspend use prospectus part shelf registration statement certain periods time provided registration rights agreement prior th day following issue date shelf registration statement filed commission ii prior th day following issue date shelf registration statement declared effective registration default additional interest liquidated damages accrue restricted security including day following registration default excluding day registration default cured liquidated damages paid semi annually arrears first semiannual payment due first interest payment date applicable respect restricted securities following date liquidated damages begin accrue accrue rate per annum equal onequarter one percent principal amount restricted securities including th day following registration default rate per annum equal onehalf one percent thereof st day following registration default pursuant registration rights agreement event shelf registration statement ceases effective holders registrable securities otherwise prevented restricted company effecting sales pursuant thereto effective failure effectiveness period days whether consecutive day period days whether consecutive month period liquidated damages accrue rate per annum equal additional onehalf one percent principal amount restricted securities st day applicable day period st day applicable month period earlier time effective failure cured b effectiveness period expires whenever security reference context payment principal premium interest respect security mention shall deemed include mention payment liquidated damages payable described preceding paragraph extent context liquidated damages would payable respect security express mention payment liquidated damages applicable provisions security shall construed excluding liquidated damages provisions security express mention made security registrable security holder security security global security insert including person beneficial interest security elects sell security pursuant shelf registration statement acceptance hereof holder security agrees bound terms registration rights agreement relating registrable securities subject election change control occurs holder security holders option shall right accordance provisions indenture require company repurchase security portion principal amount hereof least integral multiple excess thereof provided portion principal amount security outstanding repurchase least equal us repurchase price equal principal amount thereof plus interest accrued unpaid excluding repurchase date option company repurchase price may paid cash subject conditions provided indenture delivery shares common stock fair market value equal repurchase price less cash payments combination thereof purposes paragraph fair market value shares common stock shall determined company shall equal average closing prices per share five consecutive trading days ending third trading day prior repurchase date whenever security reference context principal security time reference shall deemed include reference repurchase price payable respect security extent repurchase price would payable time express mention repurchase price provision security shall construed excluding repurchase price payable provisions security express mention made following paragraph shall appear global security event deposit withdrawal interest security including exchange transfer redemption repurchase conversion security part trustee custodian depositary shall make adjustment records reflect deposit withdrawal accordance applicable procedures following paragraph shall appear security global security event redemption repurchase conversion security part new security securities unredeemed unrepurchased unconverted portion hereof issued name holder hereof event default shall occur continuing principal securities together accrued interest date declaration may declared due payable manner effect provided indenture upon payment amount principal declared due payable together accrued interest date declaration ii interest overdue principal extent permitted applicable law overdue interest companys obligations respect payment principal interest securities shall terminate indenture permits certain exceptions therein provided amendment thereof modification rights obligations company rights holders securities indenture time company trustee either written consent holders less majority principal amount securities time outstanding b adoption resolution meeting holders outstanding securities quorum present holders least majority aggregate principal amount outstanding securities represented entitled vote meeting indenture also contains provisions permitting holders specified percentages principal amount securities time outstanding behalf holders securities waive compliance company certain provisions indenture certain past defaults indenture consequences consent waiver holder security shall conclusive binding upon holder upon future holders security security issued exchange therefor lieu hereof whether notation consent waiver made upon security security provided subject provisions indenture holder security shall right institute proceeding respect indenture appointment receiver trustee remedy thereunder unless holder shall previously given trustee written notice continuing event default holders less principal amount outstanding securities shall made written request trustee institute proceedings respect event default trustee offered trustee reasonable indemnity trustee shall received holders majority principal amount securities outstanding direction inconsistent request shall failed institute proceeding days receipt notice request offer indemnity foregoing shall apply suit instituted holder security enforcement payment principal hereof premiums interest including liquidated damages hereon respective due dates expressed herein enforcement right convert security provided indenture reference herein indenture provision security indenture shall alter impair obligation company absolute unconditional pay principal premium interest including liquidated damages security times places rate coin currency herein prescribed convert security provided indenture provided indenture subject certain limitations therein set forth transfer security registrable security register upon surrender security registration transfer corporate trust office trustee office agency company may designated purpose borough manhattan city new york shall initially office agency trustee offices agencies company may designate duly endorsed accompanied written instrument transfer form satisfactory company security registrar duly executed holder thereof attorney duly authorized writing thereupon one new securities authorized denominations aggregate principal amount issued designated transferee transferees registrar service charge shall made registration transfer exchange company may require payment sum sufficient recover tax governmental charge payable connection therewith prior due presentation security registration transfer company trustee agent company trustee may treat person whose name security registered owner thereof purposes whether security overdue neither company trustee agent shall affected notice contrary recourse payment principal premium interest security recourse upon obligation covenant agreement company indenture indenture supplemental thereto security creation indebtedness represented thereby shall incorporator stockholder employee agent officer director subsidiary past present future company successor corporation either directly company successor corporation whether virtue constitution statute rule law enforcement assessment penalty otherwise liability acceptance hereof part consideration issue hereof expressly waived released indenture security shall governed construed accordance laws state new york united states america terms used security defined indenture shall meanings assigned indenture abbreviations following abbreviations used inscription face security shall construed though written full according applicable laws regulations ten com tenant common unif gift min act custodian ten ent tenants entireties cust cust minor jt ten joint tenants right survivorship uniform gifts tenants common minors act state additional abbreviations may also used though list election holder require repurchase pursuant section indenture undersigned hereby elects security repurchased company undersigned hereby directs trustee company pay amount cash companys election common stock valued set forth indenture equal principal amount repurchased less cash payments set forth combination cash common stock plus interest accrued excluding repurchase date provided indenture dated signatures signatures must guaranteed eligible guarantor institution membership approved signature guarantee program pursuant rule ad securities exchange act signature guaranteed principal amount repurchased least us integral multiple excess thereof remaining principal amount following repurchase less us notice signature foregoing election must correspond name written upon face security every particular without alteration change whatsoever section form certificate authentication trustees certificate authentication shall substantially following form one securities referred withinmentioned indenture dated jp morgan trust company national association trustee authorized signatory section form conversion notice conversion notice undersigned holder security hereby irrevocably exercises option convert security portion principal amount hereof us integral multiple us excess thereof provided unconverted portion principal amount us integral multiple us excess thereof designated shares common stock accordance terms indenture referred security directs shares together check payment fractional share securities representing unconverted principal amount hereof delivered registered name undersigned unless different name indicated shares common stock securities registered name person undersigned undersigned pay transfer taxes payable respect thereto b signatures must guaranteed eligible guarantor institution membership approved signature guarantee program pursuant rule ad securities exchange act amount required paid undersigned account interest accompanies security dated signatures shares securities registered name person holder please print persons name address name address social security identification number signatures must guaranteed eligible guarantor institution membership approved signature guarantee program pursuant rule ad securities exchange act signature guaranteed portion securities converted please indicate principal amount converted us principal amount denomination securities representing unconverted principal amount issued amount us denominations us us integral multiple us excess thereof provided unconverted portion principal amount us integral multiple us excess thereof section form assignment value received hereby sells assigns transfers unto please insert social security identifying number assignee within security hereby irrevocably constitutes appoints attorney transfer said security books company full power substitution premises dated signatures signatures must guaranteed eligible guarantor institution membership approved signature guarantee program pursuant rule ad securities exchange act signature guaranteed article iii securities section title terms aggregate principal amount securities may authenticated delivered indenture limited us initial purchaser option set forth section purchase agreement exercised full initial purchaser option except securities authenticated delivered pursuant section exchange lieu securities previously authenticated delivered indenture securities shall known designated convertible senior notes due december company stated maturity shall december shall bear interest principal amount december payable semiannually arrears june december year commencing june rate per annum principal thereof due rate per annum overdue principal extent permitted law overdue interest provided however payments shall made business day provided section principal premium interest securities shall payable provided form security set forth section repurchase price whether payable cash shares common stock combination thereof shall payable places identified company notice given pursuant section city paying agent located herein called place payment registrable securities entitled benefits registration rights agreement provided section form security set forth section securities entitled payment liquidated damages provided section time june december securities shall subject provisional redemption company whole part subject conditions otherwise provided article xi form security set forth section time december securities shall redeemable option company whole part subject conditions otherwise provided article xi form security set forth section securities shall convertible provided article xii city conversion agent located herein called place conversion securities shall subject repurchase company option holders provided article xiii section denominations securities shall issuable registered form without coupons denominations us integral multiples us excess thereof section execution authentication delivery dating securities shall executed behalf company officer company signature may manual facsimile securities bearing manual facsimile signature individuals time proper officers company shall bind company notwithstanding individuals ceased hold offices prior authentication delivery securities hold offices date securities time time time execution delivery indenture company may deliver securities executed company trustee order authentication together company order authentication delivery securities trustee accordance company order shall authenticate make available delivery securities indenture provided security shall dated date authentication security shall entitled benefit indenture valid obligatory purpose unless appears security certificate authentication substantially form provided herein executed trustee manual signature authorized signatory certificate upon security shall conclusive evidence evidence security duly authenticated delivered hereunder section global securities nonglobal securities bookentry provisions global securities global security authenticated indenture shall registered name depositary designated company global security nominee thereof delivered depositary nominee thereof custodian therefor global security shall constitute single security purposes indenture ii except exchanges global securities definitive nonglobal securities sole discretion company global security may exchanged whole part securities registered transfer global security whole part may registered name person depositary global security nominee thereof unless depositary notified company unwilling unable longer qualified continue depositary global security ii ceased clearing agency registered exchange act announces intention permanently cease business fact b shall occurred continuing event default respect global security event successor depositary global security appointed company within days company receives notice becomes aware ineligibility company execute trustee upon receipt officers certificate directing authentication delivery securities authenticate deliver securities authorized denominations aggregate principal amount equal principal amount global security exchange global security iii global security exchanged securities canceled whole shall surrendered behalf depositary nominee trustee security registrar exchange cancellation provided article iii global security exchanged securities canceled part another security exchanged whole part beneficial interest global security case provided section either global security shall surrendered exchange cancellation provided article iii b principal amount thereof shall reduced increased amount equal portion thereof exchanged canceled equal principal amount security exchanged beneficial interest therein case may means appropriate adjustment made records trustee security registrar whereupon trustee accordance applicable procedures shall instruct depositary authorized representative make corresponding adjustment records upon surrender adjustment global security trustee shall subject section otherwise provided article iii authenticate deliver securities issuable exchange global security portion thereof upon order registered names may directed depositary authorized representative upon request trustee connection occurrence events specified preceding paragraph company shall promptly make available trustee reasonable supply securities form global securities trustee shall entitled rely upon order direction request depositary authorized representative given made pursuant article iii order direction request given made accordance applicable procedures iv every security authenticated delivered upon registration transfer exchange lieu global security portion thereof whether pursuant article iii otherwise shall authenticated delivered form shall registered global security unless security registered name person depositary global security nominee thereof case security shall authenticated delivered definitive fully registered form without interest coupons v depositary nominee registered owner global security shall holder global security purposes indenture securities owners beneficial interests global security shall hold interests pursuant applicable procedures accordingly owners beneficial interest global security shown transfer interest shall effected records maintained depositary nominee agent members owners beneficial interests global security considered owners holders thereof nonglobal securities securities issued upon events described section lii shall definitive fully registered form without interest coupons shall bear restricted securities legend required indenture section registration registration transfer exchange restrictions transfer company shall cause kept corporate trust office trustee register register maintained office referred security register subject reasonable regulations may prescribe company shall provide registration securities transfers securities trustee hereby appointed security registrar purpose registering securities transfers exchanges securities herein provided upon surrender registration transfer security office agency company designated pursuant section purpose company shall execute trustee shall authenticate deliver name designated transferee transferees one new securities authorized denominations like aggregate principal amount bearing restrictive legends may required indenture option holder subject provisions section securities may exchanged securities authorized denomination like aggregate principal amount upon surrender securities exchanged office agency whenever securities surrendered exchange subject provisions section company shall execute trustee shall authenticate deliver securities holder making exchange entitled receive every security presented surrendered registration transfer exchange shall required company security registrar duly endorsed accompanied written instrument transfer form satisfactory company trustee security registrar duly executed holder thereof attorney duly authorized writing securities issued upon registration transfer exchange securities shall valid obligations company evidencing debt entitled benefits indenture securities surrendered upon registration transfer exchange service charge shall made holder registration transfer exchange securities except provided section company may require payment sum sufficient cover tax governmental charge may imposed connection registration transfer exchange securities exchanges pursuant section shares common stock issued delivered name holder security involving transfer stamp duties may imposed connection transfer exchange united states political subdivision thereof therein shall paid company event redemption securities neither company securities registrar required register transfer exchange securities period days immediately preceding date notice given identifying serial numbers securities called redemption b register transfer exchange security portion thereof called redemption certain transfers exchanges notwithstanding provision indenture securities transfers exchanges securities beneficial interests global security kinds specified section shall made accordance section restricted global security restricted nonglobal security event nonglobal securities issued pursuant section ii connection transfer securities transfer may effected accordance provisions clause subject applicable procedures upon receipt trustee security registrar company order company directing trustee security registrar x authenticate deliver one securities aggregate principal amount beneficial interest restricted global security transferred instructions contain name names designated transferee transferees authorized denomination denominations securities issued appropriate delivery instructions decrease beneficial interest specified agent members account restricted global security specified principal amount greater principal amount restricted global security b certifications legal opinions information company trustee may reasonably require confirm transfer made pursuant exemption transaction subject registration requirements securities act trustee security registrar shall decrease principal amount restricted global security specified amount authenticate deliver securities accordance instructions company provided section iii ii restricted nonglobal security restricted global security holder restricted security global security wishes time transfer portion restricted security person wishes take delivery thereof form beneficial interest restricted global security transfer may effected accordance provisions clause ii subject applicable procedures upon receipt trustee security registrar restricted security provided section instructions company directing beneficial interest restricted global security specified principal amount greater principal amount security credited specified agent members account trustee security registrar shall cancel restricted security issue new restricted security respect untransferred portion thereof provided section increase principal amount restricted global security specified principal amount provided section iii iii exchanges global security nonglobal security beneficial interest global security may exchanged security global security provided section exchange occurs connection transfer effected accordance clause provided interest beneficial interest restricted global security interest shall exchanged restricted security subject case section security global security may exchanged beneficial interest global security exchange occurs connection transfer effected accordance clause ii securities act legends securities issued pursuant indenture successor securities shall bear restricted securities legend shall subject restrictions transfer specified therein subject following subject following clauses section security portion thereof exchanged upon transfer otherwise global security portion thereof shall bear restricted securities legend borne global security security exchanged ii subject following clauses section new security global security issued exchange another security including global security portion thereof upon transfer otherwise shall bear restricted securities legend borne security new security exchanged iii securities sold otherwise disposed pursuant effective registration statement securities act including shelf registration statement together successor securities shall bear restricted securities legend company shall inform trustee writing effective date registration statement registering securities securities act shall notify trustee writing time prospectuses must delivered respect securities sold pursuant registration statement trustee shall liable action taken omitted taken good faith accordance aforementioned registration statement iv time securities may freely transferred without registration securities act without subject transfer restrictions pursuant securities act new security bear restricted securities legend may issued exchange lieu security global security portion thereof bears legend trustee received unrestricted securities certificate satisfactory trustee duly executed holder security bearing restricted securities legend attorney duly authorized writing date receipt certificate trustee shall authenticate deliver new security exchange lieu security provided article iii v new security bear restricted securities legend may issued exchange lieu security portion thereof bears legend companys judgment placing legend upon new security necessary ensure compliance registration requirements securities act trustee direction company shall authenticate deliver new security provided article iii vi notwithstanding foregoing provisions section successor security security bear restricted securities legend shall bear legend unless company reasonable cause believe successor security restricted security within meaning rule case trustee direction company shall authenticate deliver new security bearing restricted securities legend exchange successor security provided article iii stock certificate representing shares common stock issued upon conversion securities shall bear restricted securities legend borne securities extent required indenture unless shares common stock sold pursuant registration statement declared effective securities act continues effective time transfer sold pursuant rule k securities act unless otherwise agreed company writing written notice thereof transfer agent common stock respect transfer shares common stock issued upon conversion securities restricted hereunder deliveries certificates legal opinions instruments would required made security registrar case transfer securities described shall instead made transfer agent common stock neither trustee paying agent agents shall duty monitor compliance respect federal state securities tax laws ii duty obtain documentation transfers exchanges specifically required hereunder section mutilated destroyed lost stolen securities mutilated security surrendered trustee company shall execute trustee shall authenticate deliver exchange therefor new security like tenor principal amount bearing number contemporaneously outstanding delivered company trustee evidence satisfaction destruction loss theft security security indemnity may satisfactory company trustee save agent either harmless absence actual notice company trustee security acquired bona fide purchaser company shall execute trustee shall authenticate deliver lieu destroyed lost stolen security new security like tenor principal amount bearing number contemporaneously outstanding case mutilated destroyed lost stolen security become become due payable company discretion subject conversion rights may instead issuing new security pay security upon satisfaction conditions set forth preceding paragraph upon issuance new security section company may require payment sum sufficient cover tax governmental charge may imposed relation thereto stamp duties may imposed connection therewith united states political subdivision thereof therein shall paid company expenses including fees expenses trustee connected therewith every new security issued pursuant section lieu mutilated destroyed lost stolen security shall constitute original additional contractual obligation company whether mutilated destroyed lost stolen security shall time enforceable anyone new security shall entitled benefits indenture equally proportionately securities duly issued hereunder provisions section exclusive shall preclude extent lawful rights remedies holder respect replacement payment mutilated destroyed lost stolen securities section payment interest interest rights preserved subject last paragraph section interest liquidated damages security payable punctually paid duly provided interest payment date shall paid person whose name security one predecessor securities registered close business regular record date interest interest liquidated damages security payable punctually paid duly provided interest payment date herein called defaulted interest shall forthwith cease payable holder relevant regular record date virtue holder defaulted interest may paid company election case provided clause company may elect make payment defaulted interest persons whose names securities respective predecessor securities registered close business special record date payment defaulted interest shall fixed following manner company shall notify trustee writing amount defaulted interest proposed paid security date proposed payment special record date time company shall deposit trustee amount money equal aggregate amount proposed paid respect defaulted interest shall make arrangements reasonably satisfactory trustee deposit prior date proposed payment money deposited held trust benefit persons entitled defaulted interest clause provided special record date payment defaulted interest shall days less days prior date proposed payment less days receipt trustee notice proposed payment trustee name expense company shall cause notice proposed payment defaulted interest special record date therefor mailed firstclass postage prepaid holder holders address appears security register less days prior special record date notice proposed payment defaulted interest special record date therefor mailed defaulted interest shall paid persons whose names securities respective predecessor securities registered close business special record date shall longer payable pursuant following clause company may make payment defaulted interest lawful manner inconsistent requirements securities exchange securities may listed upon notice may required exchange notice given company trustee proposed payment pursuant clause manner payment shall deemed practicable trustee subject foregoing following provisions section section security delivered indenture upon registration transfer exchange lieu security shall carry rights interest accrued unpaid accrue carried security interest security converted accordance section record date period shall payable accordance provisions section section persons deemed owners prior due presentment security registration transfer company trustee paying agent agent company trustee paying agent may treat person whose name security registered owner security purpose receiving payment principal premium subject section interest security purposes whatsoever whether security overdue neither company trustee paying agent agent company trustee paying agent shall affected notice contrary section cancellation securities surrendered payment redemption repurchase registration transfer exchange conversion shall surrendered person trustee delivered trustee securities delivered trustee shall canceled promptly trustee agent securities shall authenticated lieu exchange securities canceled provided section trustee shall dispose canceled securities accordance applicable law customary practices effect time time section computation interest interest securities including liquidated damages shall computed basis day year twelve day months section cusip numbers company issuing securities may use cusip numbers generally use addition serial numbers trustee shall use cusip numbers addition serial numbers notices redemption repurchase convenience holders provided notice may state representation made correctness cusip numbers either printed securities contained notice redemption repurchase reliance may placed serial identification numbers printed securities redemption repurchase shall affected defect omission cusip numbers article iv satisfaction discharge section satisfaction discharge indenture indenture shall upon company request cease effect except surviving rights conversion registration transfer exchange replacement securities herein expressly provided right receive liquidated damages provided registration rights agreement form security set forth section companys obligations trustee pursuant section trustee expense company shall execute proper instruments form substance reasonably satisfactory trustee acknowledging satisfaction discharge indenture either securities theretofore authenticated delivered securities destroyed lost stolen replaced paid provided section b securities whose payment money theretofore deposited trust segregated held trust company thereafter repaid company discharged trust provided section delivered trustee cancellation ii securities theretofore delivered trustee agent cancellation securities referred clauses b clause become due payable b become due payable stated maturity within one year c called redemption within one year arrangements reasonably satisfactory trustee giving notice redemption trustee name expense company company case clause b c deposited caused deposited trustee trust funds immediately available holders case clause trust purpose amount cash sufficient pay discharge entire indebtedness securities theretofore delivered trustee cancellation principal premium interest including liquidated damages date deposit case securities become due payable stated maturity redemption date case may company paid caused paid sums payable hereunder company company delivered trustee officers certificate opinion counsel stating conditions precedent herein provided relating satisfaction discharge indenture complied notwithstanding satisfaction discharge indenture obligations company trustee section obligations company authenticating agent section obligation company pay liquidated damages money shall deposited trustee pursuant clause ii section obligations trustee section last paragraph section obligations company trustee section article xii shall survive section application trust money subject provisions last paragraph section money deposited trustee pursuant section shall held trust sole benefit holders monies shall applied trustee accordance provisions securities indenture payment either directly paying agent persons entitled thereto principal premium interest including liquidated damages whose payment money deposited trustee moneys deposited trustee pursuant section held paying agent payment securities subsequently converted shall returned company company shall pay indemnify trustee tax fee charge imposed assessed money deposited trustee pursuant section income taxes franchise taxes incurred payable trustee taxes fees charges incurred payable trustee directly result deposit money trustee article v remedies section events default event default wherever used herein means one following events whatever reason event default whether shall voluntary involuntary effected operation law pursuant judgment decree order court order rule regulation administrative governmental body default payment principal premium security maturity default payment interest including liquidated damages upon security becomes due payable continuance default period days failure company give company notice accordance section default performance covenant company indenture covenant default performance specifically dealt elsewhere section continuance default period days given registered certified mail company trustee company trustee holders least principal amount outstanding securities written notice specifying default breach requiring remedied stating notice notice default hereunder default payment due either stated maturity upon acceleration thereof expiration applicable grace period bonds debentures notes evidences indebtedness money borrowed guarantee thereof company significant subsidiary instrument aggregate principal amount excess us whether indebtedness exists shall hereafter created indebtedness discharged acceleration rescinded annulled within period days shall given registered certified mail company trustee company trustee holders least principal amount outstanding securities written notice specifying default requiring company cause indebtedness discharged cause default cured waived acceleration rescinded annulled stating notice notice default hereunder entry court jurisdiction premises decree order relief respect company significant subsidiary involuntary case proceeding applicable federal state bankruptcy insolvency reorganization similar law b decree order adjudging company significant subsidiary bankrupt insolvent approving properly filed petition seeking reorganization arrangement adjustment composition respect company significant subsidiary applicable federal state law appointing custodian receiver liquidator assignee trustee sequestrator similar official company significant subsidiary substantial part property either ordering winding liquidation affairs continuance decree order relief decree order unstayed effect period consecutive days commencement company significant subsidiary voluntary case proceeding applicable federal state bankruptcy insolvency reorganization similar law case proceeding adjudicated bankrupt insolvent consent either entry decree order relief respect company significant subsidiary involuntary case proceeding applicable federal state bankruptcy insolvency reorganization similar law commencement bankruptcy insolvency case proceeding either filing either petition answer consent seeking reorganization similar relief applicable federal state law consent either filing petition appointment taking possession custodian receiver liquidator assignee trustee sequestrator similar official company significant subsidiary substantial part property either making either assignment benefit creditors admission either writing inability pay debts generally become due taking corporate action company significant subsidiary furtherance action section acceleration maturity rescission annulment event default event default specified section respect company occurs continuing every case trustee holders less principal amount outstanding securities may declare principal securities due payable immediately notice writing company trustee given holders upon declaration principal accrued interest thereon shall become immediately due payable event default specified section respect company occurs principal accrued interest securities shall become immediately due payable without declaration act holders act part trustee time declaration acceleration made judgment decree payment money due obtained trustee hereinafter article v provided holders majority principal amount outstanding securities written notice company trustee may behalf holders rescind annul declaration consequences company paid deposited trustee sum sufficient pay overdue interest securities ii principal premium securities become due otherwise declaration acceleration interest thereon rate borne securities iii extent permitted applicable law interest upon overdue interest rate per annum iv sums paid advanced trustee hereunder reasonable compensation expenses disbursements advances trustee agents counsel events default nonpayment principal premium interest securities become due solely declaration acceleration cured waived provided section rescission annulment would conflict judgment decree issued appropriate judicial proceedings regarding payment trustee holders amounts referred rescission annulment referred shall affect subsequent default impair right consequent thereon section collection indebtedness suits enforcement trustee company covenants default made payment interest including liquidated damages security becomes due payable default continues period days default made payment principal premium security maturity thereof company upon demand trustee pay benefit holders securities whole amount due payable securities principal interest including liquidated damages interest overdue principal premium extent permitted applicable law overdue interest including liquidated damages rate per annum addition thereto amount shall sufficient cover reasonable costs expenses collection including reasonable compensation expenses disbursements advances trustee agents counsel company fails pay amounts forthwith upon demand trustee name trustee express trust may institute judicial proceeding collection sums due unpaid may prosecute proceeding judgment final decree may enforce company obligor upon securities collect moneys adjudged decreed payable manner provided law property company obligor upon securities wherever situated event default occurs continuing trustee may discretion proceed protect enforce rights rights holders securities appropriate judicial proceedings trustee shall deem effectual protect enforce rights whether specific enforcement covenant agreement indenture aid exercise power granted herein enforce proper remedy section trustee may file proofs claim case pendency receivership insolvency liquidation bankruptcy reorganization arrangement adjustment composition judicial proceeding relative company obligor upon securities property company obligor creditors either trustee irrespective whether principal interest securities shall due payable therein expressed declaration otherwise irrespective whether trustee shall made demand company payment overdue principal interest shall entitled empowered intervention proceeding otherwise file prove claim whole amount principal premium interest owing unpaid respect securities take actions including participating member voting otherwise official committee creditors appointed matter file papers documents foregoing cases may necessary advisable order claims trustee including claim reasonable compensation expenses disbursements advances trustee agents counsel holders securities allowed judicial proceeding collect receive moneys property payable deliverable claim distribute custodian receiver assignee trustee liquidator sequestrator similar official judicial proceeding hereby authorized holder securities make payments trustee event trustee shall consent making payments directly holders securities pay trustee amount due reasonable compensation expenses disbursements advances trustee agents counsel amounts due trustee section nothing herein contained shall deemed authorize trustee authorize consent accept adopt behalf holder security plan reorganization arrangement adjustment composition affecting securities rights holder thereof authorize trustee vote respect claim holder security proceeding provided however trustee may behalf holders vote election trustee bankruptcy similar official section trustee may enforce claims without possession securities rights action claims indenture securities may prosecuted enforced trustee without possession securities production thereof proceeding relating thereto proceeding instituted trustee shall brought name trustee express trust recovery judgment shall provision payment reasonable compensation expenses disbursements advances trustee agents counsel ratable benefit holders securities respect judgment recovered section application money collected money collected trustee pursuant article v shall applied following order date dates fixed trustee case distribution money account principal premium interest upon presentation securities notation thereon payment partially paid upon surrender thereof fully paid first payment amounts due trustee section second payment amounts due unpaid principal premium interest including liquidated damages securities respect benefit money collected ratably without preference priority kind according amounts due payable securities principal premium interest including liquidated damages respectively third person persons extent entitled thereto fourth remaining amounts shall repaid company section limitation suits holder security shall right institute proceeding judicial otherwise respect indenture appointment receiver trustee remedy hereunder unless holder previously given written notice trustee event default continuing time institution holders less principal amount outstanding securities shall made written request trustee institute proceedings respect event default name trustee hereunder holder holders offered trustee requested shall provided reasonable indemnity costs expenses liabilities incurred compliance request trustee days receipt notice request offer indemnity requested receipt indemnity failed institute proceeding direction inconsistent written request given trustee day period holders majority principal amount outstanding securities understood intended one holders shall right manner whatever virtue availing provision indenture affect disturb prejudice rights holders obtain seek obtain priority preference holders enforce right indenture except manner herein provided equal ratable benefit holders section unconditional right holders receive principal premium interest convert notwithstanding provision indenture holder security shall right absolute unconditional receive payment principal premium subject section interest including liquidated damages security respective stated maturities expressed security case redemption repurchase redemption date repurchase date case may convert security accordance article xii institute suit enforcement payment right convert rights shall impaired without consent holder section restoration rights remedies trustee holder security instituted proceeding enforce right remedy indenture proceeding discontinued abandoned reason determined adversely trustee holder every case subject determination proceeding company trustee holders securities shall restored severally respectively former positions hereunder thereafter rights remedies trustee holders shall continue though proceeding instituted section rights remedies cumulative except otherwise provided respect replacement payment mutilated destroyed lost stolen securities last paragraph section right remedy herein conferred upon reserved trustee holders securities intended exclusive right remedy every right remedy shall extent permitted law cumulative addition every right remedy given hereunder hereafter existing law equity otherwise assertion employment right remedy hereunder otherwise shall prevent concurrent assertion employment appropriate right remedy section delay omission waiver delay omission trustee holder security exercise right remedy accruing upon event default shall impair right remedy constitute waiver event default acquiescence therein every right remedy given article v law trustee holders securities may exercised time time often may deemed expedient trustee subject limitations contained indenture holders securities case may section control holders securities subject section holders majority principal amount outstanding securities shall right direct time method place conducting proceeding remedy available trustee exercising trust power conferred trustee provided direction shall conflict rule law indenture trustee may take action deemed proper trustee inconsistent direction trustee need take action might involve personal liability unjustly prejudicial holders securities consenting section waiver past defaults holders either written consent less majority principal amount outstanding securities ii adoption resolution meeting holders outstanding securities quorum present holders least majority aggregate principal amount outstanding securities represented meeting may behalf holders securities waive past default hereunder consequences except default payment principal premium interest including liquidated damages security b respect covenant provision hereof article viii modified amended without consent holder outstanding security affected upon waiver default shall cease exist event default arising therefrom shall deemed cured every purpose indenture waiver shall extend subsequent default impair right consequent thereon section undertaking costs parties indenture agree holder security acceptance thereof shall deemed agreed court may discretion require suit enforcement right remedy indenture suit trustee action taken suffered omitted trustee filing party litigant suit undertaking pay costs suit court may discretion assess reasonable costs including reasonable attorneys fees expenses party litigant suit due regard merits good faith claims defenses made party litigant provisions section shall apply suit instituted company suit instituted trustee suit instituted holder group holders holding aggregate principal amount outstanding securities suit instituted holder security enforcement payment principal premium interest security respective stated maturity maturities expressed security case redemption repurchase redemption date repurchase date case may enforcement right convert security accordance article xii section waiver stay usury extension laws company covenants extent may lawfully time insist upon plead manner whatsoever claim take benefit advantage stay usury extension law wherever enacted time hereafter force may affect covenants performance indenture company extent may lawfully hereby expressly waives benefit advantage law covenants hinder delay impede reason law execution power herein granted trustee suffer permit execution every power though law enacted article vi trustee section certain duties responsibilities except continuance event default trustee undertakes perform duties duties specifically set forth indenture implied covenants obligations shall read indenture trustee ii absence bad faith part trustee may conclusively rely truth statements correctness opinions expressed therein upon certificates opinions furnished trustee conforming requirements indenture case certificates opinions provision hereof specifically required furnished trustee trustee shall duty examine determine whether conform requirements indenture verify contents thereof case event default occurred continuing trustee shall exercise rights powers vested indenture use degree care skill exercise prudent man would exercise use circumstances conduct affairs provision indenture shall construed relieve trustee liability negligent action negligent failure act willful misconduct except paragraph shall construed limit effect paragraph section ii trustee shall liable error judgment made good faith responsible officer unless shall proved trustee negligent ascertaining pertinent facts iii trustee shall liable respect action taken omitted taken good faith accordance direction holders majority principal amount outstanding securities relating time method place conducting proceeding remedy available trustee exercising trust power conferred upon trustee indenture iv provision indenture shall require trustee expend risk funds otherwise incur financial liability performance duties hereunder exercise rights powers shall reasonable grounds believing repayment funds adequate indemnity risk liability reasonably assured whether therein expressly provided every provision indenture relating conduct affecting liability affording protection trustee shall subject provisions section trustee may refuse perform duty exercise right power unless receives indemnity satisfactory loss liability expense section notice defaults within days occurrence default hereunder trustee received written notice trustee shall give holders securities manner provided section notice default unless default shall cured waived provided however except case default payment principal premium interest security trustee shall protected withholding notice long board directors executive committee trust committee directors responsible officers trustee good faith determines withholding notice interest holders provided case default character specified section notice holders securities shall given least days occurrence thereof applicable expiration cure period specified therein purpose section term default means event notice lapse time would become event default section certain rights trustee subject provisions section trustee may rely shall protected acting refraining acting upon resolution officers certificate certificate statement instrument opinion report notice request direction consent order bond debenture note coupon evidence indebtedness paper document collectively documents believed genuine signed presented proper party parties trustee need investigate fact matter stated documents request direction company mentioned herein shall sufficiently evidenced company request company order resolution board directors shall sufficiently evidenced board resolution whenever administration indenture trustee shall deem desirable matter proved established prior taking suffering omitting action hereunder trustee unless evidence one specifically prescribed may absence bad faith part request rely upon officers certificate opinion counsel trustee may consult counsel selection advice counsel opinion counsel shall full complete authorization protection respect action taken suffered omitted hereunder good faith reliance thereon trustee shall obligation exercise rights powers vested indenture request direction holders securities pursuant indenture unless holders shall offered requested trustee delivered trustee reasonable security costs expenses liabilities might incurred compliance request direction trustee shall bound make investigation facts matters stated resolution certificate statement instrument opinion report notice request direction consent order bond debenture note coupon evidence indebtedness paper document trustee may make inquiry investigation facts matters may see fit trustee shall determine make inquiry investigation shall entitled examine books records premises company personally agent attorney trustee may execute trusts powers hereunder perform duties hereunder either directly agents attorneys trustee shall responsible misconduct negligence part agent attorney appointed due care hereunder section responsible recitals issuance securities recitals contained herein securities except trustees certificates authentication shall taken statements company trustee assumes responsibility correctness trustee makes representations validity sufficiency indenture securities common stock issuable upon conversion securities trustee shall accountable use application company securities proceeds thereof section may hold securities act trustee indentures trustee authenticating agent paying agent conversion agent agent company trustee individual capacity may become owner pledgee securities may otherwise deal company rights would trustee authenticating agent paying agent conversion agent agent trustee may become act trustee indentures securities certificates interest participation securities company outstanding manner trustee hereunder section money held trust money held trustee trust hereunder need segregated funds except extent required law trustee shall liability interest money received hereunder except otherwise agreed writing company section compensation reimbursement company agrees pay trustee time time reasonable compensation company trustee shall time time agree writing acceptance indenture services rendered hereunder compensation shall limited provision law regard compensation trustee express trust except otherwise expressly provided herein reimburse trustee upon request reasonable expenses disbursements advances incurred made trustee including costs expenses enforcing indenture defending claim whether asserted company holder securities person liability connection exercise powers duties hereunder accordance provision indenture including reasonable compensation expenses disbursements agents counsel except expense disbursement advance may attributable negligence bad faith indemnify trustee directors officers employees agents hold harmless loss liability expense incurred without negligence bad faith part arising connection acceptance administration trust including reasonable costs expenses reasonable attorneys fees defending claim liability connection exercise performance powers duties hereunder trustee shall lien prior securities money property held controlled trustee secure companys payment obligations section except held trust pay principal interest including liquidated damages securities trustee incurs expenses renders services connection event default specified section section expenses including reasonable charges counsel compensation services intended constitute expenses administration applicable federal state bankruptcy insolvency similar law provisions section shall survive termination indenture earlier resignation removal trustee section corporate trustee required eligibility shall times trustee hereunder shall person eligible pursuant trust indenture act act trustee parent corporation shall part holding company group combined capital surplus least us subject supervision examination federal state authority good standing trustee affiliate trustee shall maintain established place business borough manhattan city new york corporation publishes reports condition least annually pursuant law requirements said supervising examining authority purposes section combined capital surplus corporation shall deemed combined capital surplus set forth recent report condition published time trustee shall cease eligible accordance provisions section shall resign immediately manner effect hereinafter specified article successor shall appointed pursuant section section resignation removal appointment successor resignation removal trustee appointment successor trustee pursuant article shall become effective acceptance appointment successor trustee accordance applicable requirements section trustee may resign time giving written notice thereof company instrument acceptance successor trustee required section shall delivered trustee within days giving notice resignation resigning trustee may petition court competent jurisdiction appointment successor trustee trustee may removed time act holders majority principal amount outstanding securities delivered trustee company instrument acceptance successor trustee required section shall delivered trustee within days giving notice removal removed trustee may petition court competent jurisdiction appointment successor trustee trustee may removed time company company may appoint successor trustee pursuant article provided event default continuing time removal ii successor trustee appointed company meets eligibility requirements section iii removal resignation shall become effective acceptance appointment successor trustee accordance applicable requirements section time trustee shall cease eligible section shall fail resign written request therefor company holder security bona fide holder security least six months ii trustee shall become incapable acting shall adjudged bankrupt insolvent receiver trustee property shall appointed public officer shall take charge control trustee property affairs purpose rehabilitation conservation liquidation case company board resolution may remove trustee ii subject section holder security bona fide holder security least six months may behalf others similarly situated petition court competent jurisdiction removal trustee appointment successor trustee trustee shall resign removed become incapable acting vacancy shall occur office trustee cause company board resolution shall promptly appoint successor trustee shall comply applicable requirements section section successor trustee shall appointed company holders securities accepted appointment manner required section section holder security bona fide holder security least six months may behalf others similarly situated petition court competent jurisdiction appointment successor trustee company shall give notice resignation removal trustee appointment successor trustee holders securities manner provided section notice shall include name successor trustee address corporate trust office section acceptance appointment successor every successor trustee appointed hereunder shall execute acknowledge deliver company retiring trustee instrument accepting appointment thereupon resignation removal retiring trustee shall become effective successor trustee without act deed conveyance shall become vested rights powers trusts duties retiring trustee request company successor trustee retiring trustee shall upon payment charges execute deliver instrument transferring successor trustee rights powers trusts retiring trustee shall duly assign transfer deliver successor trustee property money held retiring trustee hereunder upon request successor trustee company shall execute instruments fully certainly vesting confirming successor trustee rights powers trusts successor trustee shall accept appointment unless time acceptance successor trustee shall eligible article section merger conversion consolidation succession business corporation trustee may merged converted may consolidated corporation resulting merger conversion consolidation trustee shall party corporation succeeding substantially corporate trust business trustee including trust created indenture shall successor trustee hereunder provided corporation shall otherwise eligible article without execution filing paper act part parties hereto case securities shall authenticated delivered trustee office successor merger conversion consolidation authenticating trustee may adopt authentication deliver securities authenticated effect successor trustee authenticated securities section authenticating agents trustee may consent company appoint authenticating agent agents acceptable company respect securities authenticating agent shall authorized act behalf trustee authenticate securities issued upon exchange substitution pursuant indenture securities authenticated authenticating agent shall entitled benefits indenture shall valid obligatory purposes authenticated trustee hereunder every reference indenture authentication delivery securities trustee trustees certificate authentication shall deemed include authentication delivery behalf trustee authenticating agent certificate authentication executed behalf trustee authenticating agent authenticating agent shall subject acceptance company shall times corporation organized business laws united states america state thereof district columbia authorized laws act authenticating agent subject supervision examination government fiscal authority time authenticating agent shall cease eligible accordance provisions section authenticating agent shall resign immediately manner effect specified section corporation authenticating agent may merged converted may consolidated corporation resulting merger conversion consolidation authenticating agent shall party corporation succeeding corporate agency corporate trust business authenticating agent shall continue authenticating agent provided corporation shall otherwise eligible section without execution filing paper act part trustee authenticating agent authenticating agent may resign time giving written notice thereof trustee company trustee may time terminate agency authenticating agent giving written notice thereof authenticating agent company upon receiving notice resignation upon termination case time authenticating agent shall cease eligible accordance provisions section trustee may appoint successor authenticating agent shall subject acceptance company successor authenticating agent upon acceptance appointment hereunder shall become vested rights powers duties predecessor hereunder like effect originally named authenticating agent successor authenticating agent shall appointed unless eligible provisions section company agrees pay authenticating agent time time reasonable compensation services section authenticating agent appointed respect securities pursuant section securities may endorsed thereon addition lieu trustees certification authentication alternative certificate authentication following form one securities referred withinmentioned indenture jp morgan trust company national association trustee authenticating agent authorized signatory section disqualification conflicting interests trustee shall acquire conflicting interest within meaning trust indenture act trustee shall either eliminate interest resign extent manner provided subject provisions trust indenture act indenture section preferential collection claims company trustee shall become creditor company obligor upon securities trustee shall subject provisions trust indenture act regarding collection claims company obligor article vii consolidation merger conveyance transfer lease section company may consolidate etc certain terms company shall consolidate merge person convey transfer sell lease mere grant security interest properties assets substantially entirety person company shall permit person consolidate merge company convey transfer sell lease mere grant security interest persons properties assets substantially entirety company unless person formed consolidation company merged person properties assets company conveyed transferred sold leased mere grant security interest shall corporation limited liability company partnership trust organized validly existing laws united states america state thereof district columbia company shall expressly assume indenture supplemental hereto executed delivered trustee form reasonably satisfactory trustee due punctual payment principal premium interest including liquidated damages securities applicable performance observance every covenant indenture part company performed observed shall provided conversion rights material respects accordance article xii immediately giving effect transaction event default event notice lapse time would become event default shall occurred continuing company delivered trustee officers certificate opinion counsel stating consolidation merger conveyance transfer lease mere grant security interest supplemental indenture required connection transaction supplemental indenture comply article conditions precedent herein provided relating transaction complied together documents required section section successor substituted upon consolidation company merger company person conveyance transfer lease mere grant security interest substantially properties assets company accordance section successor person formed consolidation company merged conveyance transfer lease mere grant security interest made shall succeed substituted may exercise every right power company indenture effect successor person named company herein thereafter except case lease predecessor person shall relieved obligations covenants indenture securities article viii supplemental indentures section supplemental indentures without consent holders securities without consent holders securities company authorized board resolution trustee time time time may enter one indentures supplemental hereto following purposes evidence succession another person company assumption successor covenants obligations company herein securities permitted article vii indenture add covenants company benefit holders securities surrender right power herein conferred upon company secure securities make provision respect conversion rights holders securities pursuant section make provision respect repurchase rights holders securities pursuant section make changes modifications indenture necessary connection registration registrable securities securities act contemplated section provided action pursuant clause shall adversely affect interests holders securities material respect comply requirements trust indenture act rules regulations commission thereunder order effect maintain qualification indenture trust indenture act contemplated indenture otherwise evidence provide acceptance appointment hereunder successor trustee provide uncertificated securities cure ambiguity correct supplement provision herein may inconsistent provision herein otherwise defective make provisions respect matters questions arising indenture company trustee may deem necessary desirable provided action pursuant clause shall adversely affect interests holders securities material respect upon company request accompanied board resolution authorizing execution supplemental indenture subject upon receipt trustee documents described section hereof trustee shall join company execution supplemental indenture authorized permitted terms indenture make appropriate agreements stipulations may therein contained notwithstanding provision indenture securities registration rights agreement obligation pay liquidated damages thereunder may amended modified waived accordance provisions registration rights agreement section supplemental indentures consent holders securities except set forth section either written consent holders less majority principal amount outstanding securities act said holders delivered company trustee ii adoption resolution meeting holders outstanding securities quorum present holders least majority aggregate principal amount outstanding securities represented meeting company authorized board resolution trustee may enter indenture indentures supplemental hereto purpose adding provisions changing manner eliminating provisions indenture modifying manner rights holders securities indenture provided however supplemental indenture shall without consent affirmative vote holder outstanding security affected thereby change stated maturity principal installment interest security reduce principal amount premium rate interest payable thereon reduce amount payable upon redemption mandatory repurchase change place currency payment principal premium interest security including payment liquidated damages except may effected amendment registration rights agreement accordance terms redemption price repurchase price respect security impair right institute suit enforcement payment respect security stated maturity thereof case redemption repurchase redemption date repurchase date case may reduce requirements section quorum voting reduce percentage principal amount outstanding securities consent whose holders required supplemental indenture consent whose holders required waiver compliance certain provisions indenture certain defaults hereunder consequences provided indenture modify provisions section section except increase percentage contained herein therein provide certain provisions indenture modified waived without consent holder outstanding security affected thereby modify ranking securities manner adverse holders modify companys right redeem securities manner adverse holders modify provisions article xii xiii manner adverse holders modify provisions section manner adverse holder shall necessary act holders securities section approve particular form proposed supplemental indenture shall sufficient act shall approve substance thereof section execution supplemental indentures executing accepting additional trusts created supplemental indenture permitted article modifications thereby trusts created indenture trustee shall entitled receive subject sections shall fully protected relying upon opinion counsel stating execution supplemental indenture authorized permitted indenture supplemental indenture duly authorized executed delivered company constitutes valid legally binding obligation company enforceable company accordance terms trustee may shall obligated enter supplemental indenture adversely affects trustees rights duties immunities indenture otherwise section effect supplemental indentures upon execution supplemental indenture article indenture shall modified accordance therewith supplemental indenture shall form part indenture purposes every holder securities theretofore thereafter authenticated delivered hereunder appertaining thereto shall bound thereby section reference securities supplemental indentures securities authenticated delivered execution supplemental indenture pursuant article may shall required trustee bear notation form approved trustee matter provided supplemental indenture company shall determine new securities modified conform opinion company trustee supplemental indenture may prepared executed company authenticated delivered trustee exchange outstanding securities section notice supplemental indentures promptly execution company trustee supplemental indenture pursuant provisions section company shall give notice holders securities fact setting forth general terms substance supplemental indenture manner provided section failure company give notice defect therein shall way impair affect validity supplemental indenture article ix meetings holders securities section purposes meetings may called meeting holders securities may called time time time pursuant article make give take request demand authorization direction notice consent waiver action provided indenture made given taken holders securities section call notice place meetings trustee companys consent prior event default thereafter may time call meeting holders securities purpose specified section held time place borough manhattan city new york trustee shall determine notice every meeting holders securities setting forth time place meeting general terms action proposed taken meeting shall given manner provided section less days prior date fixed meeting case time company pursuant board resolution event default holders least principal amount outstanding securities shall requested trustee call meeting holders securities purpose specified section written request setting forth reasonable detail action proposed taken meeting trustee shall mailed notice meeting within days receipt request shall thereafter proceed cause meeting held provided herein company event default holders securities amount specified case may may determine time place borough manhattan city new york meeting may call meeting purposes giving notice thereof provided paragraph section section persons entitled vote meetings entitled vote meeting holders securities person shall holder one outstanding securities ii person appointed instrument writing proxy holder holders one outstanding securities holder holders persons shall entitled present speak meeting holders shall persons entitled vote meeting counsel representatives trustee counsel representatives company counsel section quorum action persons entitled vote majority principal amount outstanding securities shall constitute quorum absence quorum within minutes time appointed meeting meeting shall convened request holders securities dissolved case meeting may adjourned period less days determined chairman meeting prior adjournment meeting absence quorum adjourned meeting adjourned meeting may adjourned period less days determined chairman meeting prior adjournment adjourned meeting subject repeated applications sentence notice reconvening adjourned meeting shall given provided section except notice need given less five days prior date meeting scheduled reconvened notice reconvening adjourned meeting shall state expressly percentage principal amount outstanding securities shall constitute quorum subject foregoing reconvening meeting adjourned lack quorum persons entitled vote principal amount outstanding securities time shall constitute quorum taking action set forth notice original meeting meeting adjourned meeting duly reconvened quorum present aforesaid resolution matters except limited proviso section except extent section requires different vote shall effectively passed decided passed decided lesser holders less majority principal amount outstanding securities ii persons entitled vote less majority aggregate principal amount outstanding securities represented entitled vote meeting resolution passed decisions taken meeting holders securities duly held accordance section shall binding holders securities whether present represented meeting trustee shall name expense company notify holders securities resolutions decisions pursuant section section determination voting rights conduct adjournment meetings notwithstanding provisions indenture trustee may make reasonable regulations may deem advisable meeting holders securities regard proof holding securities appointment proxies regard appointment duties inspectors votes submission examination proxies certificates evidence right vote matters concerning conduct meeting shall deem appropriate except otherwise permitted required regulations holding securities shall proved manner specified section appointment proxy shall proved manner specified section signature person executing proxy guaranteed bank broker eligible institution participating recognized medallion signature guarantee program trustee shall instrument writing appoint temporary chairman may trustee meeting unless meeting shall called company holders securities provided section case company holders securities calling meeting case may shall like manner appoint temporary chairman permanent chairman permanent secretary meeting shall elected vote persons entitled vote majority principal amount outstanding securities represented meeting meeting holder security proxy shall entitled one vote us principal amount securities held represented provided however vote shall cast counted meeting respect security challenged outstanding ruled chairman meeting outstanding chairman meeting shall right vote except holder security proxy meeting holders securities duly called pursuant section quorum present may adjourned time time persons entitled vote majority principal amount outstanding securities represented meeting meeting may held adjourned without notice section counting votes recording action meetings vote upon resolution submitted meeting holders securities shall written ballots shall subscribed signatures holders securities representatives proxy principal amounts stated maturity serial numbers outstanding securities held represented permanent chairman meeting shall appoint two inspectors votes shall count votes cast meeting resolution shall make file secretary meeting verified written reports duplicate votes cast meeting record least duplicate proceedings meeting holders securities shall prepared secretary meeting shall attached said record original reports inspectors votes vote ballot taken thereat affidavits one persons knowledge facts setting forth copy notice meeting showing said notice given provided section applicable section copy shall signed verified affidavits permanent chairman secretary meeting one copy shall delivered company another trustee preserved trustee latter attached thereto ballots voted meeting record signed verified shall conclusive evidence matters therein stated article x covenants section payment principal premium interest company covenants agrees duly punctually pay principal premium interest including liquidated damages securities accordance terms securities indenture company deposit cause deposited trustee nominee later opening business date stated maturity security later opening business due date installment interest payments due payments shall immediately available funds date stated maturity due date case may section maintenance offices agencies company maintain borough manhattan city new york office agency securities may surrendered registration transfer exchange presentation payment conversion redemption repurchase notices demands upon company respect securities indenture may served company give prompt written notice trustee location change location office agency designated appointed trustee time company shall fail maintain required office agency shall fail furnish trustee address thereof presentations surrenders notices demands may made served corporate trust office office agency trustee borough manhattan city new york company may time time time vary terminate appointment agent appoint additional agents purposes provided however securities delivered trustee cancellation moneys sufficient pay principal premium interest securities made available payment either paid returned company pursuant provisions section company maintain borough manhattan city new york office agency securities may presented surrendered payment conversion shall initially corporate trust office trustee securities may surrendered registration transfer exchange notices demands upon company respect securities indenture may served company give prompt written notice trustee notice holders accordance section appointment termination agents location change location office agency company hereby initially designates trustee paying agent security registrar conversion agent corporate trust office trustee one office agency company aforesaid purposes section money security payments held trust company shall act paying agent due date principal premium interest securities segregate hold trust benefit persons entitled thereto sum sufficient pay principal premium interest becoming due sums shall paid persons otherwise disposed herein provided company promptly notify trustee writing action failure act whenever company shall one paying agents later opening business due date principal premium interest securities deposit trustee sum funds immediately payable payment date sufficient pay principal premium interest becoming due sum held benefit persons entitled principal premium interest unless paying agent trustee company promptly notify trustee writing failure act company cause paying agent trustee execute deliver trustee instrument paying agent shall agree trustee subject provisions section paying agent hold sums held payment principal premium interest securities benefit persons entitled thereto sums shall paid persons otherwise disposed herein provided give trustee written notice default company obligor upon securities making payment principal premium interest time continuance default upon written request trustee forthwith pay trustee sums held paying agent company may time purpose obtaining satisfaction discharge indenture purpose pay company order direct paying agent pay trustee sums held trust company paying agent sums held trustee upon trusts upon sums held company paying agent upon payment paying agent trustee paying agent shall released liability respect money money deposited trustee paying agent held company trust payment principal premium interest security remaining unclaimed two years principal premium interest become due payable shall paid company company request held company shall discharged trust holder security shall thereafter unsecured general creditor look company payment thereof liability trustee paying agent respect trust money liability company trustee thereof shall thereupon cease section existence subject article vii company cause done things necessary preserve keep full force effect existence rights charter statutory franchises provided however company shall required preserve right franchise company shall determine preservation thereof longer desirable conduct business company loss thereof disadvantageous material respect holders section intentionally left blank section payment taxes claims company shall pay shall cause subsidiaries pay prior delinquency material taxes assessments governmental charges levied imposed upon company subsidiary subject sections stamps duties may imposed united states political subdivision thereof therein connection issuance transfer exchange conversion securities respect indenture except contested good faith appropriate proceedings failure effect payment adverse material respect holders section registration listing company effect registrations obtain approvals governmental authorities may necessary united states federal state law including securities act exchange act state securities blue sky laws shares common stock issuable upon conversion securities issued delivered qualified listed contemplated registration rights agreement nothing section limit application section section statement officers default company shall deliver trustee within days end fiscal year company ending date hereof officers certificate stating whether reasonable best knowledge signer thereof company default performance observance terms provisions conditions indenture without regard period grace requirement notice provided hereunder company shall default specifying defaults nature status thereof may knowledge company deliver trustee forthwith upon becoming aware default event default indenture officers certificate specifying particularity default event default stating action company taken taking proposes take respect thereto purpose section term default means event notice lapse time would become event default notice required given section shall delivered trustee corporate trust office section delivery certain information time company subject section exchange act upon request holder restricted security holder shares common stock issued upon conversion thereof company promptly furnish cause furnished rule information defined holder restricted securities holder shares common stock issued upon conversion restricted securities prospective purchaser security designated holder holder case may extent required permit compliance holder holder rule securities act successor provision thereto connection resale security provided however company shall required furnish information connection request made date two years later date security predecessor security last acquired company ii date security predecessor security last acquired affiliate company within meaning rule securities act successor provision thereto rule information shall information specified pursuant rule ad securities act successor provision thereto section resale certain securities period beginning last date original issuance securities ending date two years date shortened period rule k securities act successor rule company permit subsidiaries affiliates defined rule securities act successor provision thereto resell securities constitute restricted securities rule ii securities securities converted indenture constitute restricted securities rule either case reacquired trustee shall responsibility respect companys performance agreement preceding sentence section registration rights company agrees holders time time registrable securities defined entitled benefits registration rights agreement whenever indenture mentioned context payment principal premium interest respect security mention shall deemed include mention payment liquidated damages provided section extent context liquidated damages would payable respect thereof pursuant provisions section express mention payment liquidated damages applicable provisions hereof shall construed excluding liquidated damages provisions hereof express mention made purposes registration rights agreement registrable securities means portion securities issued time time indenture registered form shares common stock issuable upon conversion repurchase redemption securities provided however security ceases registrable security longer restricted security security shares common stock issuable upon conversion security registrable security holder thereof elects sell registrable security pursuant shelf registration statement acceptance thereof holder registrable security agreed bound terms registration rights agreement relating registrable securities subject election purposes registration rights agreement term holder means person record owner registrable securities includes person beneficial interest registrable security book entry form liquidated damages payable registration rights agreement company shall deliver trustee certificate effect stating amount liquidated damages payable ii date liquidated damages payable unless responsible officer trustee receives corporate trust office certificate trustee may assume without inquiry liquidated damages payable liquidated damages paid company directly persons entitled company shall deliver trustee certificate setting forth particulars payment section waiver certain covenants company may omit particular instance comply covenant condition set forth sections respect existence company subject article vii inclusive covenant condition article viii modified amended without consent holder outstanding security affected time compliance holders shall written consent less majority principal amount outstanding securities ii adoption resolution meeting holders outstanding securities quorum present holders less majority aggregate principal amount outstanding securities represented meeting either waive compliance instance generally waive compliance covenant condition waiver shall extend affect covenant condition except extent expressly waived waiver shall become effective obligations company duties trustee paying conversion agent respect covenant condition shall remain full force effect article xi redemption securities section right redemption securities may redeemed accordance provisions form security set forth section section applicability article redemption securities election company otherwise permitted required provision securities indenture shall made accordance provision article xi section election redeem notice trustee election company redeem securities shall evidenced board resolution case redemption election company securities company shall least days prior redemption date fixed company unless shorter notice shall satisfactory trustee notify trustee writing redemption date section selection trustee securities redeemed less securities redeemed particular securities redeemed shall selected trustee within five business days receives notice described outstanding securities previously called redemption lot method trustee may deem fair appropriate security selected partial redemption converted part termination conversion right respect portion security selected converted portion security shall deemed far may portion selected redemption securities converted selection securities redeemed may treated trustee outstanding purpose selection trustee shall promptly notify company security registrar writing securities selected redemption case securities selected partial redemption principal amount thereof redeemed purposes indenture unless context otherwise requires provisions relating redemption securities shall relate case securities redeemed redeemed part portion principal amount securities redeemed section notice redemption notice redemption shall given manner provided section holders securities redeemed less days prior redemption date notice shall irrevocable notices redemption shall state redemption date redemption price accrued interest including liquidated damages excluding redemption date less outstanding securities redeemed aggregate principal amount securities redeemed aggregate principal amount securities outstanding partial redemption redemption date redemption price accrued interest including liquidated damages excluding redemption date become due payable upon security redeemed interest thereon shall cease accrue said date whether redemption provisional redemption optional redemption redemption provisional redemption amount makewhole payment whether makewhole payment paid common stock cash combination cash common stock applicable ratio cash common stock conversion rate date right convert securities redeemed terminate places securities may surrendered conversion place places securities surrendered payment redemption price accrued interest including liquidated damages excluding redemption date case partial redemption notice shall specify serial cusip numbers portions thereof called redemption transfers exchanges may occur prior redemption date notice redemption securities redeemed election company shall given company companys written request request shall delivered trustee simultaneously notification redemption date pursuant section trustee name expense company notice redemption securities redeemed election company received trustee shall given trustee paying agent name expense company section deposit redemption price prior redemption date company shall deposit trustee company acting paying agent segregate hold trust provided section amount money applicable common stock combination thereof respect makewhole payment shall immediately available funds redemption date sufficient pay redemption price except redemption date shall interest payment date accrued interest including liquidated damages redemption date securities redeemed date securities called redemption date converted prior date deposit security called redemption converted money deposited trustee segregated held trust redemption security shall subject right holder security predecessor security receive interest provided last paragraph section paid company held company shall discharged trust section securities payable redemption date notice redemption given aforesaid securities redeemed shall redemption date become due payable redemption price therein specified date unless company shall default payment redemption price including accrued interest securities shall cease bear interest upon surrender security redemption accordance said notice security shall paid company redemption price together accrued unpaid interest including liquidated damages excluding redemption date provided however installments interest securities whose stated maturity prior redemption date shall payable holders securities one predecessor securities registered relevant record date according terms provisions section security called redemption shall paid upon surrender thereof redemption principal amount premium extent permitted applicable law accrued interest security shall paid bear interest redemption date rate per annum security shall remain convertible redemption price security portion thereof case may shall paid duly provided security redeemed part shall surrendered corporate trust office office agency company designated purpose pursuant section company trustee requires due endorsement written instrument transfer form satisfactory company trustee duly executed holder thereof attorney duly authorized writing company shall execute trustee shall authenticate make available delivery holder security without service charge new security securities authorized denomination requested holder aggregate principal amount equal exchange unredeemed portion principal security surrendered section conversion arrangement call redemption connection redemption securities company may arrange purchase conversion securities agreement one investment bankers purchasers purchasers purchase securities paying trustee trust holders redemption date amount less applicable redemption price together interest accrued unpaid excluding redemption date securities notwithstanding anything contrary contained article xi obligation company pay redemption price together interest accrued unpaid excluding redemption date shall deemed satisfied discharged extent amount paid purchasers agreement entered copy shall filed trustee prior close business business day immediately prior redemption date securities called redemption duly surrendered conversion holders thereof may option company deemed fullest extent permitted law consistent agreement agreements purchasers acquired purchasers holders notwithstanding anything contrary contained article xii surrendered purchasers conversion immediately prior close business redemption date right convert securities shall extended time subject payment amount aforesaid direction company trustee shall hold dispose amount paid purchasers holders manner would monies deposited company redemption securities without trustees prior written consent arrangement company purchasers purchase conversion securities shall increase otherwise affect powers duties responsibilities obligations trustee set forth indenture company agrees indemnify trustee hold harmless loss liability expense arising connection arrangement purchase conversion securities company purchasers including costs expenses including reasonable legal fees incurred trustee defense claim liability arising connection exercise performance powers duties responsibilities obligations indenture article xii conversion securities section conversion privilege conversion rate subject upon compliance provisions article option holder thereof us principal amount securities may converted fully paid nonassessable shares calculated conversion nearest th share common stock company conversion rate determined hereinafter provided effect time conversion conversion right shall commence initial issuance date securities expire close business date maturity unless securities previously redeemed repurchased subject case conversion global security applicable procedures case security portion thereof called redemption election company holder thereof exercises right require company repurchase security conversion right respect security portion thereof called shall expire close business second business day immediately preceding redemption date repurchase date case may unless company defaults making payment due upon redemption repurchase case may case subject aforesaid applicable procedures respect global security rate shares common stock shall delivered upon conversion herein called conversion rate shall initially shares common stock us principal amount securities conversion rate shall adjusted certain instances provided article xii section exercise conversion privilege order exercise conversion privilege holder security converted shall surrender security duly endorsed blank office agency company maintained purpose pursuant section accompanied duly signed conversion notice substantially form set forth section stating holder elects convert security less entire principal amount thereof converted portion thereof converted security surrendered conversion whole part record date period shall except case security portion thereof called redemption except pursuant call provisional redemption redemption date repurchasable repurchase date occurring either case period close business regular record date next preceding interest payment date close business third business day following interest payment date result right convert security would otherwise terminate period exercised accompanied payment new york clearing house funds funds acceptable company amount equal interest payable interest payment date principal amount security part thereof case may surrendered conversion interest payable interest payment date respect security portion thereof applicable surrendered conversion record date period shall paid holder security regular record date amount equal interest would payable security security converted close business interest payment date interest payable interest payment date respect security surrendered conversion interest payment date shall paid holder security regular record date next preceding interest payment date notwithstanding exercise right conversion except provided paragraph subject last paragraph section cash payment adjustment shall made upon conversion account interest accrued interest payment date next preceding conversion date respect security part thereof case may surrendered conversion account dividends common stock issued upon conversion companys delivery holder number shares common stock cash lieu fractions thereof provided indenture security convertible deemed satisfy companys obligation pay principal amount security securities shall deemed converted immediately prior close business day surrender securities conversion accordance foregoing provisions time rights holders securities holders shall cease person persons entitled receive common stock issuable upon conversion shall treated purposes record holder holders common stock time promptly practicable conversion date company shall issue deliver trustee delivery holder unless different person indicated conversion notice certificate certificates number full shares common stock issuable upon conversion together payment lieu fraction share provided section shares common stock delivered upon conversion restricted securities shall bear restrictive legends substantially form legends required set forth restricted securities pursuant section shall subject restrictions transfer provided legends neither trustee agent maintained purpose conversion shall responsibility inclusion content restrictive legends common stock provided however trustee agent maintained purpose conversion shall provided company companys transfer agent common stock prior concurrently request company deliver common stock written notice securities delivered conversion restricted securities case security converted part upon conversion company shall execute trustee shall authenticate deliver holder thereof expense company new security securities authorized denominations aggregate principal amount equal unconverted portion principal amount security security may converted part principal amount security converted integral multiple us principal amount security remain outstanding conversion equal us integral multiple excess thereof shares common stock issued upon conversion restricted security securities issued upon conversion restricted security part registered name beneficial owner restricted security holder must deliver conversion agent surrender certificate dated date surrender restricted security signed beneficial owner compliance restrictions transfer applicable restricted security neither trustee conversion agent registrar transfer agent shall required register name beneficial owner shares common stock securities issued upon conversion restricted security accompanied properly completed surrender certificate section fractions shares fractional shares common stock shall issued upon conversion security securities one security shall surrendered conversion one time holder number full shares shall issuable upon conversion thereof shall computed basis aggregate principal amount securities specified portions thereof surrendered instead fractional share common stock would otherwise issuable upon conversion security securities specified portions thereof company shall calculate pay cash adjustment respect fraction calculated nearest th share amount equal fraction closing price per share close business day conversion section adjustment conversion rate conversion rate shall subject adjustments time time follows case company shall pay make dividend distribution shares class capital stock payable shares common stock conversion rate effect opening business day following date fixed determination shareholders entitled receive dividend distribution shall increased dividing conversion rate effect immediately prior date fraction numerator shall number shares common stock outstanding close business date fixed determination denominator shall sum number shares total number shares constituting dividend distribution increase become effective immediately opening business day following date fixed determination date fixed determination dividend distribution fact paid conversion rate shall immediately readjusted effective date board directors determines pay dividend distribution conversion rate would effect determination date fixed purposes paragraph number shares common stock time outstanding shall include shares held treasury company shall include shares issuable respect scrip certificates issued lieu fractions shares common stock company pay dividend make distribution shares common stock held treasury company case company shall issue rights options warrants holders common stock entitling subscribe purchase shares common stock price per share less current market price per share determined provided paragraph section common stock date fixed determination stockholders entitled receive rights options warrants rights options warrants terms also issued holder upon conversion security shares common stock without action required company person conversion rate effect opening business day following date fixed determination shall increased dividing conversion rate effect immediately prior date fraction numerator shall number shares common stock outstanding close business date fixed determination plus number shares common stock aggregate offering price total number shares common stock offered subscription purchase would purchase current market price denominator shall number shares common stock outstanding close business date fixed determination plus number shares common stock offered subscription purchase increase become effective immediately opening business day following date fixed determination date fixed determination rights options warrants fact issued exercised prior expiration thereof conversion rate shall immediately readjusted effective date rights options warrants expire date board directors determines issue rights options warrants conversion rate would effect unexercised rights options warrants never granted determination date fixed case may purposes paragraph number shares common stock time outstanding shall include shares held treasury company shall include shares issuable respect scrip certificates issued lieu fractions shares common stock company issue rights options warrants respect shares common stock held treasury company case outstanding shares common stock shall subdivided greater number shares common stock conversion rate effect opening business day following day upon subdivision becomes effective shall proportionately increased conversely case outstanding shares common stock shall combined smaller number shares common stock conversion rate effect opening business day following day upon combination becomes effective shall proportionately reduced increase reduction case may become effective immediately opening business day following day upon subdivision combination becomes effective case company shall dividend otherwise distribute holders common stock evidences indebtedness shares class capital stock property including cash assets securities excluding rights options warrants referred paragraph section ii dividend distribution paid exclusively cash referred paragraphs iii dividend distribution referred paragraph section iv consideration distributed merger consolidation section applies conversion rate shall adjusted shall equal rate determined dividing conversion rate effect immediately prior close business date fixed determination stockholders entitled receive distribution fraction numerator shall current market price per share determined provided paragraph section common stock date fixed determination less fair market value determined board directors whose determination shall conclusive described board resolution filed trustee portion assets shares evidences indebtedness distributed applicable one share common stock denominator shall current market price per share common stock adjustment become effective immediately prior opening business day following date fixed determination stockholders entitled receive distribution date fixed determination distribution fact made conversion rate shall immediately readjusted effective date board directors determines make distribution conversion rate would effect determination date fixed event fair market value determined portion evidences indebtedness shares class capital stock property distributed equal greater current market price per share common stock date lieu foregoing adjustment adequate provision shall made holder security shall right receive upon conversion amount evidences indebtedness shares class capital stock property holder would received holder converted security date case company shall dividend otherwise distribute holders common stock cash excluding cash distributed upon merger consolidation section applies aggregate amount combined together aggregate amount allcash distributions holders common stock made exclusively cash within day period preceding date payment distribution respect adjustment pursuant paragraph paragraph section made ii aggregate cash plus fair market value determined board directors whose determination shall conclusive described board resolution noncash consideration payable respect tender offer company subsidiaries portion common stock concluded within day period preceding date payment distribution respect adjustment pursuant paragraph section made combined cash tender amount exceeds product current market price per share determined provided paragraph section common stock date determination holders shares common stock entitled receive distribution times number shares common stock outstanding date aggregate current market price case immediately close business date determination conversion rate shall adjusted shall equal rate determined dividing conversion rate effect immediately prior close business date fixed determination stockholders entitled receive distribution fraction numerator shall equal current market price per share determined provided paragraph section common stock date fixed determination less amount equal quotient x excess combined cash tender amount aggregate current market price divided number shares common stock outstanding date determination ii denominator shall equal current market price per share determined provided paragraph section common stock date fixed determination case tender offer made company subsidiary portion common stock shall expire tender offer amended upon expiration thereof shall require payment stockholders based acceptance maximum specified terms tender offer purchased shares defined aggregate consideration fair market value determined board directors whose determination shall conclusive described board resolution combined together aggregate cash plus fair market value determined board directors whose determination shall conclusive described board resolution expiration tender offer noncash consideration payable respect tender offer company subsidiary portion common stock expiring within day period preceding expiration tender offer respect adjustment pursuant paragraph paragraph section made ii aggregate amount cash distributions holders common stock within day period preceding expiration tender offer respect adjustment pursuant paragraph section made combined tender cash amount exceeds product current market price per share common stock determined provided paragraph section last time expiration time tenders could made pursuant tender offer may amended times number shares common stock outstanding including tendered shares expiration time case immediately prior opening business day date expiration time conversion rate shall adjusted shall equal rate determined dividing conversion rate immediately prior close business date expiration time fraction numerator shall equal product current market price per share common stock determined provided paragraph section date expiration time multiplied ii number shares common stock outstanding including tendered shares expiration time less b combined tender cash amount ii denominator shall equal product current market price per share common stock determined provided paragraph section date expiration time multiplied b number shares common stock outstanding including tendered shares expiration time less number shares validly tendered withdrawn expiration time shares deemed accepted maximum referred purchased shares reclassification common stock securities common stock reclassification upon consolidation merger section applies shall deemed involve distribution securities common stock holders common stock effective date reclassification shall deemed date fixed determination stockholders entitled receive distribution date fixed determination within meaning paragraph section b subdivision combination case may number shares common stock outstanding immediately prior reclassification number shares common stock outstanding immediately thereafter effective date reclassification shall deemed day upon subdivision becomes effective day upon combination becomes effective case may day upon subdivision combination becomes effective within meaning paragraph section purpose computation paragraphs section current market price per share common stock date shall calculated company average daily closing prices per share five consecutive trading days selected company commencing trading days ending later earlier day question day ex date respect issuance distribution requiring computation purposes paragraph term ex date used respect issuance distribution means first date common stock trades regular way applicable securities market applicable securities exchange without right receive issuance distribution adjustment conversion rate shall required unless adjustment plus adjustments previously made reason paragraph would require increase decrease least one percent rate provided however adjustments reason paragraph required made shall carried forward taken account subsequent adjustment calculations article shall made nearest cent nearest onehundredth share case may company may make increases conversion rate remaining term securities shorter term addition required paragraphs section considers advisable order avoid diminish income tax holders shares common stock resulting dividend distribution stock issuance rights warrants purchase subscribe stock event treated income tax purposes company shall power resolve ambiguity correct error paragraph actions shall absent manifest error final conclusive notwithstanding foregoing provisions section adjustment conversion rate shall required made upon issuance shares common stock pursuant present future plan reinvestment dividends b upon change par value common stock c tender exchange offer character described rule eh exchange act successor rule thereto extent permitted applicable law company time time may increase conversion rate amount period time period least twenty days increase irrevocable period board directors shall made determination increase would best interests company determination shall conclusive provided however increase shall taken account purposes determining whether closing price per share common stock equals exceeds conversion price connection event would otherwise change control pursuant section ii whether closing price per share common stock exceeds conversion price connection redemption securities accordance provisions form security set forth section hereof whenever conversion rate increased pursuant preceding sentence company shall give notice increase holders manner provided section least fifteen days prior date increased conversion rate takes effect notice shall state increased conversion rate period effect holders securities exercise right conversion date rights issued companys stock rights agreement dated october separate underlying common stock therefore entitled receive common stock rights would otherwise attributable shares common stock received upon conversion conversion rate adjusted though rights distributed holders common stock date separation adjustment made rights later redeemed invalidated terminated corresponding reversing adjustment made conversion rate equitable basis section notice adjustments conversion rate whenever conversion rate adjusted herein provided company shall compute adjusted conversion rate accordance section shall prepare certificate signed principal financial officer comptroller treasurer company setting forth adjusted conversion rate showing reasonable detail facts upon adjustment based certificate shall promptly filed trustee conversion agent upon adjustment notice stating conversion rate adjusted setting forth adjusted conversion rate shall required soon practicable required notice shall provided company holders accordance section neither trustee conversion agent shall duty responsibility respect certificate information calculations contained therein except exhibit holder securities desiring inspection thereof office normal business hours shall deemed knowledge adjustment conversion rate unless responsible officer trustee shall received certificate responsible officer trustee receives certificate trustee conversion agent may assume without inquiry last conversion rate trustee knowledge remains effect section notice certain corporate action case company shall declare dividend distribution common stock payable otherwise exclusively cash ii exclusively cash amount would require adjustment pursuant section company shall authorize granting substantially holders common stock rights options warrants subscribe purchase shares capital stock class rights reclassification common stock consolidation merger share exchange company party approval stockholders company required conveyance sale transfer lease mere grant security interest substantially assets company voluntary involuntary dissolution liquidation winding company company shall cause filed office agency maintained purpose conversion securities pursuant section shall cause provided holders accordance section least days days case specified clause days clause prior applicable record effective date hereinafter specified notice stating x date record taken purpose dividend distribution rights options warrants record taken date holders common stock record entitled dividend distribution rights options warrants determined date reclassification consolidation merger conveyance transfer sale lease mere grant security interest dissolution liquidation winding expected become effective date expected holders common stock record shall entitled exchange shares common stock securities cash property deliverable upon reclassification consolidation merger conveyance transfer sale lease dissolution liquidation winding neither failure give notice notice referred following paragraph defect therein shall affect legality validity proceedings described clauses section time trustee shall conversion agent copy notice shall also forthwith filed company trustee company shall cause filed corporate trust office office agency maintained purpose conversion securities pursuant section shall cause provided holders accordance section notice tender offer company subsidiary portion common stock time notice tender offer provided public generally section company reserve common stock company shall times reserve keep available free preemptive rights authorized unissued common stock purpose effecting conversion securities full number shares common stock issuable upon conversion outstanding securities section taxes conversions except provided next sentence company pay stamp taxes duties may payable respect issue delivery shares common stock conversion securities pursuant hereto company shall however required pay tax duty may payable respect income holder ii transfer involved issue delivery shares common stock name holder security securities converted issue delivery shall made unless person requesting issue paid company amount tax duty established satisfaction company tax duty paid section covenant common stock company agrees shares common stock may delivered upon conversion securities upon delivery duly authorized validly issued fully paid nonassessable except provided section company pay taxes liens charges respect issue thereof section cancellation converted securities securities delivered conversion shall delivered trustee agent canceled direction trustee shall dispose provided section section provision case consolidation merger sale assets case consolidation merger company person merger another person company merger result reclassification conversion exchange cancellation outstanding shares common stock company conveyance sale transfer lease mere grant security interest substantially assets company sale substantially assets company result reclassification conversion exchange cancellation outstanding shares common stock company person formed consolidation resulting merger acquires assets case may shall execute deliver trustee supplemental indenture providing holder security outstanding shall right thereafter period security shall convertible specified section convert security kind amount securities cash property receivable upon consolidation merger conveyance sale transfer lease mere grant security interest holder number shares common stock company security might converted immediately prior consolidation merger conveyance sale transfer lease mere grant security interest assuming holder common stock company person company consolidated merged merged company conveyance sale transfer lease mere grant security interest made case may constituent person b affiliate constituent person ii failed exercise rights election kind amount securities cash property receivable upon consolidation merger conveyance sale transfer lease mere grant security interest provided kind amount securities cash property receivable upon consolidation merger conveyance sale transfer lease mere grant security interest share common stock company held immediately prior consolidation merger conveyance sale transfer lease mere grant security interest others constituent person affiliate thereof respect rights election shall exercised non electing share purpose section kind amount securities cash property receivable upon consolidation merger conveyance sale transfer lease mere grant security interest holders nonelecting share shall deemed kind amount receivable per share plurality nonelecting shares supplemental indenture shall provide adjustments events subsequent effective date supplemental indenture shall nearly equivalent may practicable adjustments provided article provisions section shall similarly apply successive consolidations mergers conveyances sales transfers leases mere grant security interest notice execution supplemental indenture shall given company holder security provided section promptly upon execution neither trustee conversion agent shall responsibility determine correctness provisions contained supplemental indenture relating either kind amount shares stock securities property cash receivable holders securities upon conversion securities consolidation merger conveyance transfer sale lease mere grant security interest adjustment may accept conclusive evidence correctness provisions shall protected relying upon officers certificate opinion counsel respect thereto company shall cause furnished trustee upon request section rights issued respect common stock rights warrants distributed company holders common stock entitling holders thereof subscribe purchase shares companys capital stock either initially certain circumstances rights warrants occurrence specified event events trigger event deemed transferred shares common stock ii exercisable iii also issued respect future issuances common stock shall deemed distributed purposes section occurrence earliest trigger event addition event distribution rights warrants trigger event respect thereto shall resulted adjustment conversion rate section case rights warrants shall redeemed repurchased without exercise holders thereof conversion rate shall readjusted upon final redemption repurchase give effect distribution trigger event case may though cash distribution equal per share redemption repurchase price received holder common stock respect rights warrants assuming holder retained rights warrants made holders common stock date redemption repurchase case rights warrants shall expired without exercise holder thereof conversion price shall readjusted issuance occurred section responsibility trustee conversion provisions trustee subject provisions section conversion agent shall time duty responsibility holder securities determine whether facts exist may require adjustment conversion rate respect nature extent adjustment made respect method employed herein supplemental indenture provided employed making whether supplemental indenture need entered neither trustee subject provisions section conversion agent shall accountable respect validity value kind amount common stock securities property cash may time issued delivered upon conversion security make representation respect thereto neither trustee subject provisions section conversion agent shall responsible failure company make calculate cash payment issue transfer deliver shares common stock share certificates securities property cash upon surrender security purpose conversion trustee subject provisions section conversion agent shall responsible failure company comply covenants company contained article article xiii repurchase securities option f holder upon change control section right require repurchase event change control hereinafter defined shall occur holder shall right holders option subject provisions section require company repurchase upon exercise right company shall repurchase holders securities theretofore called redemption portion principal amount thereof equal us integral multiple us excess thereof provided single security may repurchased part unless portion principal amount security outstanding repurchase equal us integral multiples us excess thereof date repurchase date days date company notice defined section purchase price equal principal amount securities repurchased plus interest accrued unpaid excluding repurchase date repurchase price provided however installments interest securities whose stated maturity prior repurchase date shall payable holders securities one predecessor securities registered relevant record date according terms provisions section right require repurchase securities shall continue discharge company obligations respect securities accordance article iv unless change control shall occurred prior discharge option company repurchase price may paid cash subject fulfillment company conditions set forth section delivery shares common stock fair market value equal repurchase price less cash payments combination cash common stock whenever indenture including sections reference context principal security time reference shall deemed include reference repurchase price payable respect security extent repurchase price would payable time express mention repurchase price provision indenture shall construed excluding repurchase price provisions indenture express mention made section conditions companys election pay repurchase price common stock company may option pay repurchase price cash common stock combination thereof extent repurchase price paid common stock company may elect pay amount delivery shares common stock pursuant section following conditions shall satisfied shares common stock deliverable payment repurchase price less cash payments shall fair market value repurchase date less repurchase price less cash payments purposes section section fair market value shares common stock shall determined company shall equal average closing prices per share common stock five consecutive trading days ending third trading day prior repurchase date repurchase price shall paid cash event shares common stock issued upon repurchase securities hereunder require registration federal securities law shares may freely transferable without subject transfer restrictions securities act upon repurchase registration completed become effective prior repurchase date andor ii require registration approval governmental authority state law federal law shares may validly issued delivered upon repurchase registration completed become effective approval obtained prior repurchase date payment repurchase price may made common stock unless stock shall listed national securities exchange approved quotation nasdaq national market either case prior repurchase date shares common stock may issued upon repurchase securities issued companys authorized unissued common stock upon issue duly validly issued fully paid nonassessable free preemptive similar rights conditions set forth section satisfied accordance terms thereof repurchase price shall paid company cash section notices method exercising repurchase right etc unless company shall theretofore called redemption outstanding securities th day occurrence change control company request expense company th day occurrence trustee shall give holders securities manner provided section notice company notice occurrence change control repurchase right set forth herein arising result thereof company shall also deliver copy company notice trustee company notice shall state repurchase date ii date repurchase right must exercised iii repurchase price whether repurchase price shall paid company cash delivery shares common stock combination thereof applicable ratio cash common stock iv description procedure holder must follow exercise repurchase right place places securities surrendered payment repurchase price accrued interest including liquidated damages repurchase date v repurchase date repurchase price accrued interest including liquidated damages repurchase date become due payable upon security designated holder repurchased interest thereon shall cease accrue said date vi conversion rate effect date right convert principal amount securities repurchased terminate place places securities may surrendered conversion vii place places security certificate election holder require repurchase specified section shall delivered security restricted securities certificate place places surrender certificate required section shall delivered failure company give foregoing notices defect therein shall limit holder right exercise repurchase right affect validity proceedings repurchase securities foregoing provisions provisions article xiii inconsistent applicable law law shall govern exercise repurchase right holder shall deliver trustee th day date company notice irrevocable written notice holders exercise right notice shall set forth name holder principal amount securities repurchased security repurchased part serial number thereof portion principal amount thereof repurchased name person portion thereof remain outstanding repurchase registered statement election exercise repurchase right made thereby event portion repurchase price shall paid shares common stock name names addresses certificate certificates shares common stock shall issued ii securities respect repurchase right exercised written notice shall irrevocable except right holder convert securities respect repurchase right exercised shall continue close business second business day repurchase date event repurchase right shall exercised accordance terms hereof company shall pay cause paid trustee repurchase price cash shares common stock combination thereof provided payment holder repurchase date together accrued unpaid interest repurchase date payable respect securities repurchase right exercised provided however installments interest mature prior repurchase date shall payable cash holders securities one predecessor securities registered close business relevant regular record date security portion thereof surrendered repurchase shall paid repurchase date principal amount security portion thereof case may shall paid bear interest extent permitted applicable law repurchase date rate per annum security shall remain convertible common stock principal security portion thereof case may shall paid duly provided security repurchased part shall surrendered trustee company trustee requires due endorsement written instrument transfer form satisfactory company trustee duly executed holder thereof attorney duly authorized writing company shall execute trustee shall authenticate make available delivery holder security without service charge new security securities containing identical terms conditions authorized denomination aggregate principal amount equal exchange unrepurchased portion principal security surrendered issuance shares common stock respect portion repurchase price shall deemed effected immediately prior close business repurchase date person persons whose name names certificate certificates shares common stock shall issuable upon repurchase shall deemed become repurchase date holder holders record shares represented thereby provided however surrender repurchase date stock transfer books company shall closed shall constitute person persons whose name names certificate certificates shares issued record holder holders thereof purposes opening business next succeeding day stock transfer books open payment adjustment shall made dividends distributions common stock issued upon repurchase security declared prior repurchase date fractions shares shall issued upon repurchase securities one security shall repurchased holder portion repurchase price shall payable shares common stock number full shares shall issuable upon repurchase shall computed basis aggregate principal amount securities repurchased instead fractional share common stock would otherwise issuable repurchase security securities company deliver applicable holder check current market value fractional share current market value fraction share determined multiplying current market price full share fraction rounding result nearest cent purposes section current market price share common stock closing price per share common stock trading day immediately preceding repurchase date issuance delivery certificates shares common stock repurchase securities shall made without charge holder securities repurchased certificates tax duty respect issuance delivery certificates securities represented thereby provided however company shall required pay tax duty may payable respect income holder ii transfer involved issuance delivery certificates shares common stock name holder securities repurchased issuance delivery shall made unless person requesting issuance delivery paid company amount tax duty established satisfaction company tax duty paid shares common stock delivered upon repurchase security registered name beneficial owner security holder must deliver trustee surrender certificate dated date surrender restricted security signed beneficial owner compliance restrictions transfer applicable restricted security neither trustee registrar transfer agent agents shall required register name beneficial owner shares common stock issued upon repurchase restricted security accompanied properly completed surrender certificate securities delivered repurchase shall delivered trustee canceled direction trustee shall dispose provided section section certain definitions purposes article xiii term beneficial owner shall determined accordance rule effect date original execution indenture promulgated commission pursuant exchange act change control shall deemed occurred time original issuance securities acquisition person including syndicate group deemed person section exchange act beneficial ownership directly indirectly purchase merger acquisition transaction series transactions shares capital stock company entitling person exercise total voting power shares capital stock company entitled vote generally elections directors acquisition company subsidiary company employee benefit plan company ii consolidation company merger company person merger another person company conveyance sale transfer lease mere grant security interest substantially assets company another person transaction x result reclassification conversion exchange cancellation outstanding shares capital stock company pursuant holders total voting power shares companys capital stock entitled vote generally election directors immediately prior transaction entitlement exercise directly indirectly total voting power shares capital stock entitled vote generally election directors continuing surviving corporation immediately transaction b transaction effected solely change jurisdiction incorporation company results reclassification conversion exchange outstanding shares common stock solely shares common stock surviving entity iii provided however change control shall deemed occurred closing price per share common stock five trading days within period consecutive trading days ending immediately later date change control date public announcement change control case change control clause period consecutive trading days ending immediately change control case change control clause ii shall case five trading days equal exceed conversion price securities effect five trading days ii consideration excluding cash payments fractional shares cash payments made pursuant dissenters appraisal rights merger consolidation otherwise constituting change control clause andor clause ii consists shares common stock depository receipts certificates representing common equity interests traded national securities exchange quoted nasdaq national market traded quoted immediately following merger consolidation result merger consolidation securities become convertible solely common stock depository receipts certificates representing common equity interests term conversion price shall equal us divided conversion rate rounded nearest cent purposes section term person shall include syndicate group would deemed person section exchange act effect date original execution indenture section consolidation merger etc case merger consolidation conveyance sale transfer lease mere grant security interest substantially assets company section applies common stock company changed exchanged result right receive shares stock securities property assets including cash includes shares common stock company common stock another person upon issuance traded united states national securities exchange approved trading established automated overthecounter trading market united states shares constitute time change exchange becomes effective excess aggregate fair market value shares stock securities property assets including cash determined company determination shall conclusive binding person formed consolidation resulting merger combination acquires properties assets including cash company case may shall execute deliver trustee supplemental indenture shall comply trust indenture act force date execution supplemental indenture modifying provisions indenture relating right holders cause company repurchase securities following change control including without limitation applicable provisions article xiii definitions common stock change control appropriate related definitions set forth herein determined good faith company determination shall conclusive binding make provisions apply event subsequent change control common stock issuer thereof different company common stock company lieu company common stock company article xiv holders lists reports trustee company nonrecourse section company furnish trustee names addresses holders company furnish cause furnished trustee semiannually days regular record date list form trustee may reasonably require names addresses holders securities regular record date times trustee may reasonably request writing within days receipt company request list similar form content date days prior time list furnished provided however list need furnished long trustee acting security registrar section preservation information trustee shall preserve current form reasonably practicable names addresses holders contained recent list furnished trustee provided section names addresses holders received trustee capacity security registrar trustee may destroy list furnished provided section upon receipt new list furnished indenture qualified trust indenture act rights holders communicate holders respect rights indenture securities corresponding rights duties trustee shall provided trust indenture act every holder securities receiving holding agrees company trustee neither company trustee agent either shall held accountable reason disclosure information names addresses holders made pursuant trust indenture act section reports trustee indenture qualified trust indenture act trustee shall transmit holders reports concerning trustee actions indenture may required pursuant trust indenture act times manner provided pursuant thereto indenture qualified trust indenture act copy report shall time transmission holders filed trustee stock exchange upon securities listed commission company company notify trustee securities listed stock exchange section reports company indenture qualified trust indenture act company shall file trustee commission transmit holders information documents reports summaries thereof may required pursuant trust indenture act times manner provided pursuant act provided information documents reports required filed commission pursuant section securities exchange act shall filed trustee within days required filed commission article xv immunity incorporators stockholders officers directors section indenture securities solely corporate obligations recourse payment principal premium interest including liquidated damages security recourse upon obligation covenant agreement company indenture supplemental indenture security creation indebtedness represented thereby shall past present future incorporator stockholder employee agent officer director subsidiary company successor corporation whether virtue constitution statute rule law enforcement assessment penalty otherwise expressly understood liability hereby waived released condition consideration execution indenture issue securities indenture may executed number counterparts executed shall deemed original counterparts shall together constitute one instrument witness whereof parties hereto caused indenture duly executed day year first written gilead sciences inc john milligan name john milligan title sr vp cfo jp morgan trust company national association trustee james nagy name james nagy title assistant vice president annex form unrestricted securities certificate unrestricted securities certificate removal restricted securities legend pursuant section jp morgan trust company national association mission street th floor san francisco california jpmorgan institutional trust services window new york plaza ground floor new york new york convertible senior notes due december gilead sciences inc securities reference made indenture dated december indenture gilead sciences inc company jp morgan trust company national association trustee terms used herein defined indenture rule us securities act securities act used herein defined certificate relates us principal amount securities evidenced following certificates specified securities cusip ac certificate nos person whose name certificate executed undersigned hereby certifies either sole beneficial owner specified securities ii acting behalf beneficial owners specified securities duly authorized beneficial owner owners referred herein collectively owner specified securities represented global security held depositary agent member name undersigned behalf owner specified securities represented global security registered name undersigned behalf owner owner requested specified securities exchanged securities bearing restricted securities legend pursuant section indenture connection exchange owner hereby certifies exchange occurring period least two years elapsed since issue date owner preceding three months affiliate company owner also acknowledges future transfers specified securities must comply applicable securities laws states united states jurisdictionsthis certificate statements contained herein made benefit benefit company initial purchaser dated print name undersigned term defined third paragraph certificate name title undersigned corporation partnership fiduciary title person signing behalf undersigned must stated annex b form surrender certificate connection certification contemplated section relating compliance certain restrictions relating transfers restricted securities certification shall provided substantially form following certificate changes thereto shall approved company goldman sachs co certificate gilead sciences inc convertible senior notes due december certify date hereof respect us principal amount abovecaptioned securities surrendered date hereof surrendered securities registration transfer conversion repurchase securities issuable upon conversion repurchase registered name undersigned holder transaction transfer undersigned holder defined indenture certifies transfer surrendered securities associated transfer complies restrictive legend set forth face surrendered securities reason checked transfer surrendered securities complies rule securities act transfer surrendered securities complies rule united states securities act amended securities act transfer surrendered securities made institution accredited investor within meaning rule securities act transaction exempt registration requirements securities act signed letter containing certain representations agreements relating restrictions transfer securities delivered transfer aggregate principal amount less opinion counsel acceptable company requested company transfer exempt registration transfer surrendered securities made pursuant exemption registration securities act opinion counsel delivered company respect transfer name holder dated dated date surrenderexhibit gilead sciences inc convertible senior notes due december registration rights agreement december goldman sachs co broad street new york new york ladies gentlemen gilead sciences inc delaware corporation company proposes issue sell purchaser defined herein upon terms set forth purchase agreement defined rein convertible senior notes due december securities inducement purchaser enter purchase agreement satisfaction condition obligations purchaser thereunder company agrees purchaser benefit holders defined herein time time registrable securities defined herein follows definitions capitalized terms used herein without definition shall meanings ascribed purchase agreement used agreement agreement following defined terms shall following meanings act securities act means united states securities act amended affiliate specified person means person directly indirectly control controlled common control specified person purposes definition control person means power direct indirect direct cause direction management policies person whether contract otherwise terms controlling controlled meanings correlative foregoing closing date means first time delivery defined purchase agreement commission means united states securities exchange commission federal agency time administering exchange act securities act whichever relevant statute particular purpose common stock means companys common stock par value per share together associated preferred stock purchase rights dtc means depository trust company effective date meaning assigned thereto section bi hereof effective failure meaning assigned thereto section b hereof effectiveness period meaning assigned thereto section bi hereof effective time means time commission declares shelf registration statement effective shelf registration statement otherwise becomes effective electing holder meaning assigned thereto section aiii hereof exchange act means united states securities exchange act amended holder means person record owner registrable securities includes person beneficial interest registrable security bookentry form indenture means indenture dated december company jp morgan trust company national association amended supplemented time time accordance terms liquidated damages meaning assigned thereto section hereof managing underwriters means investment banker investment bankers manager managers shall administer underwritten offering conducted pursuant section hereof nasd rules means rules national association securities dealers inc amended time time notice questionnaire means notice registration statement selling securityholder questionnaire substantially form appendix hereto term person means individual partnership corporation trust unincorporated organization government agency political subdivision thereof prospectus means prospectus including without limitation preliminary prospectus final prospectus prospectus discloses information previously omitted prospectus filed part effective registration statement reliance upon rule act included shelf registration statement amended supplemented prospectus supplement respect terms offering portion registrable securities covered shelf registration statement amendments supplements prospectus including material incorporated reference prospectus documents filed date prospectus company exchange act incorporated reference therein purchase agreement means purchase agreement dated december purchaser company relating securities purchaser means goldman sachs co registrable securities means portion securities issued time time indenture registered form shares common stock issuable upon conversion repurchase redemption securities provided however security ceases registrable security longer restricted security registration default meaning assigned thereto section hereof restricted security means security share common stock issuable upon conversion thereof except security share common stock effectively registered securities act sold manner contemplated shelf registration statement ii transferred compliance rule securities act successor provision thereto transferable pursuant paragraph k rule successor provision thereto iii otherwise transferred new security share common stock subject transfer restrictions securities act delivered behalf company accordance section indenture rules regulations means published rules regulations commission promulgated securities act exchange act effect relevant time shelf registration means registration effected pursuant section hereof shelf registration statement means shelf registration statement filed securities act providing registration sale continuous delayed basis holders registrable securities pursuant rule securities act andor similar rule may adopted commission filed company pursuant provisions section agreement including prospectus contained therein amendments supplements registration statement including post effective amendments exhibits material incorporated reference registration statement trust indenture act means trust indenture act successor thereto rules regulations forms promulgated thereunder shall amended time time term underwriter means underwriter registrable securities connection offering thereof shelf registration statement b wherever reference agreement percentage principal amount registrable securities percentage registrable securities common stock shall treated representing principal amount securities surrendered conversion exchange order receive number shares common stock shelf registration company shall later calendar days following closing date file commission shelf registration statement relating offer sale registrable securities holders time time accordance methods distribution elected holders set forth shelf registration statement thereafter shall use reasonable best efforts cause shelf registration statement declared effective act later calendar days following closing date provided however company may upon written notice holders postpone shelf registration statement declared effective reasonable period exceed days company possesses material nonpublic information disclosure would material adverse effect company subsidiaries taken whole provided however holder shall entitled named selling securityholder shelf registration statement use prospectus forming part thereof resales registrable securities unless holder electing holder b company shall use reasonable best efforts keep shelf registration statement continuously effective order permit prospectus forming part thereof usable holders earliest sale registrable securities registered shelf registration statement expiration period referred rule k act respect registrable securities held persons affiliates company two years date effective date shelf registration statement declared effective period referred herein effectiveness period ii effective time shelf registration statement promptly practicable upon request holder registrable securities electing holder take action reasonably necessary enable holder use prospectus forming part thereof offers resales registrable securities including without limitation action necessary identify holder selling securityholder shelf registration statement provided however nothing subparagraph shall relieve holder obligation return completed signed notice questionnaire company accordance section aii hereof iii time securities pursuant article indenture convertible securities common stock cause cause successor indenture cause securities included shelf registration statement later date securities may convertible securities company shall deemed used reasonable best efforts keep shelf registration statement effective periods specified section b company voluntarily takes action would result holders registrable securities covered thereby able offer sell registrable securities period unless action required applicable law company thereafter promptly complies requirements paragraph j b permitted pursuant section c c company may suspend use prospectus period exceed days day period aggregate days month period board directors company shall determined good faith valid business reasons including avoidance companys obligations hereunder including acquisition divestiture assets pending corporate developments similar events best interests company suspend use prior suspending use company provides holders written notice suspension notice need specify nature event giving rise suspension registration procedures connection shelf registration statement following provisions shall apply less calendar days prior effective time shelf registration statement company shall mail notice questionnaire holders registrable securities holder shall entitled named selling securityholder shelf registration statement effective time holder shall entitled use prospectus forming part thereof offers resales registrable securities time unless holder returned completed signed notice questionnaire company deadline response set forth therein provided however holders registrable securities shall least calendar days date notice questionnaire first mailed holders return completed signed notice questionnaire company ii effective time shelf registration statement company shall upon request holder registrable securities electing holder promptly send notice questionnaire holder company shall required take action name holder selling securityholder shelf registration statement enable holder use prospectus forming part thereof offers resales registrable securities holder returned completed signed notice questionnaire company iii term electing holder shall mean holder registrable securities returned completed signed notice questionnaire company accordance section ai aii hereof b company shall furnish electing holder prior effective time copy shelf registration statement initially filed commission shall furnish holders prior filing thereof commission copies amendment thereto amendment supplement prospectus included therein shall use reasonable best efforts reflect document effective time filed commission case may comments holders counsel holders reasonably may propose c subject companys rights section c company shall promptly practicable take action may necessary shelf registration statement amendment thereto prospectus forming part thereof amendment supplement thereto report document incorporated therein reference case complies material respects securities act exchange act respective rules regulations thereunder ii shelf registration statement amendment thereto becomes effective contain untrue statement material fact omit state material fact required stated therein necessary make statements therein misleading iii prospectus forming part shelf registration statement supplemented applicable time effectiveness period include untrue statement material fact omit state material fact necessary order make statements therein light circumstances made misleading company shall promptly practicable advise electing holder shall confirm advice writing requested electing holder shelf registration statement amendment thereto filed commission shelf registration statement posteffective amendment thereto become effective case making public announcement thereof release made reuters economic services bloomberg business news ii request commission amendments shelf registration statement supplements prospectus included therein additional information iii issuance commission stop order suspending effectiveness shelf registration statement initiation proceedings purpose iv receipt company notification respect suspension qualification securities included shelf registration statement sale jurisdiction initiation proceeding purpose v happening event existence state facts requires making changes shelf registration statement prospectus included therein date shelf registration statement prospectus contain untrue statement material fact omit state material fact required stated therein necessary make statements therein case prospectus light circumstances made misleading advice shall accompanied instruction holders suspend use prospectus requisite changes made e company shall use reasonable best efforts prevent issuance issued obtain withdrawal earliest possible time order suspending effectiveness shelf registration statement f company shall furnish electing holder without charge least one copy shelf registration statement posteffective amendments thereto including financial statements schedules electing holder requests writing reports documents exhibits filed incorporated reference shelf registration statement g company shall effectiveness period deliver electing holder without charge many copies prospectus including preliminary prospectus included shelf registration statement supplement thereto electing holder may reasonably request company consents except periods specified section c continuance event described section dv use prospectus supplement thereto electing holders connection offering sale registrable securities covered prospectus supplement thereto effectiveness period h prior offering registrable securities pursuant shelf registration statement company shall register qualify cooperate electing holders respective counsel connection registration qualification registrable securities offer sale securities blue sky laws jurisdictions within united states electing holder may reasonably request ii keep registrations qualifications effect comply laws permit continuance offers sales jurisdictions long may necessary enable electing holder underwriter complete distribution registrable securities pursuant shelf registration statement iii take actions necessary advisable enable disposition jurisdictions registrable securities provided however event shall company obligated qualify foreign corporation dealer securities jurisdiction would otherwise required qualify section h b file general consent service process jurisdiction date hereof subject unless registrable securities shall bookentry form company shall cooperate electing holders facilitate timely preparation delivery certificates representing registrable securities sold pursuant shelf registration statement certificates required securities exchange upon registrable securities listed shall penned lithographed engraved produced combination methods steel engraved borders certificates shall free restrictive legends permitted denominations registered names electing holders may request connection sale registrable securities pursuant shelf registration statement j subject companys exercise rights section c upon occurrence fact event contemplated paragraph dv company shall promptly practicable prepare posteffective amendment shelf registration statement supplement related prospectus file required document thereafter delivered purchasers registrable securities included therein prospectus include untrue statement material fact omit state material fact necessary make statements therein light circumstances made misleading company notifies electing holders occurrence fact event contemplated paragraph dv electing holder shall suspend use prospectus requisite changes prospectus made k later effective time shelf registration statement company shall provide cusip number registrable securities debt securities l company shall use reasonable best efforts comply applicable rules regulations make generally available securityholders soon practicable event later eighteen months effective date defined rule c securities act shelf registration statement ii effective date posteffective amendment shelf registration statement iii date filing company commission annual report incorporated reference shelf registration statement earning statement company subsidiaries complying section securities act rules regulations commission thereunder including option company rule later effective time shelf registration statement company shall cause indenture qualified trust indenture act connection qualification company shall cooperate trustee indenture holders defined indenture effect changes indenture may required indenture qualified accordance terms trust indenture act company shall execute shall use reasonable efforts cause trustee execute documents may required effect changes forms documents required filed commission enable indenture qualified timely manner event amendment modification referred section involves appointment new trustee indenture company shall appoint new trustee thereunder pursuant applicable provisions indenture n event underwritten offering conducted pursuant section hereof company shall requested promptly include incorporate prospectus supplement posteffective amendment shelf registration statement information managing underwriters reasonably agree included therein company reasonably object shall make required filings prospectus supplement posteffective amendment soon practicable notified matters included incorporated prospectus supplement posteffective amendment company shall enter customary agreements including underwriting agreement customary form event underwritten offering conducted pursuant section hereof take appropriate action order expedite facilitate registration disposition registrable securities connection therewith underwriting agreement entered cause contain indemnification provisions procedures substantially identical substance set forth section hereof respect parties indemnified pursuant section hereof p company shall make available inspection electing holders underwriter participating disposition pursuant shelf registration statement attorney accountant agent retained electing holders underwriters collectively inspectors offices normally kept reasonable business hours time times shall mutually convenient company inspectors group financial records pertinent corporate documents instruments company subsidiaries collectively records shall reasonably necessary enable exercise applicable due diligence responsibilities cause officers directors employees company subsidiaries supply information reasonably requested inspector connection shelf registration statement records company determines good faith confidential records notifies inspectors confidential shall disclosed used inspector unless disclosure records necessary avoid correct material misstatement material omission shelf registration statement b release records ordered pursuant subpoena order court competent jurisdiction c disclosure information made court proceeding required law information records made generally available public acts inspector result breach agreement provided however prior notice shall provided soon practicable company potential disclosure information inspector pursuant clauses b c sentence permit company obtain protective order waive provisions paragraph inspector shall take actions reasonably necessary protect confidentiality information practicable extent action otherwise inconsistent impairment derogation rights interests electing holder inspector provided prior disclosure inspector records company determines good faith confidential company may require inspector execute confidentiality agreement whereby inspector shall agree limitations disclosure record extent provided ii connection underwritten offering conducted pursuant section hereof make representations warranties managing underwriters form substance scope customarily made issuers underwriters primary underwritten offerings equity convertible debt securities covering matters including limited set forth purchase agreement iii connection underwritten offering conducted pursuant section hereof obtain opinions counsel company counsel opinions form scope substance shall reasonably satisfactory managing underwriters addressed underwriters covering matters customarily covered opinions requested primary underwritten offerings equity convertible debt securitiesin addition counsel company shall provide letter underwriters stating nothing came counsels attention time delivery effective time shelf registration statement recent posteffective amendment thereto case may shelf registration statement including documents incorporated reference therein contained untrue statement material fact omission material fact required stated therein necessary make statements therein misleading prospectus including documents incorporated reference therein contained untrue statement material fact omission material fact required stated therein necessary make statements therein light circumstances made misleading iv connection underwritten offering conducted pursuant section hereof obtain cold comfort letters updates thereof independent public accountants company necessary independent public accountants subsidiary company business acquired company financial statements financial data required included shelf registration statement addressed underwriters customary form covering matters type customarily covered cold comfort letters connection primary underwritten offerings v connection underwritten offering conducted pursuant section hereof deliver documents certificates may reasonably requested managing underwriters including without limitation certificates evidence compliance section j hereof conditions contained underwriting agreement agreements entered company q company use best efforts cause common stock issuable upon conversion securities listed quotation nasdaq national market system stock exchange trading system common stock primarily trades prior effective time shelf registration statement hereunder r company shall use reasonable best efforts take steps necessary effect registration offering sale registrable securities covered shelf registration statement contemplated hereby registration expenses except otherwise provided section company shall bear fees expenses incurred connection performance obligations sections hereof shall bear reimburse electing holders reasonable fees disbursements single counsel selected plurality electing holders aggregate less registrable securities covered shelf registration statement act counsel therefor connection therewith counsel holders electing holder shall pay underwriting discounts commissions transfer taxes relating sale disposition electing holders registrable securities pursuant shelf registration statement indemnification contribution indemnification company upon registration registrable securities pursuant section hereof company shall indemnify hold harmless electing holder underwriter selling agent securities professional facilitates disposition registrable securities respective officers directors person controls electing holder underwriter selling agent securities professional within meaning section securities act section exchange act person sometimes referred indemnified person losses claims damages liabilities joint several indemnified person may become subject securities act otherwise insofar losses claims damages liabilities actions respect thereof arise based upon untrue statement alleged untrue statement material fact contained shelf registration statement registrable securities registered securities act prospectus contained therein furnished company indemnified person amendment supplement thereto arise based upon omission alleged omission state therein material fact required stated therein necessary make statements therein misleading company hereby agrees reimburse indemnified person legal expenses reasonably incurred connection investigating defending action claim expenses incurred provided however company shall liable indemnified person case extent loss claim damage liability arises based upon untrue statement alleged untrue statement omission alleged omission made shelf registration statement prospectus amendment supplement reliance upon conformity written information furnished company indemnified person expressly use therein provided company shall liable indemnified person indemnity agreement subsection respect preliminary prospectus extent loss claim damage liability indemnified person results fact indemnified person sold registrable securities person shall established sent given prior written confirmation sale copy final prospectus excluding documents incorporated reference case delivery required securities act company previously furnished copies thereof sufficient quantity timely basis indemnified party loss claim damage liability indemnified person results untrue statement alleged untrue statement material fact omission alleged omission material fact contained preliminary prospectus identified writing including email prior time delivery final prospectus indemnified party corrected final prospectus provided company shall liable indemnified person indemnity agreement subsection extent shall established loss claim damage liability indemnified person results fact indemnified person sold registrable securities indemnified person received written notice company use prospectus suspended provided section dv hereof loss claim damage liability directly caused events existence state facts gave rise suspension b indemnification electing holders agents underwriters electing holder agrees consequence inclusion electing holders registrable securities shelf registration statement underwriter selling agent securities professional facilitates disposition registrable securities shall agree consequence facilitating disposition registrable securities severally jointly indemnify hold harmless company directors officers sign shelf registration statement person controls company within meaning either section securities act section exchange act losses claims damages liabilities company persons may become subject securities act otherwise insofar losses claims damages liabilities actions respect thereof arise based upon untrue statement alleged untrue statement material fact contained shelf registration statement prospectus amendment supplement arise based upon omission alleged omission state therein material fact required stated therein necessary make statements therein misleading case extent extent untrue statement alleged untrue statement omission alleged omission made reliance upon conformity written information furnished company electing holder underwriter selling agent securities professional expressly use therein ii reimburse company legal expenses reasonably incurred company connection investigating defending action claim expenses incurred c notices claims etc promptly receipt indemnified party subsection b notice commencement action indemnified party shall claim respect thereof made indemnifying party section notify indemnifying party writing commencement thereof omission notify indemnifying party shall relieve liability may indemnified party otherwise indemnification provisions contemplated subsection b case action shall brought indemnified party shall notify indemnifying party commencement thereof indemnifying party shall entitled participate therein extent shall wish jointly indemnifying party similarly notified assume defense thereof counsel satisfactory indemnified party shall except consent indemnified party counsel indemnifying party notice indemnifying party indemnified party election assume defense thereof indemnifying party shall liable indemnified party section legal expenses counsel expenses case subsequently incurred indemnified party connection defense thereof reasonable costs investigation indemnifying party shall without written consent indemnified party effect settlement compromise consent entry judgment respect pending threatened action claim respect indemnification contribution may sought hereunder whether indemnified party actual potential party action claim unless settlement compromise judgment includes unconditional release indemnified party liability arising action claim ii include statement admission fault culpability failure act behalf indemnified party contribution indemnification provided section unavailable insufficient hold harmless indemnified party subsection b respect losses claims damages liabilities actions respect thereof referred therein indemnifying party shall contribute amount paid payable indemnified party result losses claims damages liabilities actions respect thereof proportion appropriate reflect relative fault indemnifying party indemnified party connection statements omissions resulted losses claims damages liabilities actions respect thereof well relevant equitable considerations relative fault indemnifying party indemnified party shall determined reference among things whether untrue alleged untrue statement material fact omission alleged omission state material fact relates information supplied indemnifying party indemnified party parties relative intent knowledge access information opportunity correct prevent statement omission parties hereto agree would equitable contribution pursuant section determined pro rata allocation even electing holders underwriters selling agents securities professionals treated one entity purpose method allocation take account equitable considerations referred section amount paid payable indemnified party result losses claims damages liabilities actions respect thereof referred shall deemed include legal fees expenses reasonably incurred indemnified party connection investigating defending action claim person guilty fraudulent misrepresentation within meaning section f securities act shall entitled contribution person guilty fraudulent misrepresentation obligations electing holders underwriters selling agents securities professionals section contribute shall several proportion percentage principal amount registrable securities registered underwritten case may joint e notwithstanding provision section event electing holder required undertake liability person section amounts excess dollar amount proceeds received holder sale holders registrable securities deducting fees discounts commissions applicable thereto pursuant shelf registration statement registrable securities registered securities act ii underwriter selling agent securities professional required undertake liability person hereunder amounts excess discount commission compensation payable underwriter selling agent securities professional respect registrable securities underwritten distributed public f obligations company section shall addition liability company may otherwise indemnified person obligations indemnified person section shall addition liability indemnified person may otherwise company remedies provided section exclusive shall limit rights remedies may otherwise available indemnified party law equity underwritten offering holder registrable securities desires may sell registrable securities whole part underwritten offering provided electing holders least aggregate principal amount registrable securities covered shelf registration statement shall request offering ii least aggregate principal amount registrable securities shall included offering provided company shall obligated cooperate one underwritten offering effectiveness period upon receipt request company shall provide holders registrable securities written notice request notice shall inform holders opportunity participate offering underwritten offering investment banker bankers manager managers administer offering selected underwriting arrangements respect thereto including size offering approved holders majority registrable securities included offering provided however investment bankers managers underwriting arrangements must reasonably satisfactory company holder may participate underwritten offering contemplated hereby unless holder agrees sell holders registrable securities included underwritten offering accordance approved underwriting arrangements b holder completes executes reasonable questionnaires powers attorney indemnities underwriting agreements lockup letters documents required terms approved underwriting arrangements c holder electing holder holder returns completed signed notice questionnaire company accordance section aii hereof within reasonable amount time underwritten offering holders participating underwritten offering shall responsible underwriting discounts commissions fees subject section hereof expenses counsel company shall pay expenses customarily borne issuers underwritten offering including limited filing fees fees disbursements counsel independent public accountants printing expenses incurred connection underwritten offering notwithstanding foregoing provisions section n hereof upon receipt request managing underwriter representative holders majority registrable securities included underwritten offering prepare file amendment supplement shelf registration statement prospectus connection underwritten offering company may delay filing amendment supplement days board directors company shall determined good faith company bona fide business reason delay liquidated damages pursuant section hereof company may upon written notice holders postpone shelf registration statement declared effective reasonable period exceed days company possesses material nonpublic information disclosure would material adverse effect company subsidiaries taken whole notwithstanding postponement prior th day following closing date shelf registration statement filed commission ii prior th day following closing date shelf registration statement declared effective commission registration default company shall required pay liquidated damages liquidated damages including day following registration default shelf registration statement either filed filed subsequently declared effective applicable rate per annum equal additional onequarter one percent principal amount registrable securities including th day following registration default onehalf one percent thereof st day following registration default b event shelf registration statement ceases effective holders registrable securities otherwise prevented restricted company effecting sales pursuant thereto effective failure days whether consecutive day period days whether consecutive month period company shall pay liquidated damages rate per annum equal additional onehalf one percent principal amount registrable securities st day upon effective failure occurs day period st day upon effective failure occurs month period case may earlier time shelf registration statement becomes effective holders registrable securities able make sales shelf registration statement ii time effectiveness period expires purpose determining effective failure days company obligated pay liquidated damages accordance foregoing respect prior effective failure within applicable day month period case may shall included c event company fails file posteffective amendment shelf registration statement posteffective amendment declared effective within periods required section company shall pay liquidated damages rate per annum equal additional onehalf one percent principal amount registrable securities including date registration default time registration default cured amounts paid liquidated damages pursuant paragraphs b c section shall paid semi annually arrears first semiannual payment due first interest payment date defined indenture applicable following case said paragraph c date registration default ii case said paragraph b st day upon effective failure occurs day period st day upon effective failure occurs month period case may liquidated damages accrue respect securities rates set forth paragraphs b c section applicable principal amount securities respect common stock issued upon conversion securities rates set forth paragraphs b c section applicable applied conversion price defined indenture time e except provided section b hereof liquidated damages set forth section shall exclusive monetary remedy available holders registrable securities registration default effective failure event shall company required pay liquidated damages excess applicable maximum amount onehalf one percent set forth regardless whether one multiple registration defaults exist holder shall entitled liquidated damages hereunder unless holder complied obligations furnish information documents required agreement miscellaneous registration rights company may grant registration rights would permit person third party right piggyback shelf registration statement provided managing underwriter underwritten offering conducted pursuant section hereof notifies company electing holders total amount securities electing holders holders piggyback rights intend include shelf registration statement large materially threaten success offering including price securities sold subject rights existing date hereof amount number kind securities offered account holders piggyback rights reduced extent necessary reduce total amount securities included offering amount number kind recommended managing underwriter prior reduction amount registrable securities included shelf registration statement b specific performance parties hereto acknowledge would adequate remedy law company fails perform obligations hereunder purchaser holders time time may irreparably harmed failure accordingly agree purchaser holders addition remedy may entitled law equity without limiting remedies available electing holders section hereof shall entitled compel specific performance obligations company registration rights agreement accordance terms conditions registration rights agreement court united states state thereof jurisdiction c amendments waivers agreement including section c may amended waivers consents departures provisions hereof may given written instrument duly executed company holders majority aggregate principal amount registrable securities outstanding holder registrable securities outstanding time amendment waiver consent thereafter shall bound amendment waiver consent effected pursuant section c whether notice writing marking indicating amendment waiver consent appears registrable securities delivered holder notices notices communications provided permitted hereunder shall given provided indenture e parties interest parties agreement intend holders registrable securities shall entitled receive benefits agreement electing holder shall bound terms provisions agreement reason election respect registrable securities included shelf registration statement terms provisions agreement shall binding upon shall inure benefit shall enforceable respective successors assigns parties hereto holder time time registrable securities aforesaid extent event transferee holder registrable securities shall acquire registrable securities manner whether gift bequest purchase operation law otherwise transferee shall without writing action kind entitled receive benefits electing holder conclusively deemed agreed bound perform terms provisions agreement aforesaid extent f counterparts agreement may executed number counterparts parties hereto separate counterparts executed shall deemed original taken together shall constitute one agreement g headings headings agreement convenience reference shall limit otherwise affect meaning hereof h governing law agreement shall governed construed accordance laws state new york severability event one provisions contained herein application thereof circumstances held invalid illegal unenforceable respect reason validity legality enforceability provision every respect remaining provisions hereof shall way impaired affected thereby intended rights privileges parties hereto shall enforceable fullest extent permitted law j survival respective indemnities agreements representations warranties provisions set forth agreement made pursuant hereto shall remain full force effect regardless investigation statement results thereof made behalf electing holder director officer partner holder agent underwriter director officer partner agent underwriter controlling person foregoing shall survive transfer registration registrable securities holder please confirm foregoing correctly sets forth agreement company truly gilead sciences inc john f milligan phd name john f milligan title senior vice president chief financial officer accepted date hereof goldman sachs co goldman sachs co goldman sachs co appendix gilead sciences inc instruction dtc participants urgent immediate attention requested deadline response depository trust company dtc identified dtc participant beneficial interests gilead sciences inc company convertible senior notes due december securities held company process registering securities securities act resale beneficial owners thereof order securities included registration statement beneficial owners must complete return enclosed notice registration statement selling securityholder questionnaire important beneficial owners securities receive copy enclosed materials soon possible rights securities included registration statement depend upon returning notice questionnaire please forward copy enclosed documents beneficial owner holds interests securities require copies enclosed materials questions pertaining matter please contact gregg alton gilead sciences inc lakeside drive foster city california gilead sciences inc notice registration statement selling securityholder questionnaire gilead sciences inc company filed united states securities exchange commission commission registration statement form shelf registration statement registration resale rule united states securities act amended securities act companys convertible senior notes due december securities shares common stock par value per share common stock issuable upon conversion thereof accordance registration rights agreement dated date original issuance securities registration rights agreement company purchaser named therein copy registration rights agreement attached hereto capitalized terms otherwise defined herein shall meanings ascribed thereto registration rights agreement order registrable securities included shelf registration statement supplement amendment thereto notice registration statement selling securityholder questionnaire notice questionnaire must completed executed delivered company address set forth herein receipt beneficial owners registrable securities complete execute return notice questionnaire date named selling securityholders shelf registration statement ii may use prospectus forming part thereof resales registrable securities certain legal consequences arise named selling securityholder shelf registration statement related prospectus accordingly holders beneficial owners registrable securities advised consult securities law counsel regarding consequences named named selling securityholder shelf registration statement related prospectusthe term registrable securities defined registration rights agreement mean portion securities issued time time indenture registered form shares common stock issuable upon conversion securities provided however security ceases registrable security longer restricted security term restricted security defined registration rights agreement mean security share common stock issuable upon conversion thereof except security share common stock effectively registered securities act sold manner contemplated shelf registration statement ii transferred compliance rule securities act successor provision thereto transferable pursuant paragraph k rule successor provision thereto iii otherwise transferred new security share common stock subject transfer restrictions securities act delivered behalf company accordance indenture election undersigned holder selling securityholder registrable securities hereby elects include shelf registration statement registrable securities beneficially owned listed item undersigned signing returning notice questionnaire agrees bound respect registrable securities terms conditions notice questionnaire registration rights agreement including without limitation section registration rights agreement undersigned selling securityholder original party thereto upon sale registrable securities pursuant shelf registration statement selling securityholder required deliver company trustee notice transfer completed signed set forth exhibit notice questionnaire selling securityholder hereby provides following information company represents warrants information accurate complete questionnaire full legal name selling securityholder b full legal name registered holder registrable securities listed item c full legal name dtc participant applicable b registrable securities listed item held address notices selling securityholder telephone fax contact person beneficial ownership securities except set forth item undersigned selling securityholder beneficially securities shares common stock issued upon conversion repurchase redemption securities p rincipal amount registrable securities defined registration rights agreement beneficially owned cusip nos registrable securities number shares common stock issued upon conversion repurchase redemption registrable securities b principal amount securities registrable securities beneficially owned cusip nos securities number shares common stock issued upon conversion securities principal amount registrable securities undersigned wishes included shelf c registration statement cusip nos registrable securities included shelf registration statement number shares common stock issued upon conversion registrable securities included shelf registration statement beneficial ownership securities company except set forth item undersigned selling securityholder beneficial registered owner shares common stock securities company securities shares common stock listed item state exceptions relationships company except set forth neither selling securityholder affiliates officers directors principal equity holders held position office material relationship company predecessors affiliates past three years state exceptions plan distribution except set forth undersigned selling securityholder intends distribute registrable securities listed item follows registrable securities may sold time time directly undersigned selling securityholder alternatively underwriters brokerdealers agents registrable securities may sold one transactions fixed prices prevailing market prices time sale varying prices determined time sale negotiated prices sales may effected transactions may involve crosses block transactions national securities exchange quotation service registrable securities may listed quoted time sale ii overthecounter market iii transactions otherwise exchanges services overthecounter market iv writing options connection sales registrable securities otherwise selling securityholder may enter hedging transactions brokerdealers may turn engage short sales registrable securities course hedging positions assume selling securityholder may also sell registrable securities short deliver registrable securities close short positions loan pledge registrable securities brokerdealers turn may sell securities state exceptions note event may methods distribution take form underwritten offering registrable securities without prior agreement company signing selling securityholder acknowledges understands obligation comply agrees comply prospectus delivery provisions securities act exchange act rules regulations thereunder particularly regulation event selling securityholder transfers portion registrable securities listed item date information provided company selling securityholder agrees notify transferees time transfer rights obligations notice questionnaire registration rights agreement signing selling securityholder consents disclosure information contained herein answers items inclusion information shelf registration statement related prospectus selling securityholder understands information relied upon company connection preparation shelf registration statement related prospectus accordance selling securityholders obligation section registration rights agreement provide information may required law inclusion shelf registration statement selling securityholder agrees promptly notify company inaccuracies changes information provided herein may occur subsequent date hereof time shelf registration statement remains effect notices hereunder pursuant registration rights agreement shall made writing handdelivery firstclass mail air courier guaranteeing overnight delivery follows company gilead sciences inc co cooley godward llp five palo alto square el camino real palo alto california attention joshua gillespie esq notice questionnaire executed selling securityholder received company terms notice questionnaire representations warranties contained herein shall binding shall inure benefit shall enforceable respective successors heirs personal representatives assigns company selling securityholder respect registrable securities beneficially owned selling securityholder listed item agreement shall governed respects laws state new york witness whereof undersigned authority duly given caused notice questionnaire executed delivered either person duly authorized agent dated selling securityholder printtype full legal name beneficial owner registrable securities name title please return completed executed notice questionnaire receipt company gilead sciences inc co cooley godward llp five palo alto square el camino real palo alto california attention joshua gillespie esq exhibit appendix notice transfer pursuant registration statement gilead sciences inc co cooley godward llp five palo alto square el camino real palo alto california attention joshua gillespie esq jp morgan trust company national association mission street th floor san francisco california attention institutional trust services gilead sciences inc company convertible senior notes due december notes dear sirs please advised transferred aggregate principal amount referenced notes shares companys common stock issued upon conversion repurchase redemption notes pursuant effective registration statement form file filed company hereby certify prospectus delivery requirements securities act amended satisfied respect transfer described abovenamed beneficial owner notes common stock named selling securityholder prospectus dated amendments supplements thereto aggregate principal amount notes number shares common stock transferred portion notes shares common stock listed prospectus amended supplemented opposite owners name dated truly name authorized signatureexhibit gilead world markets ltd ppg tenofovir df manufacturing supply agreement parties hereby acknowledge following supply agreement agreement entered january effective date ppgsipsy sas french company place business zi la croix cadeau bp avrille cedex france ppg gilead world markets ltd company operating laws cayman islands principal place business queensgate house south church street po box gt grand cayman gwm ppg gwm may referred singly party collectively parties agreement whereas ppg known manufacturer active pharmaceutical ingredients expertise cgmp manufacturing gwm designees manufacture market pharmaceutical products human use including tenofovir disoproxil fumarate mg viread whereas ppg gwm desire establish mutually agreeable terms commercial supply tenofovir disoproxil fumarate product active pharmaceutical ingredient ppg gwm therefore consideration ppgs agreement manufacture product supply gwm monetary amounts set forth agreement ii promises covenants agreements valuable consideration hereinafter set forth intending legally bound parties hereby agree follows agreement acceptance ppg read understands agreement understands govern ppgs written acceptance order delivery product terms conditions respect order product proposed ppg different addition agreement agreed writing gwm expressly rejected gwm shall become part agreement order gwm read understands agreement shall purchase product manufactured ppg pay supply product accordance terms provisions agreement exception product delivery pursuant delivery product effective date agreement shall governed terms agreement modifications agreement shall prior implementation mutually agreed upon parties hereto shall made accordance section neither general sales conditions ppg general purchase conditions gwm shall apply supply product ppg gwm term term agreement shall begin january shall remain effect december initial term thereafter subsequent renewal terms renewal term unless terminated end initial term renewal term either party least prior written notice unless otherwise terminated according section termination agreement supply term agreement ppg shall manufacture product gwm use viread term agreement ppg obligated manufacture product location quantities set forth herein ppg manufacture product gwm facility located facilities parties agree writing portions omitted pursuant request confidential treatment filed separately commission b initial term renewal term gwm purchase ppg shall deliver least quantities set forth exhibit result invoice issued calendar year described section quantities product ordered addition described section c forecasting first day gwm shall provide ppg projected need product period commencing date forecast quantities indicated first period projection affirmative obligation gwm purchase affirmative obligation ppg supply product within limits quantities indicated second period projection considered forecast exception calendar year notwithstanding anything agreement ppgs given period shall indicated period falls acceptance ppg shall respond order received gwm within calendar days receipt response shall include ppgs inability comply confirmation delivery dates quantities set forth order e shipment product hereunder delivered facility gwm gwm designee quantities designated gwm purchase order gwm purchase order material transfer request subsequent written instruction given gwm accordance instructions shipping packaging included gwm purchase order facility designated shall gwm location additional terms conditions provided gwm purchase orders shall apply terms conditions agreement shall apply alone f ppg unable supply sufficient quantities product meet either minimum obligations section b gwm purchase order whether accepted ppg either party perceive shortfall delivery product ppg likely occur reason parties shall discuss appropriate steps alleviate shortfall gwm shall right quantities meet shortfall shall shortfall occurs gwm must costs beyond base price agreed parties described exhibit b shortfall quantity limited total cost base price repeated shortfalls may considered material breach agreement described section agreement g release andor shipment quantity delayed ppg accepted order fault ppg quantity shall considered shortfall treated section f delay caused gwm gwm shall make remediate fault soon reasonably practicable good manufacturing practices ppg expressly warrants goods covered agreement manufactured accordance current good manufacturing practices cgmp established united states food drug administration fda european agency evaluation medicinal products emea manufacture pharmaceutical materials well applicable rules regulations fda emea governmental regulatory agencies united states european union party shall promptly notify new instructions specifications required fda federal food drug cosmetic act federal public health service act applicable rules regulations united states european union shall confer respect best means comply requirements shall allocate costs implementing changes equitable basis upon written request gwm ppg permit representatives gwm observe manufacture government inspection ppgs manufacturing process product mutually agreeable times ppg shall permit gwm inspect copies ppgs manufacturing records including batch records purposes assuring product quality compliance agreedupon manufacturing procedures manufacturing process batch release testing gwm shall make available ppg free charge knowhow information technical assistance needed ppg allow ppg manufacture tenofovir df product standard gwm precisely described gwm writing ppg start manufacturing product ppg shall manufacture product conformance specifications specifications set forth gilead sciences tenofovir df contract manufacturing manual effect effective date agreement thereafter amended contract manufacturing manual according manufacturing process description set forth contract manufacturing manual ppg shall test batch product conformance specifications according standard test methods set forth contract manufacturing manual raw materials raw materials used manufacture product conform specifications set forth contract manufacturing manual raw material specifications conformance verified accordance testing standards procedures specified therein ppg agrees facilitate changes raw material specifications necessary appropriate light fda regulatory requirements ppg shall liable hereunder raw materials meet raw material specifications product fails meet specifications raw material specifications inadequate change manufacturing process ppg shall obtain gwms prior written approval implementing planned change materials equipment process procedures used manufacture product would constitute change cgmp would impact validation status process would constitute noncompliance manufacturing process set forth contract manufacturing manual ppg shall disclose proposed changes manufacturing materials equipment process procedure gwm level sufficient allow gwm practice changed manufacturing process gwm shall notify ppg writing reasonable notice change materials equipment process analytical methods specifications procedures used manufacture product whether changes reflected updates contract manufacturing manual otherwise ppg shall provide gwm authentic copy current master batch record preparation product cost implementing amendment change whatever nature procedures specifications described contract manufacturing manual exists effective date agreement well extra costs resulting implementation change shall borne parties shall negotiate good faith process improvements agrees communicate promptly idea substantial improvement patented unpatented made developed solely jointly arising activities agreement relating processing manufacture product improvement rights title improvements foreseeable uses related processing manufacture product shall assigned shall right utilize improvements manufacture product rights title improvements patented unpatentable applications related processing manufacture product contain specific knowhow developed prior effective date shall assigned shall right utilize improvements processing manufacture product structurally related gilead pharmaceutical compound grants royaltyfree worldwide exclusive license limited processing manufacture product structurally related gilead pharmaceutical compound improvements applications related processing manufacture product contain specific knowhow developed prior effective date contracts processing manufacture product structurally related gilead pharmaceutical compounds third party improvement may disclosed contract manufacturer rights use shall restricted processing manufacture product structurally related gilead pharmaceutical compounds parties hereto discuss good faith appropriate remuneration implementing disclosure said third party quality control sample documentation manufacture product shall times strict conformance specifications conformance verified accordance testing procedures specified therein prior delivery batch product ppg shall provide gwm quality control sample held gwm analytical reference ii written confirmation batch records batch reviewed approved ppgs quality assurance unit certificate compliance iii certificate analysis confirming batch meets specifications quality control sampling unless otherwise specified gwm writing shall accordance current drug substance samplingtesting plan contained contract manufacturing manual quantity price subject adjustment provided agreement gwm shall pay ppg prices exhibit b using exhibit b invoice price set calendar year subsequent calendar year using plus forecast given gwm second accordance section c adjustment made based year corresponding calendar year based ppg agrees process improvements discovered mutually agreed upon accordance sections material effect product manufacturing cost parties negotiate good faith shipping billing payment unless otherwise agreed parties writing shipments shall shipped incoterms pursuant written instructions provided gwm ppg however shall responsible ppg package ship products accordance ppgs customary practices pharmaceutical compounds unless otherwise specified gwm within calendar days receipt shipping instructions gwm ppg shall ship invoiced amount product destination invoices ppg gwm covering product shipped gwm shall stated payments ppg gwm shall made payments due ppg shall made wire transfer bank account ppg ppg shall advise gwm time time invoices issued upon completion batches issuance applicable quality control samples accordance section ppgs invoice shall paid gwm later calendar days following later receipt applicable invoice ii receipt certificate analysis certificate compliance invoiced amount paid within due date shall assessed late payment fee rate maximum rate permitted applicable law respect obligations whichever less credit terms adjusted justified termination either party may terminate agreement material breach party material breach may encountered either party repudiates breaches agreement b fails perform services deliver goods provided agreement termination section must performed giving breaching party written notice specifying circumstances breach including provisions agreement breached breaching party breach indeed occurred calendar days cure breach agreement breach cured end calendar day period breaching party making diligent good faith efforts cure breach upon immediate notice breaching party breaching party shall default nonbreaching party may terminate agreement breaching party making diligent good faith efforts cure breach breaching party shall granted additional calendar day period cure said breach unless termination grounds material breach resulting gwm shall purchase raw material intermediates ppgs actual cost inventories product purchase price effect according provisions appendix b hereto amended performance agreement otherwise gwm shall right obligation purchase raw materials intermediates inventories product pursuant section gwm may determine sole discretion event either party becomes bankrupt party may immediate notice first party terminate agreement liabilities whatsoever subject relevant legislation provisions herein contained gwm may terminate agreement whole part time giving days written notice ppg gwm sole discretion determines gwm may terminate agreement result gwm terminate agreement due reasons contained article ppg shall take reasonable measures cease ongoing production limit expenses associated ongoing production gwm shall purchase raw material intermediates ppgs actual cost inventories product purchase price effect according provisions appendix b hereto amended performance agreement reimburse ppg reasonable expenses incurred ppg respect remainder said gwm purchase order prior effective date termination except otherwise set forth agreement termination agreement shall release party hereto payment liability obligation existing date termination limited warranty ppg warrants product delivered hereunder manufactured ppg accordance cgmp applicable fda emea rules regulations united states european union ii manufactured accordance agreedupon manufacturing procedures described master batch records supplied gwm accordance provisions section may modified disclosed gwm accordance provisions section iii conform specifications set forth contract manufacturing manual time product manufacture iv provided compliance applicable laws regulations fully set forth section gwms remedies ppgs liability respect warranties set forth representations warranties ppg makes express implied warranties statute arising otherwise law course dealing usage trade including without limitation warranty fitness particular purpose use disclaimed ppg product fails conform warranties herein ppgs exclusive obligation gwms gwms affiliates exclusive remedy subject sections shall set forth section except provided immediately preceding sentence event ppg liable theory recovery whether based negligence kind strict liability tort direct indirect special incidental consequential damages way related arising resulting use made product nothing section intended limitation indemnification obligations ppg pursuant section recall obligations ppg section rejection gwm may reject product delivered ppg failure comply warranties section giving ppg written notice upon parties cooperate determine whether rejection necessary justified ppg notify gwm promptly whether accepts gwms basis rejection parties disagree whether product batch comply warranties submit sample product batch applicable documentation mutually acceptable independent third party laboratory third party laboratory shall determine whether product batch conforms warranties determination shall final binding determinative whether rejection product batch justified party third party tester rules shall bear costs third party testing gwm given notice rejection gwms request ppg shall use best efforts replace rejected product third party tester rules rejected batch meets warranties gwm purchase batch irrespective whether ppg already replaced ppg accepts gwms basis rejection third party tester rules rejected batch meet warranties ppg charge gwm batch shipping insurance freight costs therefor shall promptly refund amounts already paid gwm election gwm may unless finally determined batch complied warranties section indemnification ppg ppg agrees indemnify hold harmless defend gwm gwms directors officers employees agents directors officers employees agents gwm parent subsidiary related company gwm indemnitees losses liabilities judgments damages costs reasonable fees expenses including reasonable attorneys fees collectively losses resulting third party claim demand action suit proceeding collectively third party claim arising ppgs manufacture product fails comply ppgs obligations agreement ii transportation storage use product ppg product control iii negligent wrongful act omission ppg ppg indemnitee relating agreement including without limiting generality foregoing losses whatsoever respect third party claims death injury person damage property provided gwm provides ppg prompt notice third party claim exclusive ability defend reasonable cooperation gwm settle third party claim except extent ppg right indemnification defense respect loss third party claim pursuant section indemnification gwm gwm agrees indemnify hold harmless defend ppg ppgs directors officers employees agents directors officers employees agents ppg parent subsidiary related company ppg indemnitees losses resulting third party claims arising relating manufacture product made available gwm ppg ii possession use transformation sale product person ppg indemnitee iii negligent wrongful act omission gwm gwm indemnitee relating agreement including without limiting generality foregoing losses whatsoever respect third party claims death injury person damage property provided ppg provides gwm prompt notice third party claim exclusive ability defend reasonable cooperation ppg settle third party claim except extent gwm right indemnification defense respect loss third party claim pursuant section recalls adverse events recall adverse events product may related processing manufacture product ppg ppg shall provide gwms cost assistance reasonably requested gwm connection recall adverse events product recalled due breach warranty section ppg shall responsible reasonable outofpocket expenses incurred connection recall seizure including loss viread notification transportation destruction expenses replacement costs implied licenses right express implied granted agreement either party use manner name trade name trademark intellectual property rights connection performance work covered agreement independent contractors party hereto shall act independent contractor nothing agreement shall construed give either party authority act bind commit party way whatsoever force majeure neither party shall liable failure perform delay performing obligations agreement failure delay caused lack supply materials fault party act god riot fire explosion flood hostilities war executive legislation administrative order conditions reasonably beyond control party provided party experiencing delay promptly notifies party delay uses continues use best efforts overcome cause cause shall continue period overcome party whose performance affected party subject force majeure may without liability date expiration period except provided specifically excluded provision interference caused ability ppg perform obligations ppg shall inform gwm interference extent duration without delay interference caused ability ppg perform obligations shall constitute shortfall per sections f g agreement nonassignability neither party may assign transfer agreement rights obligations hereunder without prior written consent party except gwm may make assignment transfer without partys consent assignment transfer successor substantially business gwm relating product whether merger sale stock sale assets similar transaction b ppg may make assignment transfer without prior written consent provided event gwm shall option minimum written notice shall leave gwm without liability beyond assignment transfer attempted assignment transfer either party violation terms section shall null void legal effect case permitted assignment transfer agreement agreement shall binding upon inure benefit successors executors heirs representatives administrators assigns parties hereto governing law agreement made accordance shall governed construed interpreted enforced applied laws excluding choice law rules excluding united nations convention contracts sale goods part agreement conflict applicable law provisions order shall remain force parties hereto shall mutually good faith modify invalid unenforceable provisions maintain essentially spirit hereof original parties severability event term agreement held invalid unenforceable statute regulation ordinance executive order rule law term shall deemed modified deleted extent necessary comply statute regulation ordinance order rule valid enforceable portion thereof remaining terms agreement remain full force effect unless invalid unenforceable provisions essential importance agreement reasonably assumed parties would entered agreement without invalid terms warehousing ownership product transferred gwm upon agreement parties ppg agrees hold supplies product ppgs facility shipping instructions available gwm storage product shall accordance cgmp applicable fda emea rules regulations united states european union shall bear cost insurance loss product maintained ppgs facility gwm make appropriate efforts move product ppgs facility reasonable period time notification policy terms conditions shall apply processing manufacture product agreement gwm substituted purposes notices notices agreement shall writing shall delivered personally sent next day delivery internationally recognized courier service transmitted facsimile transmission confirmed confirmation next day delivery internationally recognized courier service following addresses facsimiles respective parties address facsimile notified pursuant section gwm copy gilead world markets ltd gilead sciences inc queensgate house lakeside drive south church street foster city ca po box gt usa grand cayman attention associate director chemical manufacturing attention gregg h alton director facsimile facsimile ppg copy ppgsipsy ppg industries inc zi la croix cadeau one ppg place e bp pittsburgh pa usa avrille cedex france attention general manager fine chemicals attention european operations manager fax fax confidentiality confidential information means proprietary confidential information data knowhow results trade secrets techniques inventions ideas process formulas drawings diagrams disclosed one party party course negotiating performing agreement whether marked identified confidential proprietary gwms confidential information shall include confidential information gilead sciences inc defined disclosed ppgs predecessor interest pursuant confidential disclosure agreement made effective january gilead sciences inc ppgsipsy successor interest sipsy chimie fine sca except information hereafter becomes act failure act part receiving party employees contractors breach hereof generally known available ii known receiving party time receiving information evidenced contemporaneous written records iii hereafter furnished receiving party third party matter right without restriction disclosure iv independently developed receiving party without reference confidential information shown independent contemporaneous written records term agreement party maintain confidential information party received agreement confidence without prior written permission party shall disclose confidential information party third party use confidential information purposes extent necessary permitted performance agreement parties shall disclose confidential information party employees agents consultants affiliates sublicensees need information performance agreement subject binding obligations hold confidence make use confidential information party purpose permitted agreement least restrictive section party protect confidentiality partys confidential information using standard care uses protect confidential information similar nature less reasonable care party notify party promptly upon discovery unauthorized use disclosure confidential information party notwithstanding provision agreement party affiliate applicable may disclose confidential information disclosure response valid order court governmental body united states foreign country political subdivision thereof provided however receiving party shall first given notice party hereto shall made reasonable effort obtain protective order requiring confidential information disclosed used purposes order issued ii otherwise required governmental law rule regulation including without limitation rules regulations us securities exchange commission rules national association securities dealers provided however receiving party shall first given notice party hereto order allow party opportunity seek confidential treatment confidential information iii otherwise necessary prosecute defend litigation comply applicable governmental regulations make governmental patent regulatory filings otherwise enforce obligations agreement extent disclosure necessary enforcement agreement terminates expires party partys election promptly return destroy confidential information received party shall certify writing party completion thereof entire agreement amendments agreement together attachments exhibits supplements specifically referenced agreement constitutes entire final complete exclusive agreement parties supersedes previous agreements representations written oral respect subject matter agreement agreement may modified amended waived discharged terminated orally instrument writing signed duly authorized representative party subject amendment terms conditions set forth herein constitute final complete exclusive entire agreement gwm ppg respect subject matter hereof term condition agreement confirmation document furnished gwm ppg way inconsistent terms set forth herein hereby expressly rejected insurance party shall maintain cost insurance policies respect activities obligations agreement commercially reasonable terms coverage coverage limits view scope partys activities obligations agreement partys request party supply certificates insurance evidencing coverages survival provisions sections respect last sentence shall survive termination expiration agreement gilead world markets ltd mark l perry name mark l perry date january title managing director accepted acknowledged ppgsipsy rene devaumas name rene devaumas date december title president ppgsipsy exhibit tenofovir df purchase quantities calendar year exhibit b tenofovir df base prices base price using table invoice price set calendar year subsequent calendar year using plus forecast given gwm second accordance section c adjustment made based year corresponding calendar year based portions omitted pursuant request confidential treatment filed separately commission quicklinks click rapidly navigate document exhibit subsidiaries gilead sciences inc name subsidiary country state incorporation gilead sciences limited ireland gilead irish holdings limited cayman islands gilead world markets ltd cayman islands gilead international ltd cayman islands gilead international holdings ltd cayman islands gilead sciences gmbh germany gilead sciences sarl france gilead sciences srl italy gilead sciences sl spain gilead sciences lda portugal gilead sciences ltd united kingdom gilead sciences international ltd united kingdom gilead sciences pty limited australia gilead sciences bv netherlands gilead sciences hellas epe greece simbolo acquisition sub inc delaware quicklinks exhibit quicklinks click rapidly navigate document exhibit consent ernst young llp independent auditors consent incorporation reference registration statements form nos pertaining stock option plan incentive stock option plan supplemental stock option plan employee stock purchase plan nonemployee directors ' stock option plan gilead sciences inc nexstar pharmaceuticals inc incentive stock plan nexstar pharmaceuticals inc director option plan vestar inc stock option plan triangle pharmaceuticals inc stock incentive plan option agreements dated august triangle pharmaceuticals inc daniel g welch registration statements form nos gilead sciences inc related prospectuses applicable report dated january respect consolidated financial statements schedule gilead sciences inc included annual report year ended december ernst young llp palo alto california march quicklinks exhibit consent ernst young llp independent auditors quicklinks click rapidly navigate document exhibit consent independent accountants hereby consent inclusion annual report gilead sciences inc report dated january relating financial statements proligo llc thirteenmonth period ended december incorporated reference annual report pricewaterhousecoopers llp denver colorado march quicklinks exhibit consent independent accountants quicklinks click rapidly navigate document exhibit certification pursuant section public company accounting reform investor protection act usc adopted john c martin chief executive officer gilead sciences inc company john f milligan chief financial officer company hereby certifies best knowledge company 's annual report period ended december certification attached exhibit annual report fully complies requirements section section securities exchange act amended information contained annual report fairly presents material respects financial condition results operations company periods covered annual report dated march john c martin john f milligan john c martin john f milligan chief executive officer chief financial officer quicklinks exhibit certificationend filing edgar online inc